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ABSTRACT 
 
PING-JIE XIAO:  Pharmacological and Biophysical Dissections of the Trafficking and 
Infection of Adeno-Associated Virus In Vitro and In Vivo. 
(Under the direction of Dr. R. Jude Samulski) 
 
 
Adeno-associated virus (AAV) is a defective and non-pathogenic human parvovirus 
that is dependent on the co-infection of a helper virus, such as Adenovirus or Herpes Virus, 
to fulfill its productive life cycle. While many traits of this virus have made it an attractive 
vector for gene therapy as well as the wide application in over 100 clinical trials, there 
remains a great need to further improve the performance of AAV in gene delivery. As a most 
promising solution to fit such need, development of novel AAV vectors with improved 
efficiency on cellular trafficking and processing was partially achieved by several strategies 
in the last decade, including isolation of natural serotypes, directed evolution, and rational 
design. Being a most effective approach for the development of new AAV vectors in the 
future, rational design requires extensive knowledge on AAV-host interaction, which is 
mainly a multi-step trafficking and intracellular processing from cell surface binding to 
nuclear entry. However, much is unknown about the details of interactions between AAV 
and its host, which has limited one’s ability to improve the delivery efficacy of AAV vectors 
and therefore restricted their medical applications.   
The primary goal of this dissertation is to advance our current knowledge of AAV-
host interactions by developing new methodologies and providing more insights on how 
virion components and host machineries at molecular level affect the infectious pathway of 
 iv 
AAV. Typically, a successful transduction is achieved upon the accomplishment of virions 
on cell surface attachment, endocytosis and endosomal sorting, cytoplasmic trafficking, 
nuclear targeting, and genome processing. Prior to this work, an efficient method to 
quantitatively evaluate the intracellular trafficking of AAV particles is not available. 
Additionally, it was unknown how the AAV traverses the crowded cytoplasm in host cells 
prior to the nuclear entry. While microtubules (MTs) have been reported to facilitate the 
trafficking of many other viruses, it was unclear whether and how this cellular machinery 
may regulate the intracellular behavior of AAV. Therefore, we set out to build on the known 
foundation of AAV biology and hypothesize that MTs play an important role on AAV 
infection especially the cytoplasmic trafficking of this virus. In this thesis, we have 
established a method of computer-assisted quantitative 3D bio-distribution microscopy that 
samples the whole population of fluorescently-labeled vectors and documents their 
trafficking routes through cells and tissues. This method shall facilitate a quantitative 
evaluation of the effects of pharmacological reagents and vector variants on the delivery 
performance of viral vectors. With this method, we have demonstrated that AAV particles 
exploit MT-mediated endosome transportation to traverse the dense cytoplasm to reach the 
host nucleus. In addition, we have discovered a new cellular barrier composed of MTs at 
MTOC region that limits the nuclear entry and transduction of AAV virions, defining a novel 
defense mechanism by which host cells restrain viral invasion. On the basis of above 
findings, we have proposed a model to better illustrate the infectious pathway of AAV and its 
fine-tuning by MTs. Moreover, we have also documented the trafficking of AAV in animal 
tissues, providing new insights to the AAV biology and vectorology in vivo. While focusing 
on how AAV traffics through the subcellular maze, this work intersects areas of cell biology, 
 v 
biophysics, virology, and gene delivery. This work provides valuable research tools, 
rationales, and assays for future exploration of the details of AAV trafficking and will 
contribute to the knowledge of AAV biology, facilitating the rational development of gene 
therapy vectors.  
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CHAPTER 1 
INTRODUCTION TO GENE THERAPY AND AAV BIOLOGY 
 
Viral vectors for gene therapy 
 
Gene therapy. The idea to treat heritable genetic disorders by delivering a functional 
copy of a mutant chromosomal gene was conceived as early as the 1970s (Osterman et al. 
1971; Rogers 1971). Since then, the innovations in methods of gene delivery have expanded 
to include strategies, such as gene knockdown (i.e. shRNA delivery) and cell killing (i.e. 
cytotoxic gene delivery), to treat disorders resulting from gain-of-function or aberrant 
function mutations, in addition to rescuing loss-of-function genetic disorders. Spurred by the 
potential therapeutic impact of gene delivery and innovations in vector technology, the first 
clinical trial using gene therapy was reported in 1990 (Rosenberg et al. 1990). Since then, 
over 1700 clinical trials have been initiated with delivery methods spanning chemical carrier 
molecules to viral vectors and therapeutic targets including cardiovascular, neurological, 
muscular diseases, and cancer (www.wiley.co.uk/genmed/clinical). Adeno-associated virus 
(AAV) in particular possesses several biological properties that make it an ideal vector for 
gene delivery. Data from clinical trials demonstrate that AAV has a robust safety profile and 
therapeutic efficacy in several contexts. However, these data have also revealed that further 
improvement in the efficiency of delivery is needed. This has become one of the primary 
focuses of the field. Strategies of engineering the capsid to enhance AAV transduction offer a 
potential solution for improving therapeutic performance of this vector.  
 2 
Developing a method to introduce therapeutic nucleic acids into specific cells or 
tissues within the body is not straightforward. Many different strategies have been employed. 
In general, all of these strategies can be classified into two categories based on the 
mechanism of delivery, non-viral or viral. Non-viral methods are typified by the delivery of 
naked nucleic acids (DNA or RNA) by physical means (e.g. gene gun or ultrasonic) or with 
the help of chemical reagents (e.g. cationic polymers) (Table 1). Viral methods rely on 
packaging nucleic acid encoding the functional protein or RNA inside of a viral particle and 
subsequent delivery to target cells via viruses’ natural infection pathways.  
Non-viral delivery. Delivery of ‘naked’ nucleic acid is probably the most straight forward 
approach to introducing genetic material into a cell (Kawabata et al. 1995). Delivery of naked 
nucleic acid (e.g. plasmid DNA (pDNA)) in this manner offers several desirable merits, 
including scalable production, low immunogenicity, and low rate of insertional mutagenesis 
(Wolff et al. 2005; Yazawa et al. 2006; Gray et al. 2008). However, the uptake and 
expression of pDNA is highly inefficient and is minimally tissue specific. This inefficiency 
of pDNA delivery is due to several factors. Naked nucleic acids are susceptible to 
degradation by nucleases present in the body (Pollard et al. 1998; Hoen et al. 2006; Liu et al. 
2007). Additionally, the negative charge of these molecules causes electrostatic repulsive 
forces with the cell surface, partly accounting for the low level of uptake by cells (Bieber et 
al. 2002). Finally, once internalized into a cell, escape from endosomes/lysosomes as well as 
in the process of crossing the nuclear membrane is highly inefficient (Dean et al. 2005; 
Watson et al. 2005). To increase the efficiency of this delivery method, several strategies 
have been employed to protect the nucleic acid and improve cell entry. Cationic carrier 
molecules, including lipids and polymers (e.g. Polyethyleneimine), condense and protect 
 3 
nucleic acids from exposure to nuclease degradation (Luo et al. 2000). These molecules coat 
the nucleic acid with excessive positive charges to improve association with the cell surface 
(Chen et al. 2007).The effect of these carriers is limited, however, due to promiscuous 
binding, which leads to low circulation times and the inability to target specific tissues or cell 
types (e.g. tumors) (Luo et al. 2000). Tissue specific delivery of naked nucleic acids can be 
achieved, to a certain degree, by conjugating specific ligands, such as transferrin, peptides, or 
growth factors (Gupta et al. 2005; Watson et al. 2005). The addition of these ligands targets 
the molecule to certain cell surface receptors, thus improving specificity. Sugars, such as 
galactose, mannose and saccharides, can also be added to enhance cellular uptake of nucleic 
acids and provide some level of specificity in tissue targeting (Hashida et al. 2001; Yu et al. 
2009). However, most carriers and ligands do not assist crossing of the nuclear membrane 
and thus, transfer of plasmid to the nucleus only occurs when there is breakdown of the 
nuclear membrane during cell division (Wells 2010).  
Viral vectors for gene delivery. Compared with non-viral methods, virus-mediated 
gene transfer can deliver genetic materials to cells or tissues with much higher efficiency and 
greater specificity. Several viruses have been explored for use as vectors for gene delivery. 
All of these viral systems rely on a similar approach, replacing part or all of the genome of 
the virus with the desired transgene, which can then be packaged and delivered to cells via 
the virus’ natural transduction pathway. For this reason, each virus offers distinct advantages 
and disadvantages depending on the specific needs in the therapeutic protocols (e.g. target 
cells, size of transgene, etc.). Vectors have been developed based on Retroviruses, 
Adenoviruses, Herpes simplex viruses, and AAV.  
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Table 1. Comparison of methods of gene delivery 
       
  
 5 
Retroviruses. Retroviruses are characterized by the ability to reverse transcribe a 
single-stranded RNA (ssRNA) genome into double-stranded DNA (dsDNA) and integrate 
into the host genome as part of their natural life cycle. The retroviral virion consists of an 
exterior envelope, averaging 80-100nm in diameter, which surrounds a protein capsid. The 
capsid contains two copies of the linear ssRNA genome, each 7-12kb in length (Osten et al. 
2007). Viral infection begins with binding to the cell via interaction between glycoproteins 
on the viral envelope and specific receptors on the host cell surface. The viral envelope then 
fuses with the cell membrane and releases the capsid into the cytoplasm. Subsequently, the 
genetic material is released and transported to the nucleus with the aid of viral and cellular 
proteins. Once inside the nucleus, the viral genome integrates into the host chromosomes as a 
natural feature of its replication cycle.  
Initially, vectors for gene delivery were derived from simple retroviruses, such as the 
gamma-retrovirus Moloney Murine Leukemia virus (MMLV). Long-term gene expression as 
a result of chromosomal integration was viewed as a significant advantage (Miller et al. 
1990; Robbins et al. 1998). Such vectors were prominently featured in early gene therapy 
trials to treat X-linked SCID among other diseases (accounting for ~20% of clinical trials) 
(Gaspar et al. 2004; Chinen et al. 2007). However, the risk of insertional mutagenesis and 
failure of these vectors to infect non-dividing/differentiated cells have greatly limited their 
use (Miller et al. 1990; Robbins et al. 1998; Cavazzana-Calvo et al. 2007). In light of these 
concerns, vectors were developed based on “complex” retroviruses (e.g. lentiviruses HIV and 
SIV) (Miyoshi et al. 1998). In contrast to simple retroviral vectors, lentiviral vectors 
transduce non-dividing cells and can be engineered to have a much lower risk of insertional 
mutagenesis (Schnell et al. 2000; Bahner et al. 2007). Currently, lentiviral vectors have been 
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or are used in 2.3% clinical trials, treating diseases such as adrenoleukodystrophy (ALD), 
parkinson’s disease, sickle cell anemia, and cancer immunotherapy (Bank et al. 2005; Li et 
al. 2005; Cartier et al. 2009; Williams 2009). Several advancements in vector engineering 
have made lentiviruses a viable option for clinical therapy. Among these, pseudotyping of 
vectors with different surface glycoproteins, such as vesicular stomatitis virus glycoprotein, 
has expanded targeting to a wider variety of cell/tissue types. Additionally, insights into the 
mechanism of vector integration have yielded non-integrating lentiviral (NIL) vectors that 
have nearly eliminated the risk of insertional mutagenesis. Despite these promising 
improvements, several hurdles remain. One problem is that these vectors are subject to 
transgene silencing (Bonci et al. 2003; Ellis 2005). The mechanism of this is not well 
understood, but long-term gene expression is limited. The innate immune response and 
preexisting immunity to glycoproteins used to pseudotype these vectors have also limited 
their efficacy (Towers 2007). Finally, a means of scalable production of clinical grade vector 
is lacking and challenges future advancement of this system. 
Adenovirus. Adenovirus (Ad) possesses several properties that are desirable for a 
gene delivery vector and has been developed extensively for this purpose. In contrast to 
retroviruses, the Ad virion is made up of only a protein capsid of 70-100 nm in diameter and 
a 26-40 kb linear dsDNA genome (Campos et al. 2007). Transduction of Ad is mediated 
through interaction of the Fiber protein, which extends from the capsid surface, with the 
coxsackievirus and adenovirus receptor (CAR) on the cell surface. The virus is then 
internalized and transported to the nuclear envelop where its genome is released through the 
nuclear pore.  
 7 
Development of Ad as a gene therapy vector has undergone several generational 
advancements. First generation vectors were created by removal of the E1 region of the 
genome. This deletion prevents replication of the virus and provides space in the genome for 
insertion of exogenous DNA (Kovesdi et al. 1997). To propagate these vectors, the E1 
proteins must be provided in trans. The major concern with this method is that recombination 
events during vector production between the vector and complementing E1 sequence can 
result in restoration of wild type (WT) Ad. Second generation vectors remove a greater 
portion of the genome, including regions E2, E3, and E4. This reduces, but does not 
eliminate the risk of recombination events resulting in WT virus and expands the capacity for 
transgenes. Third generation ‘gutless’ vectors take this principle to the maximum by 
removing all non-essential sequence in the genome (Chen et al. 1997).  
Ad-based vectors can infect dividing and non-dividing cells, have high transgene 
capacity, and a low rate of insertional mutagenesis. Additionally, scalable methods of 
production allow high titer preparations. Ad vectors have been widely used to treat a variety 
of diseases and account for ~24% of clinical trials ((Ghosh et al. 2006; Roth 2006; Gray et al. 
2008; Mata-Espinosa et al. 2008); www.wiley.co.uk/genmed/clinical). The greatest hurdle to 
use of Ads is that they are highly immunogenic and inflammatory. Many patients have 
preexisting immunity to the virus and therapeutic effect of derived vectors can be limited by 
the host immune response (Douglas 2007). As a result, Ad vectors may be best suited for 
treating diseases in which only transient gene expression is needed, such as cancer.  
Herpes simplex virus. Among members of the family Herpesviridae, the most 
progress toward developing gene therapy vectors has been made with herpes simplex virus 
(HSV). HSV is a large virus (~180 nm in diameter) comprised of an exterior envelope 
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containing a proteinaceous layer (i.e. tegument) and an icosahedral protein capsid. The 
packaged genome is a linear double-stranded DNA of ~152kb in length. Similar to 
retroviruses, HSV binds to specific receptors on target cells via glycoproteins on the surface 
of the viral envelope. The envelope then fuses with the cell membrane and the capsid and 
tegument are released into the cytoplasm. The capsid is trafficked to the nucleus with the aid 
of viral and cellular factors and the genome released through the nuclear pore. Once in the 
nucleus, the linear genome circularizes and persists in the cell as an extrachromosomal 
episome. Vectors derived from HSV are able to transduce dividing and non-dividing cells 
and can be targeted to various cell types by surface protein pseudotyping, much like 
retroviruses. Due to its size, HSV can deliver large pieces of exogenous DNA, the largest 
capacity among commonly used viral vectors (Fink et al. 1997; Geller 1997). HSV vectors 
account for ~3% of clinical trials. However, also much like retroviruses, a limitation of these 
vectors has been silencing of gene expression caused by DNA methylation, which has made 
these vectors less effective for long-term therapy (Kass et al. 1997; Lilley et al. 2001; Sun et 
al. 2003; Suzuki et al. 2008). Host immune responses to the vector and lack of scalable 
production have limited the application of these vectors as well (Fraefel et al. 1996).  
In summary, the above viruses have been developed extensively as vectors for gene 
delivery to treat a number of human genetic disorders. Although each possesses desirable 
traits, several limitations confront their application in humans, including risk of insertional 
mutagenesis, host immune response, restricted tissue tropism, and limited duration of 
transgene expression. Further improvement of these vectors is required to overcome these 
challenges. 
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AAV biology and vectorology 
 
AAV shares many features in common with the viral vectors discussed above, 
however, it also has unique advantages that make it an exceptional vector for gene delivery. 
Unlike other viral systems, WT AAV is not associated with disease or pathology and derived 
vectors have an excellent safety profile in humans (Mueller et al. 2008). Moreover, the 
natural persistence of this virus in many tissues facilitates long-term transgene expression 
(Berns et al. 1975). A number of innovations have contributed to the success of AAV as a 
vector for gene therapy as well. For example, the ability to package AAV serotype-2 genome 
into capsids from various serotypes (transencapsidation) gives this vector a wide range of 
potential tissue tropisms (Rabinowitz et al. 2002). The following sections review the biology 
of AAV, successes and challenges that are already visible from clinical trials, and current 
strategies to improve AAV vectors further.  
AAV biology. AAV was first discovered in 1965 as a contaminant in an Adenovirus 
preparation (Atchison et al. 1965; Hoggan et al. 1966). It was later classified as a member of 
the genus Dependovirus of the Parvovirus family because its replication depends on co-
infection of a helper virus such as Adenovirus. AAV is a relatively small virus (~20nm) and 
consists of an icosahedral protein capsid containing the viral genome. The capsid possesses 
specificity for binding specific cell surface receptors and different serotypes have unique 
binding properties (McCarty et al. 2003; Ding et al. 2005). The viral genome is a single-
stranded DNA (ssDNA) of ~4.7kb in length and is flanked by 145bp inverted terminal 
repeats (ITR). The ITR contains complementary sequences that result in formation of a ‘T’ 
shaped hairpin structure at both termini of the genome. This secondary structure facilitates 
synthesis of the second-strand and thus formation of a double-stranded molecule, which 
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severs as the template for transcription. The genome encodes open reading frames (ORF) Rep 
and Cap (Fig.I-1). Rep, is positioned 5’ on the AAV genome and encodes four replication-
related proteins, Rep78, Rep68, Rep52, and Rep40 (Kyostio et al. 1994). Rep78 and Rep68 
interact with sequences within the ITR, termed the Rep-binding element (RBE), and are 
required for resolution of the secondary structures during replication. Rep52 and Rep40 are 
necessary for generation of single-stranded genomes and packaging. The Cap ORF is 
positioned 3’ on the viral genome and encodes three structural proteins VP1, VP2 and VP3. 
These proteins assemble at a ratio of 1:1:10 (VP1:VP2:VP3) to form the viral capsid (Buning 
et al. 2004) consistent of 12 pentamers or 20 trimers of VP subunits (Fig.I-2). The three 
structural proteins share a common carboxyl terminal region, but have different amino-
termini. This grants different functions to each of these proteins because the amino-terminus 
is involved in virus binding, entry, and intracellular trafficking (Johnson et al. 2010). 
Structural modules on the capsid surface and inside have to work accordantly for successful 
transduction. VP3 makes up the framework of the capsid, and the crystal structure portrays a 
rigid -barrel core surrounded by eight loops (a.k.a variable regions), providing virions with 
interfacial interactions and receptor binding motifs on the capsid surface. The N-termini of 
VP1 and VP2 are more flexible than the -barrel core and yet to be crystallized. While 
dispensable for virus assembly, genome packaging, cell surface binding and internalization, 
VP1 and VP2 are critical for productive infection and deletion of these proteins severely 
impairs the viral transduction. The structure of AAV2 icosahedral capsid is illustrated in 
figure I-2. Recently, coding for an additional protein, assembly activating protein (AAP), was 
described to overlap with the Cap gene and may be involved in AAV capsid assembly 
(Sonntag et al. 2010; Sonntag et al. 2011) (Fig. I-1). 
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Figure I-1. AAV genome. Two open reading frames (ORFs) code proteins essential for 
virion replication and capsid composition. The left ORF ‘Rep’ encodes four Rep proteins 
driven by two promoters. Both Rep78 (non-spliced) and Rep 68 (spliced) are initiated by the 
p5 promoter. Both transcripts of Rep 52 (non-spliced) and Rep 40 (spliced) are initiated by 
the p19 promoter. The right ORF ‘Cap’ encodes three structural proteins (VP1-3) and one 
non-structural protein (AAV). Capsid transcripts are driven from the p40 promoter, which 
produces a minor splice variant for coding VP1 and a major splice variant for coding VP2 
and VP3. Three capsid proteins exist in an overlapping reading frame with an identical C-
terminus. 
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Current understanding of the AAV life cycle is derived primarily from the studies of 
serotype-2 (AAV2). Though many aspects are conserved among all serotypes, the reader 
should bear in mind that there are differences that make each unique. The life cycle of AAV2 
involves receptor-mediated cell entry (Summerford et al. 1998), endosomal trafficking and 
escape (Ding et al. 2005), nuclear entry, and uncoating (Xiao et al. 2002; Grieger et al. 2006). 
Once the genome is released from the capsid, second-strand synthesis initiates from the 3’ 
ITR. The secondary structure of the ITR is critical for this priming event as it positions the 
3’end of single-stranded genome to act as the primer for the second strand. The resulting 
double-stranded molecule can then serve as the template for gene expression. In the absence 
of helper virus function the virus enters a state of latency (Samulski et al. 1991). In this state, 
viral gene expression is repressed and the genome persists episomally (Giraud et al. 1995). In 
the presence of Rep proteins, AAV DNA can integrate into a specific site in the human 
genome (chromosome 19), which shares homology with the ITR sequence and can be bound 
by the Rep proteins (Kotin et al. 1992; Miller et al. 2005; Nakai et al. 2005). It has been 
proposed that integration of AAV at this site may be part of the latent stage of AAV 
infection, aiding persistence in the absence of helper virus (Kotin et al. 1992). However, this 
has not been demonstrated conclusively. Genome replication commences with co-infection 
by a helper virus or other genotoxic stimuli (Atchison et al. 1965; Grossman et al. 1984; 
Yakobson et al. 1987; Yalkinoglu et al. 1988; Walz et al. 1997). Helper viruses provide 
several functions, including assisting transport to the nucleus, activation of transcription, and 
promoting an environment that is conducive to DNA replication (Chang et al. 1990; Shi et al. 
1991; Duan et al. 1999; Xiao et al. 2002). For example, Ad proteins E1B55k and E4orf6 
disrupt cell cycle regulatory proteins (Ferrari et al. 1996; Fisher et al. 1996). Similarly,  
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Figure I-2. Structural dissection of the AAV capsid. A) Model of icosahedral AAV capsid 
with highlighted pentamer (dashed cyan pentagon) and trimer (dashed blue ‘triangle’). B) 
Surface representation of a pentamer composed of five VP3 subunits. C) Surface 
representation of a trimer composed of three VP3 subunits. Three 3-fold spikes in the trimer 
are highlighted by dashed black circles as in A). D) Top panel: Cartoon ribbon representation 
of a VP3 subunit of AAV2. Bottom panel: Cartoon ribbon representation is superimposed 
with the surface representation of a VP3 subunit. The positions of amino acid motif for HS 
binding, Integrin binding, and HI loop are highlighted in B-E. The parts of VP3 that form the 
2-, 3-, and 5-fold axes of capsid symmetry are marked by black line, blue triangle, and cyan 
pentagon respectively in B and D. E) The AAV capsid is superimposed with the cartoon line 
representation of two VP3 subunits.  
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genotoxic stimuli, such as hydroxyurea or UV irradiation, can induce AAV replication as 
well (Grossman et al. 1984; Yakobson et al. 1987; Yalkinoglu et al. 1988). 
AAV vectorology. Since generation of the first infectious clone of AAV2, the 
potential of recombinant AAV (rAAV) as a vector for gene therapy has become increasingly 
evident (Samulski et al. 1982; Samulski et al. 1983). Among many desirable attributes, AAV 
can transduce a variety of cell types, both dividing and non-dividing, and it is capable of 
long-term gene expression. Vectors derived from AAV retain only the ITR sequence, which 
is required for viral packaging and assembly, from the WT virus and do not express any viral 
genes (Xiao et al. 1997). This removes the possibility of unwanted consequences from 
introducing viral genes or genomic sequence. Additionally, scalable systems of production 
have been developed. Production of vector requires co-expression of Rep/Cap genes. Current 
methods supply these proteins as well as necessary helper virus proteins in trans and have 
virtually eliminated the risk of producing WT AAV (Samulski et al. 1989; Grieger et al. 
2006). rAAV vectors utilize the same mechanisms and pathways of entry and trafficking as 
WT AAV, except that they do not integrate into the host chromosome due to the absence of 
the Rep proteins. Instead, the genomes form predominantly concatamers and persist as 
circular episomes (Miao et al. 1998; Nakai et al. 2001). 
rAAV vectors have been tested for the treatments of a variety of disorders. In fact, 
more than 60 clinical trials have been initiated or completed with AAV-based vectors. The 
data from these trials establish an excellent safety profile for in vivo gene transfer, but also 
suggests that the efficiency of rAAV vectors bears further improvement.  
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Applications and challenges of AAV in clinic 
 
The first AAV vector to be delivered to human subjects carried the CFTR gene in a 
clinical trial to treat cystic fibrosis in 1995 (Flotte et al. 2003). Since then the number of 
AAV-based clinical trials has increased to more than 60. Here, I will briefly summarize these 
trials and discuss the challenges AAV vectors must overcome. A brief summary of these 
clinical trials is provided in Table 2.  
Cystic fibrosis. Cystic fibrosis (CF) is an autosomal recessive disease that affects the lung 
most critically, but can also afflict the liver, pancreas, and intestine. This disease is caused by 
malfunction of the cystic fibrosis transmembrane regulator (CFTR), a chloride ion channel 
protein expressed in epithelial cells. Protein replacement therapy for a non-secreted protein 
such as CFTR is currently not feasible. As a result, gene therapy approaches to introduce a 
functional copy of the CFTR gene are being pursued as a strategy of treatment. In total, nine 
clinical trials have been initiated using AAV vectors to treat this disease 
(www.wiley.co.uk/genetherapy/clinical). The first was a phase I, dose-escalating trial, which 
introduced vector directly into the lung of 25 patients. Administration of the vector was well 
tolerated and only a mild neutralizing antibody response was detected in serum at the highest 
dosage (Flotte et al. 2003). However, the levels of gene expression observed were very low. 
Following this first attempt, subsequent trials have targeted the epithelium of the maxillary 
sinus for delivery in order to alleviate the symptom of persistent sinusitis associated with CF. 
As with delivery to the lung, targeting to this site had no significant side effects and the level 
of expression of CFTR, though insufficient for therapy, correlated with vector dose (Wagner 
et al. 1999; Wagner et al. 2002). More recent trials have tested introducing vector by inhaled 
aerosol. One such trial clearly demonstrated the safety of aerosolized delivery and, similar to 
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other methods of delivery, reported a dose-dependent response in gene expression (Aitken et 
al. 2001). In an attempt to reach therapeutic levels of expression, a multi-dose approach was 
conducted in which patients received multiple injections of vector. In this trial, repeated 
doses were well tolerated by the host immune system and an encouraging trend in 
improvement of pulmonary function was suggested by measurement of interleukin-8 (IL-8) 
and forced expiratory volume (Moss et al. 2004). However, a follow up study, which 
expanded treatment to additional patients, did not find the same effect, which brings into 
question the efficacy of this treatment protocol (Moss et al. 2007). Overall, these results 
provide data on the safety of rAAV delivery to the airway epithelium, but indicate that more 
efficient gene transfer is required to achieve therapeutic effect. A more comprehensive review 
can be found at Griesenbach et al (Griesenbach et al. 2012). 
Alpha1-antitrypsin deficiency. Alpha1-antitrypsin (AAT) deficiency is an autosomal 
recessive disorder caused by reduced circulating levels of AAT protein (normally 1.5-3.5 
mg/ml), which is secreted into the serum by hepatocytes and provides protease protection of 
the lung. Certain mutations of the AAT gene can also result in accumulation of abnormal 
protein in hepatocytes, causing disease of the liver. The symptoms of AAT-deficiency are 
emphysema, chronic obstructive lung disease, and liver damage. Current treatments include 
protein replacement therapy and avoidance of risk factors, such as smoking. Protein 
replacement therapy is costly and requires weekly infusions. Gene therapy has been explored 
for this disease primarily because restoration of only low levels of AAT (~800 g/ml) can 
have therapeutic effect. 
Based on successes in preclinical studies, several clinical trials have been initiated to treat AAT 
deficiency (Song et al. 2002; Lu et al. 2006). Two phase I trials are underway to test intramuscular delivery 
of rAAV expressing the AAT gene (Flotte et al. 2004; Brantly et al. 2009). Mild neutralization antibody and 
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Table 2. Summary of AAV mediated clinical trials 
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T-cell immune response against the viral capsid were observed, but this did not adversely 
affect patient health and was dependent on vector dose. Although the level of AAT 
expression was below that required for therapeutic effect, transgene expression persisted for 
over 1 year and the safety data revealed no adverse reactions. These results suggest this 
method of delivery may produce therapeutic effect with increased vector dosage (Brantly et 
al. 2006; Brantly et al. 2009). This was tested in a subsequent study in which dose-escalation 
was performed in conjunction with IM delivery of rAAV serotype 1, shown to transduce 
muscle with high efficiency in animal models (Flotte et al. 2011). At three months of 
observation, vector administration was well tolerated, but all subjects developed neutralizing 
antibodies to AAV1 capsid. Antibody response was not observed against the transgene 
product, WT AAT. In this context, the level of transgene expression corresponded with 
vector dose and the level of circulating AAT in the serum reached >20 g/ml in all patients 
(~2.5% of the required level). Thus, significant progress has been made toward developing a 
therapeutic for AAT deficiency, but further improvement is necessary to achieve rescue of 
function. Flotte et al provides a more comprehensive review on this disease (Flotte et al. 
2011). 
Leber’s congenital amaurosis. Leber’s congenital amaurosis (LCA) is a rare disease 
(estimated prevalence of about 1:80,000) in which vision is lost due to degeneration of the 
retina (Stone 2007). This disorder can be caused by mutations in one of more than a dozen 
genes. Mutation of the gene RPE65 represents about 6% of all cases of LCA (den Hollander 
et al. 2008). Recent success has been achieved with gene therapy approaches to provide this 
gene. Sub-retinal injection of rAAV carrying RPE65 has been demonstrated to restore vision 
in a canine model of LCA and expression of the protein has persisted for ~7.5 years (Acland 
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et al. 2001). When this strategy was extended into patients, restoration of vision was 
observed in most patients several weeks after treatment (Bainbridge et al. 2008; Cideciyan et 
al. 2008; Maguire et al. 2008). Continued observation revealed improvement in vision for up 
to 1.5 years and no adverse effects or pathology was observed (Simonelli et al. 2010). This is 
now regarded as the first successful AAV-based gene therapy trial in humans. These results 
demonstrate the safety and efficacy of delivering rAAV to the eye by sub-retinal injection and 
introduce a method of therapy that could potentially be used to treat other ocular diseases in 
addition to LCA. A more comprehensive review can be found at Stein et al (Stein et al. 
2011). 
Hemophilia B. Hemophilia B is an X-linked recessive disorder caused by defects in 
the gene encoding blood coagulation factor IX (FIX). Persons with a level of functional FIX 
less than 1% that of normal have severe hemophilia B and suffer from bleeding into the joints 
and soft tissues. This disease can even be fatal if bleeding occurs in the brain. Levels of FIX 
at 1-5% that of normal are associated with decreased bleeding episodes and levels over 5% 
provide normal function. Similarly to AAT deficiency, current treatment for Hemophilia B is 
protein replacement therapy, which is expensive and requires repeated intravenous injections. 
rAAV gene delivery may offer a more suitable strategy of treatment. rAAV vectors 
expressing the FIX gene have been administered to muscle and liver in animal models of 
Hemophilia B. Because the protein product is secreted to the blood stream, both tissues are 
suitable targets for expression. Based on data from these studies, four clinical trials have been 
initiated (High 2011). The first one attempted intramuscular injection. Although gene transfer 
and expression were not prevented by the pre-existing high titer of neutralization antibodies 
against the capsid, only limited transgene expression (<2%) was achieved at the highest dose 
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used (Kay et al. 2000; Manno et al. 2003). The second trial altered targeting to the liver via 
infusion through the hepatic artery. This approach did achieve expression of therapeutic 
levels of FIX, but only transiently (~2-4 weeks). Host immune response mediated by T 
lymphocytes against the vector capsid has been suggested to clear the transduced hepatocytes 
and thus limit the efficiency of delivery (Manno et al. 2006; Mingozzi et al. 2007). Based on 
these results, a third trial has been initiated using the same strategy as the second trial, 
targeting the liver, with co-administration of immunosuppressive drugs (High 2011). Results 
of this trial have not yet been reported, but it will be interesting to see if vector transduction 
is increased as a result. More recently, Nathwani and colleagues have taken a different angle 
to evade the immune system and increase gene expression, including utilization of serotype 8 
capsid, which transduces the liver with higher efficiency and is less immunogenic than 
serotype 2 in animal models, and codon optimization of the transgene expression cassette 
(High 2011; Nathwani et al. 2011). With this strategy, therapeutic levels of FIX were 
observed (2-11% of normal) in all patients and gene expression persisted up to 16 months 
(Nathwani et al. 2011). Thus, efforts are close to a successful therapy. This evolution of 
treatment for FIX deficiency offers insight into the planning of future trials with AAV. 
Foremost, that there may be considerable flexibility in the immunogenicity and efficiency of 
transduction with capsids of different serotypes. High et al provides a more comprehensive 
perspective of gene therapy to treat this disease (High 2011). 
Neurological diseases. rAAV vectors have been used to treat several diseases 
affecting the central nervous system (CNS), including Canavan’s disease, Parkinson’s 
disease (PD), Alzheimer’s disease (AD), Batten’s disease, and Epilepsy. To date, a total of 
twelve clinical trials have been conducted, six phase I, one phase I/II, and five phase II. The 
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first of these trials targeted Canavan’s disease, a childhood form of leukodystrophy caused by 
mutations in the gene coding the enzyme aspartoacylase (ASPA). This disease causes 
irreversible brain damage and often death within the first decade of life (Leone et al. 1999). 
To treat this disease, rAAV expressing ASPA was injected intracranially into ten patients. 
This was the first attempt to deliver a rAAV vector to the CNS in humans and a considerable 
amount of data was collected to assess the safety of this approach. Importantly, no adverse 
side effects were experienced by any of the patients and host immune response to the vector 
was limited to a low level antibody response in patient serum (Janson et al. 2002; McPhee et 
al. 2006). Though data on the efficacy of treatment in this trial has not been reported, the 
safety information alone has paved the way for additional studies. Following this initial 
success, trials have been initiated for Parkinson’s disease (PD) as well (Carlsson et al. 2007). 
PD is a progressive neurodegenerative disease caused by loss of dopaminergic neurons in the 
substantia nigra and a deficiency of the neurotransmitter dopamine. It appears in 5% of the 
population over 65 years of age and the predominant symptom is progressive loss of motor 
function. Strategies to reverse this disease have focused on providing either nerve growth 
factors (NGF) to reduce neuronal death or enzymes to enhance dopamine synthesis. To date, 
five clinical trials have been initiated with rAAV carrying the gene CERE-120 (i.e. neurturin) 
or the glial derived neurotrophic factor (GDNF) (Mochizuki et al. 2003). Delivery into 
patients had minimal adverse effects and a moderate reversal in disease state was observed 
(Marks et al. 2008). In another approach, rAAV expressing the enzyme aromatic amino acid 
decarboxylase (AADC) was used with the hope of increasing dopamine synthesis in patients. 
Administration of this vector was also shown to be safe and therapeutic effect was observed 
at six months after administration (Eberling et al. 2008; Christine et al. 2009; Muramatsu et 
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al. 2010). A third strategy is infusion of the subthalamic nucleus with rAAV expressing two 
isoforms of the enzyme glutamic acid decarboxylase (GAD65 and GAD67), which are 
responsible for the production of inhibitory neurotransmitter GABA (Luo et al. 2002). The 
subthalamic nucleus (STN) region of the brain has a central role in regulating movement and 
its dis-inhibition is believed to be responsible for the hyperkinetic motor activity symptoms 
in PD patients. The hypothesis is that introduction of these enzymes will alleviate the motor 
symptom of PD (Luo et al. 2002). As a result of this treatment most patients experienced 
significant improvement in motor function through one year post treatment (Kaplitt et al. 
2007). A follow-up phase II trial with this approach is now underway. All the above results 
demonstrate the safety and long-term efficacy of rAAV for delivery into the CNS delivery. A 
more comprehensive review can be found at Weinberg et al (Weinberg et al. 2012). 
Muscular dystrophy. Building on the experience of proceeding trials, in which the 
vector capsid was shown to be a significant factor in vector transduction, strategies to treat 
muscular dystrophy have exploited capsid serotypes specific for muscle. The first of these 
trials was designed to treat limb-girdle muscular dystrophy type 2D (LGMD-2D), which is 
caused by a defect in the synthesis of -sarcoglycan. rAAV serotype 1, which transduces 
muscle with high efficiency, expressing -sarcoglycan from a muscle specific promoter was 
introduced via IM injection (Mendell et al. 2009; Mendell et al. 2010). A ~5-fold increase 
was seen in the level of -sarcoglycan and a corresponding increase in muscle fiber density 
was also observed. Gene expression was sustained in the muscle for six months. A later dose-
escalating trial for LGMD-2C used a similar approach as the first trial, IM injection of 
rAAV1 expressing -sarcoglycan, but with a different muscle specific promoter (Herson et 
al. 2012). Data from 9 patients showed a mild antibody response against rAAV1 capsid with 
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one patient developing a T-cell immune response to the capsid. In addition to LGMD-2C, 
clinical efforts have begun to treat Duchenne muscular dystrophy (DMD), an X-linked 
disease caused by mutation of the gene that encodes dystrophin (Bowles et al. 2011; Mendell 
et al. 2011). In trial, six children with DMD were given vectors by intramuscular delivery. 
This trial was the first instance in which an engineered capsid (AAV2.5), derived from 
serotypes 1 and 2, has been used. The novel capsid did not elicit a significant host immune 
response and there were no unanticipated side effects from the treatment. However, the 
therapeutic dystrophin protein did elicit an auto-reactive T-cell response in one patient 
(Mendell et al. 2011). Diprimio et al provides a more comprehensive view on this disease 
(DiPrimio et al. 2010). 
Other diseases. A number of clinical trials have been conducted using rAAV to treat 
diseases other than those described above as well, diseases such as inflammatory arthritis, 
heart disease, and metabolic diseases. Currently, there is one phase I trial to treat 
inflammatory arthritis using a vector to express a fusion protein of the human tumor necrosis 
factor-immunoglobulin Fc domain (TNFR:Fc), an antagonist of TNF- For delivery, vector 
was introduced into fifteen patients via intra-artery injection with the goal of reaching the 
joints (Mease et al. 2009). The objective of this trail was to determine safety, and though 
successful, was dosed too low to see therapeutic effect.  
Efforts to treat heart disease have targeted heart failure patients, a major cause of 
morbidity and mortality in the United States. Serotype 1 encapsidated vector containing the 
SERCA2a gene was introduced via intra-coronary injection (Hajjar et al. 2008). SERCA2a is 
a calcium regulating protein expressed in cardiomyocytes and reduced level of this protein 
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has been linked with heart failure (Lipskaia et al. 2010). Results of this study have not yet 
been reported.  
Lipoprotein lipase (LPL) deficiency, a monogenic metabolic disease leading to high 
serum triglyceride levels and pancreatitis, is another disease that may benefit from gene 
therapy. The approach in this trial was to introduce rAAV1 expressing LPL via IM injection. 
Eight patients were treated and three months after treatment average serum triglyceride levels 
were reduced by 27% and 41% in the low-dose and high-dose cohorts, respectively. Levels 
returned to baseline, however, at 18-31 months after treatment (Stroes et al. 2008). Transient 
expression in this trial may have been caused by a neutralization antibody and T-cell immune 
response against the capsid (Mingozzi et al. 2009).  
 
Challenges associated with AAV in clinic  
The clinical trials discussed above have demonstrated the safety, versatility, and 
adaptability of AAV-based gene therapy. On the other hand, they have also pointed out the 
current limitations and challenges for the future of AAV vectorology: cell/tissue specific 
targeting, efficiency of transduction, and immunogenicity. For example, in multiple trials 
(e.g. Hemophilia B and LPL) loss of gene expression occurred after only weeks and 
correlated with a T-cell immune response against the vector capsid (Manno et al. 2006; 
Stroes et al. 2008). For more detailed review on immune response to AAV vectors in clinical 
trials, please refer to Mingozzi et al (Mingozzi et al. 2011). In other trials (e.g. AAT and CF), 
though transgene expression was sustained for >1 year after delivery, the level in high-dose 
treated patients was still insufficient for therapeutic effect. Thus, more efficient vectors or 
routes of delivery are required (Flotte et al. 2011). For treatment of ocular diseases, targeting 
of specific types of cells in eye, such as retinal pigment epithelia (RPE), Müller cells, and 
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retinal ganglion cells (RGC), will require cell-type-specific vectors or promoters (Martin et 
al. 2002). 
  
Strategies for enhancing rAAV capsid 
The limitations of rAAV, learned from pre-clinical and clinical studies alike, have 
given momentum to efforts to improve this vector. Various strategies have been pursued, 
including development of novel capsids, transgene cassettes, and employment of 
pharmacological reagents to enhance gene delivery and expression. This section focuses on 
perhaps the most promising of these strategies, development of novel vector capsids to 
improve specific targeting and transduction efficiency (Table 3, Fig.I-3). The immune 
response associated with AAV vectors and potential strategies to tackle this issue have been 
extensively summarized in several most recent reviews (Bartel et al. 2011; Mingozzi et al. 
2011; Rogers et al. 2011). 
Natural serotypes. Over 100 natural serotypes of AAV have been isolated, many with 
unique properties of tropism and infectivity (Bantel-Schaal et al. 1984; Rutledge et al. 1998; 
Chao et al. 2000; Gao et al. 2002; Grimm et al. 2003; Gao et al. 2004; Mori et al. 2004; 
Pacak et al. 2006). A majority of clinical trials have been performed with rAAV encapsidated 
with serotype 2 capsid proteins largely because this serotype was the first to be isolated and 
characterized. Information about the transduction profiles of other serotypes is only 
beginning to come to light. New serotypes 1, 4, 5, 6, 7, 8, and 9 have been tested or are 
currently in testing with pre-clinical or clinical studies. rAAV1 shows high level of 
transduction of muscle tissues and has been used for intramuscular injection to treat AAT-
deficiency and several cardiac/skeletal muscular diseases (Lu et al. 2006; Flotte et al. 2007; 
Hajjar et al. 2008; Brantly et al. 2009; Mendell et al. 2009; Herson et al. 2012). This serotype 
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has also been shown to have specificity for transducing non-neuronal cells in the retina. 
Alternatively, serotypes 4 and 5, though not tropic for muscle, have a greater specificity for 
transduction of the eye, specifically the retinal pigment epithelium (RPE), than 1 or other 
serotypes (Martin et al. 2002). rAAV5 is currently the most efficient for transduction of 
photoreceptor cells in the eye (Sun et al. 2010). Serotype 6 capsid has been shown to be 
efficient at transducing human airway epithelium cultures (Limberis et al. 2008). Based on 
these results, rAAV6 is currently in phase I clinical trial to deliver the human placental 
alkaline phosphatase gene to the upper airway in cystic fibrosis patients. Serotype 7 
transduces muscle as efficient as AAV1, the most efficient serotype for muscle transduction 
identified so far (Gao et al. 2002).Serotype 8 displays ~100-fold higher transduction of the 
liver than serotype 2 and other serotypes (Gao et al. 2002; Cooper et al. 2009). rAAV8 is 
being used extensively in pre-clinical trials and has gone into patients to treat Hemophilia B 
(Nathwani et al. 2011). Serotypes 8 and 9 can also transduce myocardium much more 
efficiently (20-fold and 200-fold, respectively) than AAV1 (Pacak et al. 2006). In fact, 
AAV9 appears to be superior to other serotypes in a majority of tissues tested (Gao et al. 
2004). A brief summary of AAV serotypes 1-9 is provided in Table 3. 
Mutagenesis-based directed evolution. Directed evolution is a powerful tool to 
select for novel properties or to enhance pre-existing functions of the vector capsid. This 
process enriches for capsids able to succeed in the context of a designed selective pressure. 
Three steps are required to perform directed evolution: 1) Diversification; 2) Function-based 
selection; 3) Recovery. Diversification can be achieved by creating a large library of variants 
via randomized mutation or recombination. Function-based selection requires development 
of specific conditions of transduction that filter out vectors that do not have the desired 
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Table 3. Summary of AAV serotypes 1-9 
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property. Recovery is accomplished by subsequently amplifying the capsid variants that were 
successful. One of the first attempts to use this approach created a mutant capsid library 
(~10^6-10^7 variants) by error-prone PCR. For a function-based selection, the library was 
incubated with rabbit or human anti-AAV2 sera and transduced onto 293T or Hela cells, 
respectively (Maheshri et al. 2006; Perabo et al. 2006). This yielded two distinct groups of 
capsid variants, both with reduced reactivity with antibodies against serotype 2 (Maheshri et 
al. 2006; Perabo et al. 2006). A later design shuffled the Cap gene sequence among several 
natural serotypes in combination with error-prone PCR to create a potentially more diverse 
library (Grimm et al. 2008; Koerber et al. 2008; Li et al. 2008). Shuffling was performed 
between human serotypes 2, 4, 5, 8, and 9 along with avian, bovine, and caprine capsids. The 
resulting library was selected for transduction of human hepatocytes in the presence of 
human sera. A chimeric capsid of serotypes 2/8/9, AAV-DJ, was recovered (Grimm et al. 
2008). This variant was shown to have higher efficiency of transduction than parent 
serotypes in several different tissues and transduced mouse liver much more efficiently than 
serotype 2.  
The power of these biopanning studies is compromised, however, by the intrinsic bias 
associated with the method of selection, in these cases cultured cells. Cultured cells do not 
accurately reflect the obstacles to a vectors success in vivo, including inactivation by 
neutralizing antibodies, altered binding specificity in the sera, and physical barriers (e.g. 
endothelial cell layers and extracellular matrix) (Mingozzi et al. 2007; Asokan et al. 2010). 
To avoid this bias, two groups have adapted directed evolution to more relevant in vivo 
settings (Gray et al. 2009; Yang et al. 2009). In a screen of a library of capsids generated by 
shuffling serotypes 1-9 for muscle-tropic variants, Yang et al. recovered a heart-tropic vector 
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(AAVM41) with similar transduction efficiency to AAV9 in cardiac-muscle, but de-targeted 
from the liver and other tissues (Yang et al. 2009). Gray et al. also employed selection of a 
chimeric capsid library in the CNS of rats whose blood brain barrier (BBB) was 
compromised by kanic acid-induced seizure. Following recovery, a chimera (clone83) was 
obtained that efficiently transduces neurons and oligodendrocytes, while being de-targeted 
for most other tissues (Gray et al. 2009). 
Directed evolution has proven to be a very efficient approach for generating novel 
vector capsids with enhanced transduction efficiency for specific tissues. This strategy may 
provide a way to advance clinical approaches otherwise limited by the tissue tropisms of 
parental rAAV vectors. For example, therapy for cystic fibrosis (CF) has been hindered by 
the low efficiency with which rAAV transduces the airway epithelium. Using a directed 
evolution approach, two groups were able to generate several AAV chimeras, which display 
significantly higher transduction of the apical airway compared with its parental serotypes 
(Excoffon et al. 2009; Li et al. 2009). Efforts using this method are ongoing and will likely 
make a significant contribution to AAV-based gene therapy in the future. 
As an alternative to mutagenesis-based approach, directed evolution can also be 
applied using a peptide-insertion-based library to select for cell targeting properties. This 
approach, termed biopanning, has been applied to capsid libraries created by inserting 
peptides that have been randomized for sequence and size. The site of insertion was chosen 
to disrupt heparin-binding activity of the parent serotype in an effort to minimize binding to 
this receptor. Once the library is applied to target cells, only capsids capable of transduction 
will be recovered. In this way, capsids with specific tropism for myeloid, lymphoid leukemia, 
coronary endothelial, and other cell types have been developed (Muller et al. 2003; Perabo et 
 30 
al. 2003; Waterkamp et al. 2006; Michelfelder et al. 2007). Similar approaches have also 
been used to select for vectors that survive circulation in vivo, where selective pressures more 
closely reflect those in patients (Michelfelder et al. 2007; Grimm et al. 2008; Michelfelder et 
al. 2009).  
Rational design. For AAV vector, rational design is an engineering method to make 
artificial capsids with enhanced performance in gene delivery based on current understanding 
of AAV or other related materials’ properties. To date, rational design of vector capsids has 
been used to enhance tissue-specific targeting, reduce non-specific targeting, and improve 
vector production (Zhang et al. 2002; Zhong et al. 2008; Petrs-Silva et al. 2009; Asokan et al. 
2010; Bowles et al. 2011). Currently used strategies for rational design are illustrated as in 
figure I-3.  
Rational design by mosaic capsid. Mosaic capsid engineering is a process of 
creating vectors with capsids made up of protein subunits from more than one serotype of 
AAV. In this technique, plasmids encoding capsid subunits of each serotype are mixed in 
specific ratios to achieve a desired proportion in the resulting mosaic capsid. Several studies 
have demonstrated the utility of this approach. Hauck et al. engineered several vectors using 
AAV1 and AAV2 capsid proteins in ratios of 9:1, 1:1, and 1:9 (Hauck et al. 2003). All of the 
resulting mutants exhibited transduction profiles with attributes from both parental serotypes, 
with efficient transduction of muscle (AAV1) and liver (AAV2). Similarly, Rabinowitz et al. 
carried out pair-wise combinations of AAV serotypes 1-5 at various ratios (Rabinowitz et al. 
2004). One resulting mutant, AAV3/5, inherited the receptor binding profiles from both 
parent serotypes, heparin and mucin (Rabinowitz et al. 2004). Interestingly, inclusion of 
AAV5 capsid at levels as low as 10% was sufficient to confer mucin binding on mosaic 
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capsids AAV1/5, 2/5, or 3/5. In contrast, inclusion of AAV2 capsid as high as 75% was 
unable to make AAV2/5 bind to heparin. This phenomenon may be a result of binding 
affinities of those two capsids for their respective receptors, but this remains to be shown.  
Rational design by peptide insertion. Peptides with specific cell binding properties, 
when inserting onto the surface of the vector, can alter the cell specificity of rAAV. It has 
been determined that the N-terminus of VP2 tolerates insertion of peptide sequences without 
disrupting capsid structure or vector production. Initially this was tested by insertion of 
peptides with known receptor binding properties or identified to bind specific targets in 
phage-display assays. Based on use of well-characterized peptides, insertion of the 14 amino-
acid peptide L14 re-targeted vector to cells expressing integrin receptor, which were 
otherwise resistant to rAAV transduction (Girod et al. 1999). Similarly, insertion of the 
ligands for the serpin receptor or the luteinizing hormone receptor directed rAAV to lung 
epithelia and ovarian cancer cells, respectively (Wu et al. 2000; Shi et al. 2001). 
Alternatively, insertion of peptides identified by phage display has been used to generate 
tropism for CD13- and integrin-expressing cells, endothelial cells, brain, lung, and muscle 
tissues (Grifman et al. 2001; Nicklin et al. 2001; Shi et al. 2003; White et al. 2004; Work et 
al. 2006; White et al. 2008; Yu et al. 2009).  
Despite numerous successes in retargeting rAAV by peptide insertion, it has proven difficult 
to eliminate the natural broad tropism of some serotypes, such as AAV2. Boucas et al. have 
found a solution to this problem by mutating the heparin binding motif (Boucas et al. 2009). 
However, modification of the heparin binding motif may not be sufficient to eliminate non-
specific cell transduction, given the evidence that vectors selected for specificity to tumor or 
lung cells by insertion of targeting peptides at heparin binding sites transduced a number of 
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other tissues, including the heart (Michelfelder et al. 2009). This indicates that additional 
binding motifs exist on the capsid surface and contribute to the virus’s natural tropism. 
Rational design by site mutation or domain swap. Functional analysis and 
mutagenesis studies have mapped several conserved structural determinants on the AAV 
capsid (Girod et al. 1999; Kern et al. 2003; Opie et al. 2003; Bleker et al. 2005; Wu et al. 
2006; DiPrimio et al. 2008). This information, together with crystal and cryo-EM structural 
data, has opened the door to the design of capsid based on the relationship among sequence, 
structure, and function (Kronenberg et al. 2001; Kaludov et al. 2003; Walters et al. 2004; 
Miller et al. 2006; Nam et al. 2007; Quesada et al. 2007; Lerch et al. 2009; Mitchell et al. 
2009; O'Donnell et al. 2009). In this manner, Bowles et al. identified five amino acids on the 
AAV1 capsid that appear to be responsible for transduction of skeletal muscle and 
incorporated these into serotype 2 in an attempt to redirect the specificity of this capsid 
(Bowles et al. 2011). While has properties in common with both parental serotypes, the 
derived mutant, AAV2.5, displays high level transduction in skeletal muscle and lower 
reactivity to neutralizing antibodies specific for serotype 2. The increasing knowledge of the 
structure of AAV capsids gives insight into the physical aspects of AAV biology, but also 
provides a template with which to model specific capsid alterations and predict their impact 
(Xie et al. 2002; Nam et al. 2007). Asokan et al. identified and replaced a positively charged 
patch of amino acids (585-590) on the serotype 2 capsid, a surface loop known for its 
interaction with heparin sulfate, with the corresponding region of serotype 8, a serotype with 
highly efficient systemic transduction (Asokan et al. 2010). The resulting capsid (AAV2i8) 
exhibited significantly reduced (by a factor of 40) tropism for the liver and increased 
transduction in muscle cells compared with AAV2. These results support the notion that  
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Figure I-3. Illustration for capsid rational design. (A) A pentamer of AAV capsid subunit. 
(B) Rational design by peptide insertion: Novel AAV variants with insertion of specific 
targeting ligand/peptide through strategy “peptide insertion”. Both insertion at N-terminus of 
VP2 and receptor binding sites have been utilized for this strategy. (C) Rational design by 
mutations: Novel AAV variants with single or multiple site mutations and/or domain swaps 
through strategies including “mutagenesis based directed evolution” and “rational design by 
site mutation or domain swap”. (D) Rational design by mosaic capsid: Novel AAV variants 
composed of heterogeneous capsid subunits from two or more different types of AAV. This 
strategy may equip the novel AAV capsid with the desired traits of its parental serotypes.  
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rational design can be used to derive new vectors well suited to clinical applications in gene 
therapy. 
The use of AAV-based vectors continues to increase compared to other viral and non-
viral gene transfer systems in clinical trials. Due to its unique properties, the ability to 
transduce a broad spectrum of dividing or non-dividing cells, low immunogenicity, and 
sustained gene expression, this vector is well suited to most gene therapy applications. The 
potential to treat human monogenic disorders has been demonstrated with recent successes in 
clinical trials for LCA and Hemophilia B. However, there is still a great need for 
improvement in the specificity and efficiency of gene delivery. In the last decade, significant 
advancement has been achieved with various methods of rAAV engineering to address these 
challenges. Increasing knowledge of AAV trafficking promises to extend strategies of capsid 
design to these processes of transduction as well (Johnson et al. 2008; Xiao et al. 2011; 
Kaminsky et al. 2012). In addition, our increased understanding of the interactions between 
AAV and the host immune system will allow further reduction of vector immunogenicity 
(Mingozzi et al. 2007; Bartel et al. 2011; Mingozzi et al. 2011; Rogers et al. 2011).  
It is my personal prediction that rational design will be the most promising strategy 
for vector development and in the future clinical trials will include novel rAAV capsids from 
rational design to evade the host immune system and transduce target tissues with greater 
specificity and efficiency. However, it should be noted that our capacity to create new AAV 
vector through rational design is highly dependent on the knowledge regarding how each 
capsid motif functions in and interacts with host cells during viral transduction. To this end, 
intensive investigation to acquire sufficient knowledge on AAV and host interaction is 
critical and essential for further development of this vector. 
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Subcellular events during AAV infection 
 
Despite many advances in vector developments, administration of high dose viral 
particles is required to achieve efficient transduction due to rate-limiting steps including pre-
existing immune response and non-specific targeting (Rogers et al. 2011). In addition to 
these limitations, host cells also exploit various cellular components as barriers to AAV 
productive infection, including the critical steps required for viral trafficking (e.g. cell 
surface uptake, cytoplasmic trafficking, endosomal escape, nuclear entry, etc.) (Wang et al. 
2011). Better understanding of the AAV cellular trafficking will advance our knowledge in 
AAV biology and facilitate the development of enhanced AAV vectors. 
To successfully transduce a cell, AAV virions have to travel through a variety of cellular 
structures and organelles consecutively, including cell surface binding and internalization, 
cytoplasmic trafficking, and finally nuclear entry. Like many other viruses, AAV have found 
a way to exploit host machineries for nuclear targeting to fulfill their own life cycle. Current 
understanding of the AAV life cycle is derived primarily from the studies of serotype 2 
(AAV2). Though many aspects are conserved among all serotypes, there are differences that 
make each of them unique. The life cycle of AAV2 begins with docking to the host cell via 
interaction between viral capsid and heparin sulfate proteoglycan (HSPG) on the cell surface 
(Summerford et al. 1998). Entry of the cell involves the contribution of secondary receptors 
in addition to HSPG. Integrins and FGF receptors have both been identified to act as co-
receptors for viral attachment and subsequent internalization (Qing et al. 1999; Summerford 
et al. 1999; Kaminsky et al. 2012). Internalization of the virus occurs via clathrin-mediated 
endocytosis (Summerford et al. 1998) as well as a clathrin independent route as suggested by 
a recent report (Nonnenmacher et al. 2011). The virus traffics through a variety of endosomal 
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compartments until acidification of the compartment triggers exposure of the amino-terminus 
of VP1 (Ding et al. 2005). It is suggested that the N-termini of VP1 and VP2 initially reside 
inside the capsid and are exposed on the surface in the acidic environment of the endosome 
(Bleker et al. 2005; Kronenberg et al. 2005), which allows virions to escape from these 
vesicles (Fig.I-4). It is believed that the N-terminus of VP1 carries phospholipase activity and 
facilitates the escape of the viral particle by breaking down the endosome membrane (Girod 
et al. 2002). This endosomal processing of AAV is required for successful infection 
(Vihinen-Ranta et al. 1998; Ding et al. 2005).  
The N-termini of VPs are suggested to be very important for virus-host interactions. 
For instance, two functional elements of the capsid, a phospholipase A2 (PLA2) domain and 
several putative nuclear localization signals (NLSs), have been identified in that region. Most 
parvoviruses contain a motif of ~70 amino acids in VP1 highly homologous to the catalytic 
domain of PLA2, which is comprised of histidine and aspartic acid residues (75HD) (Zadori 
et al. 2001). Mutation of these residues to alanine and asparagine (75HD/AN) does not affect 
cell surface attachment or endocytosis, but strongly inhibits PLA2 activity and viral 
infectivity (Zadori et al. 2001). PLA2 activity is proposed to penetrate the endosomal 
membrane to permit the escape of AAV into the cytosol.   
After endosomal escape, its genome is required to be delivered into the nucleus of the 
host cell. Typically, macromolecular traversing the nuclear envelope is an ATP-dependent 
event and is accomplished by the cooperation between cytoplasmic factors like Ran-1 and 
specific NLSs on target proteins (Nigg 1997; Gorlich et al. 1999). NLSs have been identified 
on N-terminus of VP1 from various parvoviruses and are integral to nuclear targeting 
(Vihinen-Ranta et al. 1997; Lombardo et al. 2000; Lombardo et al. 2002).  While the first 10 
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Figure I-4. Exposure of VP1/2 N-termini through the 5-fold pore.  A) An equatorial slice 
of the capsid atomic model with 2-, 3-, and 5-fold axes of symmetry. B) 3D reconstruction of 
a portion of the AAV2 capsid where the unique N-terminus of VP1 is predicted to fold. C) 
Partial unfolding of VP1 after a capsid conformational change allows its exposure through a 
channel at a 5-fold axis.  D) A model of VP1up exposure through the 5-fold axis (residues 1 
to 185 become accessible). (Adapted from Kronenberg et al., 2005) 
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residues of VP1 in CPV and many other parvoviruses is a canonical NLS (Vihinen-Ranta et 
al. 1997), several conserved, hydrophilic, basic regions have been identified in AAV2 as 
potential NLSs, named BR1 (
120
QAKKR), BR2 (
140
PGKKR), and BR3 (
168
PARKR) (Wu et 
al. 2000). Interestingly, one study shows that MVM is able to disrupt the nuclear envelope 
during infection, suggesting an alternative mechanism for the nuclear entry of parvovirus that 
PLA2 domain may also act at the nuclear membrane, in addition to the endosomal membrane 
(Cohen et al. 2006).  
Upon reaching the nucleus, the virion must uncoat, while the details of this event and 
underlying mechanism are not well understood. It is unclear whether virion uncoating occurs 
prior to nuclear entry, concomitant with nuclear entry, or inside the nucleus. Intact capsids 
have been found to enter the nucleus, but whether the capsid disassembles completely or 
partially to release the genome and if this process is active or passive remain to be 
determined (Xiao et al. 2002; Grieger et al. 2006). The details of cellular trafficking of AAV 
are illustrated in figure I-5. More detailed information regarding the AAV trafficking may be 
found in two most recent reviews (Wang et al. 2011; Nonnenmacher et al. 2012).  
Once the genome is released from the capsid, second-strand synthesis initiates from 
the 3’ ITR. The secondary structure of the ITR is critical for this priming event as it positions 
the 3’ end of single-stranded genome to act as the primer for the second strand. The resulting 
double-stranded molecule can then serve as the template for gene expression. In the absence 
of helper virus, AAV enters a state of latency (Samulski et al. 1991). In this state, viral gene 
expression is repressed and the genome persists episomally (Giraud et al. 1995). In the 
presence of Rep proteins, AAV DNA can integrate into a specific site in the human genome 
(chromosome 19), which shares homology with the ITR sequence and can be bound by the 
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Rep proteins (Kotin et al. 1992; Miller et al. 2005; Nakai et al. 2005). The episome scenario 
of AAV is exploited by gene therapy. 
 
Microscopy as a method to study viral trafficking 
 
Therapeutic gene delivery is becoming one of the major strategies to improve human 
health. For example, both viral and non-viral vectors (e.g. adenovirus, AAV), liposomes and 
nanospheres) have recently been engineered to transfer therapeutic agents in an effort to treat 
human diseases (Warrington et al. 2006; Rissanen et al. 2007). Encapsulation of the 
intracellularly-acting materials (i.e. nucleotides, proteins) into specialized delivery vehicles 
(i.e. viral capsids, nanospheres) that can deliver these agents to specific organelle in a 
controlled manner is critical to achieve efficient and selective pharmacological effects 
(Torchilin 2006; Breunig et al. 2008). To accomplish such functions, these vectors have to 
partially or fully pass through a biological jungle, which is mainly a multi-step trafficking 
process from cell surface binding to nuclear entry (Bartlett et al. 2000; Brandenburg et al. 
2007). As a result, development of therapeutic delivery vectors has concentrated on 
pharmacological reagents and vector variants that affect these pathways (Duan et al. 2000; 
Maheshri et al. 2006; Asokan et al. 2009; Yang et al. 2009). Effective achievement of such 
efforts requires quantitatively evaluating the biological effect(s) of those reagents or vector 
variants on these complex trafficking routes and bio-distribution of delivery vehicles.  
Several sophisticated fluorescence microscopy techniques including confocal and 
total internal reflection fluorescence (TIRF) microscopy have dramatically advanced our 
knowledge on the trafficking of viruses in cultured cells during the past decades (Ding et al. 
2006; Schelhaas et al. 2008; Vaughan et al. 2009). For instance, confocal microscopy with 
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Figure I-5. AAV trafficking scheme. Binding and internalization: AAV virions attaches to 
the cell surface and then are internalized through endocytosis. After binding to the heparan 
sulfate proteoglycan (HSPG) on cell surface, AAV2 interacts with cell surface receptors (i.e. 
integrin and FGFR) and internalized through clathrin-mediated endocytosis. AAV5 has also 
been shown to utilize caveolae, and recently AAV2 has been also shown to use an 
endocytosis pathway independent of clathrin and caveolin. Endosomal trafficking and 
escape: AAV2 has been shown to utilize multiple types of endosome (i.e. early/recycling/late 
endosomes) for its intracellular trafficking. Endosomal escape is typically assisted by the 
exposure of N-terminus of VP1 on capsid triggered by the acidification of endosomes. It is 
currently still debatable whether the viral particles escape at the stage of late endosome or at 
an earlier one, both of which have been supported by previous studies. Viral degradation and 
capsid antigen presentation: Proteasomes have been shown to be the major machinery for 
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AAV degradation. Proteasome inhibitors can dramatically enhance AAV transduction. It is 
currently not clear if the capsid antigen presentation is mediated by lysosomal degradation or 
proteasome degradation. Nuclear entry and genome uncoating: Nuclear entry of viral genome 
is regarded as an essential event for successful AAV transduction. Currently, it remains 
unclear whether nuclear entry is through the nuclear pore complex or other routes. It is also 
unknown when, where and how genome uncoating takes place.    
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the assistance of 2D co-localization assay helped to demonstrate that AAV2 differentially 
traffics through late and recycling endosomes in a dose dependent manner (Ding et al. 2006), 
while TIRF microscopy assisted live cell imaging helped to show that actin disruption drugs 
could block the retrograde flow of Human papillomavirus on cell surface (Schelhaas et al. 
2008).  
Despite advances of 2D imaging and analysis (Seisenberger et al. 2001; Akita et al. 
2004; Grieger et al. 2006), to date there is no method available to quantify the number and 
bio-distribution of nano-scaled viral particles in animal cells and tissues, which is essential in 
evaluating the effects of pharmacological reagents and viral vector variants on nanoparticle 
delivery. For example, many viral vectors have high particle-to-plaque forming unit (pfu) 
ratios, requiring hundreds to thousands of virions to successfully infect a single cell. This 
strongly suggests: 1) virions may take several different pathways during infection; 2) most 
viral entry and trafficking events may be futile (Brandenburg et al. 2007; Johnson et al. 
2008), 3) a significant number of the particles are defective or not assembled properly 
(Zeltner et al. 2010). Before one can distinguish productive events from non-productive ones, 
it is essential to sample the entire population of intracellular viral particles without bias. 
Analysis of 2D images, utilized by current microscopy approaches, is not unbiased because it 
only samples one focal plane of viral particles within infected cells. In addition, each labeled 
particle is displayed as a discrete and intact multi-voxel fluorescent spot, and the distribution 
of particles in cells varies on each focal plane along the z-axis. 2D image from any focal 
plane selected for quantification is arbitrary, therefore classical pixel-by-pixel co-localization 
analysis is not suitable to examine intracellular distribution of viral particles that actually 
exist in 3D. Finally, current centroid-counting method fails to quantitate viral particles in 
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cells because of the fact that particles may aggregate or move into a sub-resolutional region 
like vesicles to give a single fluorescent spot, which is common for nanoparticle trafficking. 
As a result, no method to date is available for quantitatively determining the bio-distribution 
of nano-scaled vectors in three dimensions (such as outside or inside nucleus, or traversing 
nuclear membrane).  
In Chapter-2, based on recent advances with computational image processing 
(Sedarat et al. 2004; Feng et al. 2007), we developed a sensitive and reliable methodology by 
integrating single particle imaging and 3D quantification into classical immunofluorescence 
to quantitate the trafficking kinetics and bio-distribution of nanoparticles in three 
dimensional animal cells and tissues. Using Cy5-labeled AAV as a working model, we 
quantitatively investigated the nuclear entry kinetics and bio-distribution of AAV2 in human 
cells and mouse tissues. This study demonstrates the potential of this methodology in 
screening pharmacological reagents and vector variants for the development of therapeutic-
material delivery strategies, as well as in understanding the intracellular behavior of delivery 
viral vectors in vitro and in vivo.  
 
Microtubules in viral trafficking 
 
Microtubules (MTs) are a component of cytoskeleton and are rope-like polymers of 
tubulins. MTs are highly dynamic as characterized by alternate phases of elongation and 
shrinkage, and play critical roles in a variety of cellular processes including maintaining cell 
structure, intracellular transportation, forming the spindle during mitosis, to name a few 
(Desai et al. 1997). Their roles in intracellular transport are usually achieved by either their 
own growth dynamics (Roohvand et al. 2009) or the activities of associated motor proteins, 
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particularly kinesin and dynein (Leopold et al. 2006). MTs forms a radial filamentous 
network with minus end anchored at a perinuclear site and plus end reaching cell surface 
area. This structural architecture of MTs allows the shuttling of intracellular molecules and 
vesicles between peri-nuclear region and other areas of a cell (Giannakakou et al. 2000; 
Niklinski et al. 2000) (Fig. I-6). For instance, intact MTs are required for the nuclear import 
of several transcription factors (e.g. p53, NF-kB, pRb) and on other hand, these structures are 
required to sequester other proteins (e.g. c-myc, MIZ-1, smad3) in the cytoplasm to block 
their nuclear entry (Giannakakou et al. 2000; Niklinski et al. 2000; Ziegelbauer et al. 2001; 
Roth et al. 2007; Gong et al. 2011). 
Pathogens, especially DNA viruses (i.e. Ad, HSV, Baculovirus), hijack MT system to 
traverse dense cytoplasm and reach nucleus for their successful infection. Numerous studies 
have shown that both non-enveloped and enveloped viruses utilize MTs in infecting their 
host cells (Fig.I-6). This is typically exemplified by the utilization of dynein by viral particles 
to traffic through the crowded cytoplasmic environment to the nucleus, which is achieved in 
two ways: 1) virion itself binds to the MTs or MT-associated motors and then migrates on the 
MTs; 2) virions stay inside of membraneous endocytic vesicles that bind to and migrate on 
the MTs. AAV’s helper viruses, both Ad and HSV, have to escape from the endosomes 
before trafficking on MTs. Both viruses can directly interact with both minus-end-directed 
and plus-end-directed MT motor proteins, allowing the bi-directional motions documented 
for both Ad and HSV on these filaments (Dodding et al. 2011; Engelke et al. 2011; Radtke et 
al. 2011). As these viruses escape from endosomes at an early stage, the infection of these 
viruses is not sensitive to the inhibition of endosomal acidification by Bafilomycin or 
Chloroquine as early as 20-30 minutes after viral inoculation (Greber et al. 1993). In contrast, 
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influenza virus migrates on the MTs towards the perinuclear region while staying inside of 
the endocytic vesicles (Lakadamyali, Rust et al. 2003). Acidification of endosomes is 
essential for escape of influenza virus from vesicles into cytoplasm, which can be blocked by 
Bafilomycin and Chloroquine. 
For AAV, previous studies have reported that MT disruption impairs AAV 
transduction (Sanlioglu et al. 2000) and AAV can bind the cytoplasmic dynein in an in vitro 
binding assay (Kelkar et al. 2006). However, these studies were contrasted by another 
publication suggesting AAV transduction was not affected by the disrupted MT network or 
dynein motor activity (Hirosue et al. 2007). Additionally, it remains controversial whether 
AAV escapes from endosomes at early or late stage. As a result, the exact roles of MTs and 
endosomes on AAV transduction as well as the underling mechanisms are yet unclear.  
In chapter 3, we have investigated the exact role(s) of MTs on AAV transduction and 
corresponding potential mechanisms using multiple techniques including confocal 
microscopy, live cell imaging, quantitative 3D microscopy, pharmacological reagents, and 
single particle tracking. Moreover, we also determine for the first time that AAV2 traffics on 
MTs in endosomal compartment and acidification of such structure is dependent on intact 
MTs. This study strongly supports an as yet undocumented model in which AAV2 exploits 
MTs for its rapid-directed cytoplasmic transportation towards the peri-nuclear sites where 
acidification of endosomes for viral escape takes place.   
 
Overcome cellular barriers: momentum of vector development 
 
Cells have many structures and machineries to protect themselves from exogenous 
infectious agents (e.g. viruses, bacteria etc.). For example, the plasma membrane is the first 
structure to restrict viral infection, and molecularly dense cytoplasm and the nuclear 
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Figure I-6. MT mediated trafficking of cellular factors and viruses. Cellular materials 
like vesicles (route-1), proteins, and misfolded proteins (route-2) are transported on MTs. 
Viruses inside endocytic vesicles (route-3 and 5) or by itself (route-4) can also migrate on 
MTs.  
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envelope sever as additional barriers for viruses to reach their replication sites. As a 
consequence, viruses have to overcome these cellular barriers in host cells before delivering 
their genome to the target region for successful infection. Like many other viruses, AAV 
employs receptor-mediated endocytosis to penetrate the plasma membrane of host cells. 
Although not clear for AAV yet, many viruses exploit MTs as an effective strategy to 
traverse the crowded cytoplasm in order to deliver their genetic materials to the replication 
sites as discuss above. Moreover, like most DNA viruses, it is critical for AAV to deposit its 
genome in the nucleus. Typically there are three possible mechanisms for viruses to shuttle 
their genomes into the nucleus. The first mechanism, as exemplified by polyomavirus 
infection, is importing DNA into the nucleus through an intact virion, followed by intra-
nuclear capsid uncoating and genome release (Whittaker et al. 2000). The second approach, 
as demonstrated by Herpes-simplex-virus (HSV) and Adenovirus (Ad), involves pre-steps of 
capsid uncoating before the viral genome itself is imported into the nucleus (Greber et al. 
1997; Ojala et al. 2000). These two nuclear entry approaches are typically mediated by 
nuclear pore complex (NPC) on the nuclear envelope. Finally, as exemplified by retrovirus 
infection, some viruses utilize mitosis to import DNA into the nucleus. This presents a 
unique situation where the virus takes advantage of the breakdown of the nuclear envelope 
during the cell cycle.  
Comprehensive knowledge in these barriers and virus-host interactions are critical to 
improve our understanding of basic virology and viral pathogenesis. Either strengthening 
these cellular barriers or weakening the viral capacity to penetrate these barriers presents 
potentially powerful means for inhibition of viral infection. On the other hand, attenuating 
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these barriers or designing capsid with enhanced ability to penetrate these barriers will offer 
promising opportunities to improve current vectors for gene therapy.   
It has been documented that AAV2 enters the nucleus as an intact particle. Studies 
using nuclear injection of AAV monoclonal antibody (A20) can block viral transduction 
(Xiao et al. 2002; Sonntag et al. 2006). Sonntag and colleagues further demonstrated that 
most AAV genomes, unlike other parvoviruses such as MVM, are shuttled into nucleus by 
intact virions and subsequently uncoated there (Sonntag et al. 2006). Several nuclear 
localization signal (NLS) motifs including BR1-4 have been identified across the entire AAV 
capsid proteins VP1, VP2 and VP3. BR1-3 motifs at the N-terminus of VP1 protein have 
been shown to be critical for the nuclear targeting of post-entry virions (Grieger et al. 2006). 
Although some of these motifs have sufficient NLS activity to allow a protein to penetrate 
the nuclear envelope into the nucleus, the nuclear entry of AAV virions has been noted to be 
highly inefficient (Lux et al. 2005; Grieger et al. 2006; Sonntag et al. 2006; Xiao et al. 2011). 
These findings suggest that there may be another barrier besides nuclear envelope that limits 
the nuclear entry of AAV and successful transduction. 
The Microtubule-Organization-Center (MTOC) is a subcellular structure at 
perinuclear region, from which microtubules (MTs) are nucleated to form a radial 
filamentous network with minus ends anchored at MTOC and plus end reaching cell surface 
area. Due to these features, MTs and MTOC coordinate, as a trafficking center, the transport 
of intracellular machineries between the perinuclear region and other areas of a cell (Fig. I-
6). Numerous studies have shown that cellular misfolded proteins are also transported on the 
MTs towards MTOC region, where these misfolded proteins are sequestered or degraded by 
proteasomes and lysosomes at this region (Garcia-Mata et al. 2002; Wileman 2007).  
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Strikingly, during the early stage of infection, many incoming viruses are also 
delivered to and retained at a perinuclear site after entering the cells (Sodeik et al. 1997; 
Dohner et al. 2002; Suikkanen et al. 2002; Mani et al. 2006; Yea et al. 2007; Boisvert et al. 
2010; Liu et al. 2012). This perinuclear site has been suggested to be co-localized with the 
MTOC region and as observed for cellular proteins, transport of these viruses is facilitated by 
dynein motors and transport along MTs (Fackler et al. 2006; Greber et al. 2006; Wileman 
2007). Although this perinuclear retention of incoming virions seems to be a common 
phenomenon among many viruses, especially those that enter the nucleus, it remains unclear 
whether this accumulation is beneficial or inhibitory to viral infection (Wileman 2007). 
In chapter 4, we have employed several recombinant viral vectors to investigate the 
role of perinuclear retention on the infection of both enveloped and non-enveloped viruses, 
and have further explored the detailed mechanism using Adeno-associated virus (AAV) as a 
model system. This study for the first time experimentally demonstrates that perinuclear 
accumulation of incoming virions at the MTOC is a barrier limiting infection of most nuclear 
viruses and more specifically restricting the nuclear entry of AAV, defining a novel defense 
mechanism by which host cells restrain viral invasion. 
  
CHAPTER 2 
 
QUANTITATIVE 3D TRACING OF GENE-DELIVERY VIRAL VECTORS IN 
HUMAN CELLS AND ANIMAL TISSUES 
 
Summary 
 
Trafficking through a variety of cellular structures and organelles is essential for the 
interaction between gene delivery vectors (i.e. Adeno-associated Virus (AAV), Adenovirus, 
and liposomes) and host cells/tissues. Here we present a method of computer-assisted 
quantitative 3D bio-distribution microscopy that samples the whole population of 
fluorescently-labeled vectors and document their trafficking routes through cells and tissues. 
Using adeno-associated virus (AAV) as a working model, we first experimentally defined 
numerical parameters for the singularity of Cy5-labeled particles in a cellular environment by 
combining confocal microscopy and atomic force microscopy (AFM). We then developed a 
robust approach that integrates single-particle fluorescence imaging with 3D deconvolution 
and isosurface rendering to quantitate viral distribution and trafficking in human cells as well 
as animal tissues at the single particle level. Using this quantitative method, we uncovered an 
as yet uncharacterized rate-limiting step during viral cell entry, while delineating nuclear 
accumulation of virions during the first 8hrs post-infection. Further, our studies revealed for 
the first time that following intramuscular injection, AAV spread progressively across muscle 
tissues through endomysium between myofibers instead of traversing through target cells. 
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Such three-dimensional resolution and quantitative dissection of vector-host interactions at 
the subcellular level should significantly enhance our ability to resolve trafficking 
mechanisms of gene-delivery particles, and facilitate the development of novel viral vectors. 
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Introduction 
 
Therapeutic gene delivery is becoming one of the major strategies to improve human 
health. For example, both viral and non-viral vectors (e.g. adenovirus, adeno-associated 
virus(AAV), liposomes and nanospheres) have recently been adapted to deliver therapeutic 
agents in an endeavor to treat human disorders(Warrington et al. 2006; Rissanen et al. 2007). 
Encapsulation of the intracellularly-acting materials (i.e. nucleotides, proteins) into 
specialized delivery vehicles (i.e. viral capsids, nanospheres) that can deliver these agents to 
specific organelle in a controlled fashion is critical to attain efficient and selective 
pharmacological effects (Torchilin 2006; Breunig et al. 2008). To achieve such functions, 
these vectors have to partially or fully transverse a biological maze, which is mainly a multi-
step trafficking process from cell surface binding to nuclear entry(Bartlett et al. 2000; 
Brandenburg et al. 2007). Consequently, development of therapeutic delivery vectors has 
concentrated on pharmacological reagents and vector variants that affect these 
pathways(Duan et al. 2000; Maheshri et al. 2006; Asokan et al. 2009; Yang et al. 2009). 
Effective achievement of such efforts requires quantitatively evaluating the biological 
effect(s) of those reagents or vector variants on these complex trafficking routes and bio-
distribution of delivery vehicles.  
During the past decades, several sophisticated fluorescence microscopy techniques 
including confocal and total internal reflection fluorescence (TIRF) microscopy have 
revolutionized our knowledge of specific viral trafficking events in cultured cells(Ding et al. 
2006; Schelhaas et al. 2008; Vaughan et al. 2009). For example, confocal microscopy with 
the assistance of 2-dimensional co-localization assay helped to suggest that AAV2 
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differentially traffic through late and recycling endosomes in a dose dependent manner(Ding 
et al. 2006), while TIRF microscopy assisted live cell imaging helped to show that actin 
disruption drugs could block the retrograde flow of Human papillomavirus on cell 
surface(Schelhaas et al. 2008).  
However, despite advances of 2D imaging and analysis (Seisenberger et al. 2001; 
Akita et al. 2004; Grieger et al. 2006), to date there is no method available to quantify the 
number and bio-distribution of nano-scaled viral particles in animal cells and tissues, which 
is essential in evaluating the effects of pharmacological reagents and viral vector variants on 
nanoparticle delivery. For example, many viral vectors have high particle-to-plaque forming 
unit (pfu) ratios, requiring hundreds to thousands of virions to successfully infect a single 
cell. This strongly suggest: 1) virions may take several different pathways during infection 
and, 2) most viral entry and trafficking events might be futile(Brandenburg et al. 2007; 
Johnson et al. 2008), 3) a significant number of the particles are defective or not assembled 
properly(Zeltner et al. 2010). Before one can distinguish productive events from non-
productive ones, it is essential to sample the entire population of intracellular viral particles 
without bias. Analysis of 2D images, utilized by current microscopy approaches, is not 
unbiased because it only samples one focal plane of viral particles within infected cells. In 
addition, each labeled particle is displayed as a discrete and intact multi-voxel fluorescent 
spot, and the distribution of particles in cells varies on each focal plane along the z-axis. 2D 
image from any focal plane selected for quantification is arbitrary, therefore classical pixel-
by-pixel co-localization analysis is not suitable to examine intracellular distribution of viral 
particles that actually exist in 3D. Finally, current centroid-counting method fails to 
quantitate viral particles in cells because of the fact that particles may aggregate or move into 
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a sub-resolutional region like vesicles to give a single fluorescent spot, as is common for 
nanoparticle trafficking. As a result, no method to date is available for quantitatively 
determining the bio-distribution of nano-scaled vectors in three dimensions (such as outside 
or inside nucleus, or traversing nuclear membrane).  
Here, based on recent advances with computational image processing(Sedarat et al. 
2004; Feng et al. 2007), we developed a sensitive and reliable methodology by integrating 
single particle imaging and 3D quantification into classical immunofluorescence to quantitate 
the trafficking kinetics and bio-distribution of nanoparticles in three dimensional animal cells 
and tissues. Using Cy5-labeled Adeno-associated virus (AAV) as a working model, we 
quantitatively investigated the nuclear entry kinetics and bio-distribution of AAV2 in human 
cells and mouse tissues. This study demonstrates the potential of this methodology in 
screening pharmacological reagents and vector variants for the development of therapeutic-
material delivery strategies, as well as in understanding the intracellular behavior of delivery 
viral vectors in vitro and in vivo.  
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Materials and Methods 
 
Production and purification of viruses. Virus was produced in HEK-293 cells as 
previously described(Xiao et al. 1998). Briefly, using polyethylenimine (linear molecular 
weight, ~25,000), cells were triple transfected with pXR2, the pXX680 helper plasmid, and 
pTR-CMV-GFP containing the GFP reporter transgene flanked by inverted terminal repeats. 
At 60hrs post-transfection, cells were harvested and nuclei were isolated as previously 
described(Grieger et al. 2006). The nuclear pellet from 10 plates was resuspended in 10ml 
PBS with 0.5% Deoxycholate (DOC) and then sonicated for 1min. This suspension was 
incubated at 37℃ for 45 minutes in the presence of 100μg/ml DNase. Virus suspension was 
subjected to one round of cesium chloride (CsCl) step gradient density (1.3g/cm
3
 and 
1.5g/cm
3
) fractionation. The viral fraction that resided in the interface between the two 
gradients was collected and subjected to another round of fractionation using CsCl 
continuous gradient density. Fractions that contained peak virus titers as determined by both 
slot dot blots and SDS-PAGE electrophoresis were dialyzed against 1× phosphate-buffered 
saline (PBS) supplemented with 5% sorbitol. Viral titers were determined by both dot 
blot(Grieger et al. 2006) and qPCR. The infectivity of AAV is determined to about 1 
transduction unit per 100 particles. 
Cy5 labeling of viral particles. AAV2 was covalently labeled with fluorophores as 
described(Bartlett et al. 1998). AAV2 labeling followed essentially the same protocol with 
slight modification. Briefly, purified AAV2 were incubated for 1hr at 4℃ in PBS with a ten-
fold molar excess of Cy5 mono NHS esters (GE Healthcare) over the capsid protein units. 
Labeled viruses were separated from the free dyes by dialysis against PBS containing 5% 
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sorbitol and stored at -80℃ as small aliquots. The degree of labeling (DOL) was determined 
by spectophotometry using DOL= Amax / ([virus] ×Edye), with Amax =absorbance of dye at 
absorbance maximum, [virus] =virus concentration, and Edye = extinction coefficient of the 
dye at its absorbance maximum. Please refer to the manufacturer’s instructions for further 
details. Labeled viral titers were determined by both dot blot(Grieger et al. 2006) and qPCR. 
Vector administration and animal studies. Housing and handling of BALB/c mice 
used in the current study were carried out in compliance with National Institutes of Health 
guidelines and approved by the IACUC at the University of North Carolina-Chapel Hill. 
Recombinant AAV2 vectors packaging GFP transgenes were administered through the 
intramuscular (2E+09vgs into the hind limb) in a volume of 20μl PBS. At 0.5, 2, 4 hours and 
6 days after intramuscular injection, animals received an overdose of pentobarbital 
(100mg/kg intraperitoneally) and were perfused transcardially with ice-cold 100mM sodium 
PBS (pH 7.4), followed by 4% paraformaldehyde in PBS (pH 7.4). After muscle was post-
fixed for 24hrs at 4°C in paraformaldehyde/PBS (Xiao et al. 2007), 15μm cross sections were 
cut using a cyrosection microtome. Then the slides were directly sealed with mounting 
medium (Prolong Antifade Gold with DAPI [4’,6’- diamidino-2-phenylindole]; Molecular 
Probes). 
Immunofluorescence. Similarly to what we have previously described(Johnson et al. 
2008), HeLa cells (3E+04 per well) were plated on 12-mm glass coverslips at 24hrs before 
infection. Next day, after incubation in DMEM containing 20mM HEPES at 4℃ for 5min, 
cells were incubated with Cy5-labeled virions (5,000 or 25,000 vgs/cell) at 4℃ for another 
40min. Cells were washed three times with PBS to remove unbound viruses and transferred 
to 37℃ incubator (regarded as 0hr p.i.). At the indicated time points, cells were washed with 
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PBS and then fixed with 4% paraformaldehyde (PFA) for 15min at room temperature (RT). 
The cells were then permeabilized with 0.2% Triton X-100 in PBS for 5min at RT. 
Following four washes with PBS, the permeabilized cells were blocked with 
immunofluorescence buffer (IFB) (5% normal goat serum in PBS containing 0.05% Tween-
20) for 1hr at RT. The cells were incubated with primary antibody to detect Lamp1 
(monoclonal from Santa Cruz Biotechnology Inc.) diluted in 50% IFB for overnight at 4°C. 
The cells were then incubated in secondary antibody, diluted 1:2,000 in 50% IFB (anti-
mouse Alexa-Fluor 488 [Molecular Probes]), for 1hr at RT. After six washes with PBS, 
coverslips were mounted cell side down on glass slides with mounting medium (Prolong 
Antifade Gold with DAPI [4’,6’- diamidino-2-phenylindole]; Molecular Probes).  
3D confocal fluorescence microscopy and 3D blind deconvolution. The labeled 
Hela cells were examined by use of a Zeiss LSM710 laser scanning confocal microscope 
equipped with a Zeiss Plan-Apochromat 63×/NA 1.40 oil objective. The confocal pinhole 
aperture was set to the diameter of the first Airy disk. Stacks of 20-30 focal planes were 
captured at 0.31μm z-intervals through the depth of the cell. 3D images of the cells were 
reconstructed by using the image stacks. The Nyquist theorem, which utilizes the limitation 
of the microscope optics [full-width half-maximum (FWHM)] to dictate adequate sampling, 
was used to determined that pixel dimensions of 0.13×0.13×0.31μm (X, Y, Z) were required 
to properly sample the data.  
Deconvolution was performed by AutoDeblur software (Media Cybernetics Inc.), 
using iterative and constrained algorithms. The procedure started with a theoretical PSF 
derived from the actual setting of Zeiss710 confocal microscope. To generate the theoretical 
PSF, AutoDeblur took the following factors into consideration: NA of the microscope 
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objective, refractive index of the medium, excitation wavelength, emission wavelength, 
confocal pinhole radius, pixel size, z-axis interval, microscope type (i.e., wide field, 
confocal), and number of excitation photons. A new adjusted adaptive PSF derived from the 
previous deconvolution round was used to generate next adaptive PSF that fits the real 
imaging data better than the previous one (termed as one iteration or deconvolution 
round(Pawley 2006)). The number of iterations may serve as a regularization factor. In 
general, the remaining restoration error decreases with an increasing number of iterations. At 
the same time, the error due to noise amplification increases. The procedure should be 
stopped at an iteration number in which the sum of both errors is minimal(Vandervoort et al. 
1995). To determine the optimal number of iteration, intracellular Cy5-AAV2 particles were 
deconvolved up to 50 rounds and the resulting images were saved every 5 rounds. The 
resulting images from 10 deconvolution rounds (number of iteration) displayed the highest 
SNR, best spatial resolution and most closely resemble the fluorescence signal from a point 
light source (Fig.II-2). This iteration number (10 rounds) was then used to deconvolve all the 
confocal images in this paper.  
Computer assisted 3D visualization and analysis. All deconvolved image stacks 
was processed using IMARIS software package (Bitplane AG, Zurich, Switzerland) for 
visualization and quantification purpose. Briefly, a deconvolved image stack was 
reconstructed using a volume rendering module and smoothened by a 3D-median filter. 
Subsequently, an isosurface rendering module was applied through thresholding by the 
fluorescence intensity that is slightly higher than background. For Cy5-AAV2, the isosurface 
rendering was thresholded at the fluorescence intensity of 1000a.u. (the upper boundary of 
background). For AF488-Lamp1, the fluorescence intensity of 530a.u. was used. For DAPI, 
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isosurface rendering was thresholded at the fluorescence intensity of 2500a.u.. The 
parameters (volume, MFI, TFI) for these isosurface coated Cy5-AAV2 objects were 
extracted from the IMARIS program and analyzed as described in result section. The 
localization of Cy5-AAV2 in nucleus or lysosomes was analyzed as described in result 
section. Aberrations caused by refractive index mismatch results in a suboptimal z resolution. 
FWHM changes of the point spread functions of the two channels (DAPI and Cy5) differed 
one voxel (0.13 × 0.13 × 0.31 μm3) in XY- and Z-directions, while no significant changes 
was observed between AF488 and Cy5. The channel registration difference between DAPI 
and Cy5 was fixed by adjusting the DAPI channel using channel shift module in IMARIS to 
avoid potential false-positive localization results.  
AFM. After imaging with confocal microscope, the coverslips were removed from 
glass slides and gently rinsed with PBS. The coverslips were quickly rinsed in ddH2O, 
blotted dry and then slightly dried under a stream of nitrogen. The images were captured in 
air with a Nanoscope IIIa (Digital Instruments) microscope in tapping mode. Pointprobe 
tapping mode silicon probes (Molecular Imaging Corporation) with spring constants of ~50 
N/m and resonance frequencies ~170 kHz were used for all imaging. The images were 
collected at a speed of 4Hz, a size of 4μm × 4μm, and a resolution of 512 × 512 pixels. 
Electron microscopy (EM). Purified and dialyzed virus particles in 1× PBS were 
pipetted onto a glow-discharged copper grid. The grid was washed twice with water and then 
stained with 2% uranyl acetate. EM images were taken with a LEO EM 910 transmission 
electron microscope (TEM) at various magnifications. 
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Results 
 
Quantitative 3D distribution microscopy. To precisely tracking and localize labeled 
particles in cells and tissues, we developed an object-based quantitative 3D distribution 
microscopy which is composed of two steps: 1) assess the localization of particles, 2) 
quantitate the number of particles in each cellular structure. Here we used localization of 
particles in nucleus as an example to explain this method. As diagramed in Figure II-1A-a, 
five nanoparticles (P1-P5 in four groups G1-G4) are differentially localized in a cell, with P1 
inside the nucleus, P2 transversing nuclear membrane, P3-P5 outside of the nucleus, and 
especially P4 and P5 associated with a sub-resolutional region (i.e. vesicles with diameter 
less than 200nm). Confocal microscope is used to create a z-stack sectioning through the 
entire cell and generate 3D fluorescence images. Image distortions are a natural aspect of an 
optical microscope (noise, scatter, glare and blur) and diminish the contrast and resolution of 
raw images, thus impairing the accuracy of quantitative image analysis. To counteract these 
problems, restorative 3D deconvolution is used to reverse the optical distortions, negating the 
effects of the optical system that are represented by its point spread function (PSF, Fig.II-
2A). After 3D deconvolution, the fluorescence images are visualized by 3D volume 
rendering as shown in Figure II-1A-b, with four fluorescence spots (#1-#4) formed by 
corresponding particles.  
To determine the localization of each particle in an object-by-object manner, we first 
employ isosurface rendering by thresholding fluorescence intensity to distinguish signal from 
the background (Fig.II-2A, dashed blue line). With this method, we will create a Volume of 
Interest (VOI) for each fluorescence spot from an optically resolvable particle  
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Figure II-1. Object-based quantitative 3D distribution microscopy. A) Working model 
for object-based 3D bio-distribution measurement is shown in X/Z dimensions. (a) actual 
localization of labeled particles and nucleus, with five particles localized in four optically 
resolvable groups (G1-G4), (b) expected fluorescence signal (spots #1-#4) from four groups 
of labeled particles by 3D confocal microscopy, and (c) four volume of interest (V1-V4) 
defined by the fluorescence spots in (b) with the assistance of isosurface rendering. B) 
Distribution of Cy5-AAV2 particles in Hela cells at 6hrs post infection (p.i.). Upper panel is 
the fluorescence signal from 3D confocal microscopy, with red Cy5-AAV2 and blue DAPI-
stained nucleus. Scale bar represents 6μm. Lower panel is the isosurface rendering and shows 
the different localization of viral particles: red is in cytoplasm, cyan is traversing nuclear 
membrane and yellow is inside of nucleus. C) Example of 3D deconvolution of fluorescence 
signal of Cy5-AAV2 particles. This improves the Signal-to-Noise Ratio (SNR) and 
dimensional resolution of fluorescence signal from a single Cy5-AAV2. 3D surface plots 
(right panel) of the fluorescence signal from a single particle before and after deconvolution 
were generated by Image J. Pixel size in X and Y is 0.13×0.13 μm.  
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Figure II-2. Theoretical point spread function (PSF) of confocal images and 
optimization of 3D deconvolution. A) Theoretical confocal PSF displayed in X/Y and X/Z 
dimensions (top). In the bottom figure, the red region usually represents 84% of fluorescence 
signal from a point light source and defined by full-width-at-half-maximum (FWHM: 
indicator of resolution defined by Rayleigh criteria) in all three dimensions. The blue region 
is usually defined as the threshold separating the real signal from background (dotted blue 
line) and represents 95% of fluorescence signal. B) A single Cy5-AAV particle within cells 
was imaged as described in Methods. Z-stack images were processed with different iteration 
numbers (5, 10, 15) of 3D blind deconvolution. a) Micrographs of fluorescence signal from 
pre- and post-deconvolved images were displayed in X/Y and X/Z dimensions. b). 3D 
surface plot of corresponding fluorescence signal was generated by Image J and suggested 
~3-4 fold improvement in Signal-to-Noise Ratio (SNR). 
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group (Fig. II-1A-a: G1-G4). The localization of each particle is then determined by the 
amount of DAPI signal within its VOI (Fig. II-1A-c: V1-V4). Specifically, the mean 
fluorescence intensity (MFI) of DAPI in V1 is the same as that in nucleus, demonstrating that 
P1 is inside the nucleus; the MFI of DAPI in V3 and V4 is the same as that in the cytoplasm, 
but much lower than that in nucleus, demonstrating that P3-P5 are outside the nucleus; and 
the MFI of DAPI in V2 is between those in nucleus and in cytoplasm, demonstrating that P2 
is traversing the nuclear membrane.  
To count the number of particles, classical centroid counting method fails when 
several particles associate with a sub-resolutional region and display as a single fluorescent 
spot (Fig. II-1A-b: spot #4), which is very common in nanoparticle trafficking. In addition, 
the amount of dyes (or dye-labeled particles) should be calculated by the number of emitted 
photon or fluorescence intensity instead of fluorescence volume(Akita et al. 2004; Chen et al. 
2008), since there is no linear correlation between the amount of dyes and fluorescence 
volume ((Pawley 2006) and Fig.II-3). To quantitate particles including those within sub-
resolutional regions, we calculate such number using the total fluorescence intensity (TFI) of 
each fluorescence spot by the formula: number of particles in structure-X =∑TFIstrX/mTFIs, 
in which TFIstrX denotes the TFI of fluorescence spots formed by labeled particles in cellular 
structure X, and mTFIs denotes the mean value of TFI experimentally calculated from 
fluorescence spots formed by a single particle. Using quantitatively labeled fluorescence 
beads (InSpect Image Intensity Calibration beads from Invitrogen), we demonstrated that TFI 
but not volume linearly correlated with the amount of dyes on beads (Fig.II-3A) and the 
number of dye-labeled objects can be precisely calculated from TFI (Fig.II-3B), which 
validated the accuracy of this intensity-based quantification. In addition, compared with 
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Figure II-3. Total fluorescence intensity (TFI) is proportional to the amount of dyes and 
dye-labeled beads. A) Differentially labeled fluorescence beads (0.3%, 1%, 3% and 10% of 
maximum labeled beads obtained from Invitrogen Inc.) were imaged for 3D quantification, 
and both TFI and fluorescence volume are plotted against the labeling degree of these 
fluorescence beads. This panel shows that only TFI is proportional to the labeling degree of 
these beads but fluorescence volume is not. B) Calculated TFI of fluorescence signal from 
single beads or those in doublets. For beads of any labeling degree, the TFI of beads in 
doublets is always 2 times of that of single beads, further demonstrating the linear correlation 
between TFI and the number of labeled particles. 
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earlier studies (Akita et al. 2004; Chen et al. 2008), this object-by-object quantification 
method only calculates the signal from viral particles but not the automatically system-
generated noise signal prevalent in the digital images, because these noise are usually bright 
fluorescence sports with only one or two pixels/voxels that are filtered away from the 
particle-formed fluorescence spots with 10 or more voxels (Fig. II-1B, II-5C, II-7A). Such 
feature further improves the precision of this method. 
AAV particle labeling, localization and quantification. With this method, one is 
able to quantitate the bio-distribution of nano-scaled particles in cells/tissues by specifying 
the number and localization of particles in each cellular structure. In the following context, 
we will quantitate the distribution of Cy5-AAV2 particles in Hela cells at 6hrs post infection 
(p.i.) to fully demonstrate this method. 
Labeling viruses with fluorochromes has been used in imaging particle trafficking (Pelkmans 
et al. 2001; Schelhaas et al. 2008; Vaughan et al. 2009). We chemically conjugated viral 
particles with Cy5 to minimize autofluorescence in cells and tissues. Electron microscopy 
data demonstrated that the physical morphology of AAV2 was not affected by Cy5 
conjugation and most of the labeled virions remained as single particles (Fig.II-4A). Labeling 
did not impact transduction efficiency significantly as indicated by GFP reporter gene assay 
(Fig.II-4B,C). SDS-PAGE and fluorography of Cy5-AAV2 demonstrated that fluorochromes 
were specifically coupled to all three capsid proteins (VP1,2,3) as indicated by three 
fluorescence bands (Fig.II-4D). This specificity of labeling was validated in human cells 
using mouse monoclonal antibody A20 which only recognizes the intact AAV2 particles 
(Fig.II-4E). These results demonstrated that both morphology and functionality (A20 binding 
and infectivity) of these labeled virions are the same as un-labeled ones. 
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Figure II-4. Evaluation of AAV2 morphology and infectivity after chemical conjugation 
with Cy5. A) Electron micrographs of Cy5-AAV2. Scale bar represents 0.1μm. B) and C) 
Hela cells were incubated with PBS, AAV2 or Cy5-AAV2 (2,000 vgs/cell). B) GFP 
transgene expression captured with epi-fluorescence microscope. C) Histogram indicating 
percentage of GFP positive cells determined by flow cytometry analysis 24 hours p.i.. Error 
bars represent the standard deviation (STDEV) for three independent experiments. D) SDS-
PAGE electrophoresis of Cy5-AAV2 capsid and directly detect Cy5 signal using LI-COR 
Odyssey. M: protein marker, 1: 2E+09, 2: 1E+09, 3: 5E+08, 4: 2.5E+08, 5: 1.25E+08, 6: 
6.25E+07 vector genomes as determined by QPCR. E) Hela cells were infected with Cy5-
AAV2 at 5,000 vgs/cell for 40 minutes, and visualized for Cy5 signal (Red) and monoclonal 
antibody A20 staining of intact capsids (Green). Cell edge is outlined with white line.  
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At 6hrs p.i. with Cy5-AAV2 at 5,000 vector genomes per cell (vgs/cell), Hela cells 
were fixed and their nuclei were stained with DAPI. A Zeiss710 confocal fluorescence 
microscope was used to create a z-stack sectioning through the entire cell for each 
fluorochrome at the optimal z-step (well-characterized Nyquist Sampling Frequency). We 
employed AutoDeblur software (Media Cybernetics Inc.) for the deconvolution using an 
iterative constrained blind algorithm to remove out-of-focus haze, blur and noise. After 3D 
deconvolution, the fluorescence signal from AAV particles was visualized by 3D volume 
rendering (Fig.II-1B). Consistent with theoretical confocal point spread function 
(PSF(Pawley 2006)), the fluorescence signal from a labeled particle is shaped as prolate-
spheroid in 3D, with an approximate equatorial radius a = 0.2-0.3μm and polar radius b = 
0.3-0.4μm, which resulted in the volume range of less than 0.13μm3. These signals with 
prolate-spheroid-shape had improved Signal-to-Noise Ratio (SNR) up to 3-4 fold (Fig.II-1C). 
Resolution was also enhanced in all three dimensions evaluated by FWHM (Full Width at 
Half Maximum: 0.15-0.2μm in X/Y and 0.3μm in Z compared with standard confocal 
resolution limit of 0.3-0.4μm in X/Y and 0.6μm in Z, Fig.II-1C, II-2). We then employed 
isosurface rendering module in IMARIS software (Bitplane Inc.) to generate VOIs for the 
signals from each optically resolvable Cy5-AAV2 group and thereafter determined the 
localization of Cy5-AAV2 particles to nucleus by DAPI signal. As shown in lower panel of 
Figure II-1B, red spots represent the particles outside of nucleus, cyan spots represent the 
particles associated with nuclear membrane and yellow spots represent the particles inside of 
nucleus. ∑TFIstrX was then calculated by the TFIstrX for each fluorescence spot. To quantitate 
the particles in each type of localization, we will derive the value of mTFIs in the following 
studies. 
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Figure II-5. Characterization of fluorescence signal for single Cy5-AAV2 particles. A) 
Representative confocal image (left) of Cy5-AAV2 bound to coverslip. Scale bar represents 
2μm. Representative fluorescence intensity profiles (right 1-2) of two Cy5-AAV2 particles 
(indicated at left).  B) Atomic force microscopy image of Cy5-AAV2 particles (arrowheads) 
from the same glass coverslip as in A demonstrated the dispersity of viral particles on the 
coverslip. C) 3D reconstruction of deconvolved confocal images (left: Cy5-AAV2 in red) 
and subsequent 3D isosurface rendering images (right: Cy5-AAV2 in yellow). Bars represent 
5μm. D) Histograms of volume (a) and TFI (b) for all Cy5-AAV2 particles recorded from the 
coverslip in A and B. The mean values of TFI was 44834 ± 16447.3 a.u..   
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We characterized the fluorescent signal of a single Cy5-AAV2 particle by three 
parameters (volume, mean fluorescence intensity (MFI) and TFI). 4-6e+07 Cy5-AAV2 
particles were loaded onto grid coverslips to yield a distribution of approximately 1 particle 
per 5μm2. Uniformly labeled particles were obtained as indicated by confocal microscopy of 
Cy5-AAV2 on the coverslip (Fig.II-5A, left). Profiles of fluorescence signal intensity for two 
representative Cy5-AAV2 particles follow Gaussian distribution (Fig.II-5A, right), 
suggesting that fluorescence signal was from single particles(Schelhaas et al. 2008). The 
fluorescence signal (thresholded as dashed blue line in Fig.II-2A) from Cy5-AAV2 had a 
diameter of 0.5-0.6μm, comparable to the fluorescence signal generated by other nano-scaled 
viruses (e.g. SV40) (Pelkmans et al. 2001; Schelhaas et al. 2008). 3-5 regions from each 
coverslip were imaged using the microscope settings for quantitative analysis (see Methods), 
and 2-3 Z-stack images were taken for each region. The distribution of Cy5-AAV2 on the 
same regions was verified using atomic force microscopy (AFM). Only the regions on which 
the minimum distance between every two physically dissociated Cy5-AAV2 particles was 
larger than 0.5μm (Fig.II-5B) were chosen for later quantification. Thus, we demonstrated 
that each fluorescence spot visualized by fluorescence microscopy represented a single Cy5-
AAV2 particle. Images from these chosen regions were processed with 3D deconvolution, 
reconstruction and isosurface rendering (Fig.II-5C). Three statistics (volume, Cy5 MFI and 
Cy5 TFI) of each isosurface coated fluorescence spot were used to define the singularity of 
labeled particles. Volume was plotted for all fluorescent objects (Fig.II-5D-a), and could fit 
to a Gaussian curve indicating a normal distribution. According to theoretical confocal PSF 
(Pawley 2006), we defined Cy5-AAV2 objects with volume smaller than 0.13μm3 as the 3D 
fluorescence pattern for a single Cy5-AAV2. These defined single  
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Figure II-6. Visualization of Cy5-AAV2 particles within cells by fluorescence 
microscopy. Hela cells were incubated with AAV2 or Cy5-AAV2 (5,000 vgs/cell) at 4℃ for 
40 minutes and then moved to 37℃ after washing. Cells were fixed with 4% PFA at 13 hours 
and nuclei were stained with DAPI. Stacks of images throughout the whole cells were taken 
using Zeiss710 confocal microscope at sampling frequency of 0.13×0.13×0.31μm in X/Y/Z 
dimensions. All images were subjected to 3D deconvolution. 3D reconstructed images are 
displayed. Bottom panels are side view of Cy5 channel in X/Z dimensions.  Bars represent 
5μm.  
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Figure II-7. Fluorescence properties of single Cy5-AAV2 particles within cells.  Hela 
cells were incubated with Cy5-AAV2 (5,000 vgs/cell) and fixed and nuclei were stained with 
DAPI. Stacks of images throughout the cells were taken using a Zeiss710 confocal 
microscope. A) Representative 3D confocal image of Cy5-AAV2 within cells after being 
deconvolved and reconstructed (left). Right panel shows the corresponding 3D isosurface 
rendered image. Scale bar represents 5μm. B) Histograms of volume (a) and TFI (b) for all 
Cy5-AAV2 particles within cells (n = 5) as calculated by Imaris program. The mean value of 
TFI was 47568 ± 13345.5 a.u.. 
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Figure II-8. Mean fluorescence intensity of single Cy5-AAV2 on coverslips and in 
cellular environment. While determining both volume and TFI of the fluorescence signal 
from Cy5-AAV2, we also calculated the corresponding MFI value: A) single Cy5-AAV2 on 
coverslips has a mean value of MFI at 2438 ± 310.6 a.u., and B) single Cy5-AAV2 on 
coverslips has a mean value of MFI at 2516 ± 256.5 a.u.. 
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Cy5-AAV2 objects had a mean value of Cy5 TFIs at 44834 ± 16447.3 a.u. (Fig.II-5D-b), and 
a mean value of Cy5 MFI at 2438 ± 310.6 a.u.  (Fig.II-8A).  
The complexity of the cellular environment may affect the fluorescent properties 
from a single Cy5-AAV2. We analyzed whether single Cy5-AAV2 particles on glass had 
similar fluorescent properties on cells. Briefly, we incubated 5,000 Cy5-AAV2 per Hela cells 
(over a surface area of ~2000 μm2) at 4℃ for 40 minutes to allow a dispersed distribution of 
Cy5-AAV2 particles over the cell surface (Fig.II-7A). Specificity of viral fluorescence signal 
was verified by comparison to non-labeled AAV2 infected cells (Fig.II-6). We then collected 
the imaging data and analyzed the three parameters (volume, MFI and TFI) exactly as 
described above for in vitro characterization. The distribution of volumes was almost 
identical to the results from the analysis on coverslip (Fig.II-5D-a, II-7B-a). The same range 
of volumes (<= 0.13μm3) was used to define the fluorescence signal from single Cy5-AAV2 
in cells. In the cellular environment, single Cy5-AAV2 objects have a mean value of Cy5 
TFIs at 47568 ± 13345.5 a.u. (II-7B-b) and Cy5 MFI at 2516 ± 256.5 a.u. (Fig.II-8B), which 
is not significantly different from the values determined on coverslip. Consistency between 
the fluorescent signal from coverslip and cell culture supports that our characterization and 
quantification by this method is reliable. With this calculated mTFIs (=47568 a.u.), we then 
determined the number of Cy5-AAV for each location at 6hrs p.i.: 150 in the whole cell, 37 
in nucleus, 6 associated with nuclear membrane and 107 localized in cytoplasm (Fig.II-1B).  
With this scenario, the subset of Cy5-AAV2 fluorescence spots with specific nuclear 
localization can be quantitated by DAPI fluorescence signal within each viral VOI and 
calculated mTFIs. By applying isosurface rendering to the nuclear DAPI signal, the relative 
localization between AAV2 particles and nucleus can be easily and unambiguously 
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visualized. Compared with previous studies (Akita et al. 2004; Grieger et al. 2006; Chen et 
al. 2008), this method not only allows one to assess the viral distribution from the view of 
entire population but also allows one to locate each individual particle into finer sub-cellular 
structures (i.e. inside/outside nucleus or traversing nucleus, as shown in Fig.II-1B). By 
determining the fluorescence parameters for single particles, this method also first time 
allows one to quantitate the number of virions in various cellular structures. For example, 
including nuclear targeting, co-localization of AAV2 with other specific cellular structures 
(e.g. AAV-cell membrane, AAV-lysosome) and corresponding trafficking kinetics were 
quantitatively investigated using this method. 
Kinetics of AAV2 trafficking in endo/lyso vesicles and nucleus. Intracellular 
trafficking in small vesicles like endosomes and lysosomes is essential for productive viral 
infection. For example, AAV2 has been shown to undergo successive endosomal trafficking 
and sorting after viral entry (Ding et al. 2006). We tested the applicability of this method 
toward elucidating these essential events using lysosomal association of AAV2 as an 
example. Hela cells were incubated with Cy5-AAV2 (5,000 vgs/cell) at 4℃ for 40 minutes. 
After removing unbound virions, cells were incubated at 37℃ and harvested at 0hr, 2hrs, 
4hrs, 8hrs and 13hrs p.i., and fixed with paraformaldehyde. Lysosomes were labeled with 
monoclonal Lamp1 antibody. Z-stack images were captured through the entire cell using a 
Zeiss LSM710 laser scanning confocal microscope. After 3D deconvolution and 
reconstruction of image stacks, we measured the association between lysosomes and AAV2 
particles over time. Our results demonstrated that about 40% of intracellular AAV2 
consistently associated with lysosomes between 2hrs and 13hrs after infection (Fig.II-9). 
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Figure II-9. Association of Cy5-AAV2 with the lysosomes. A) Representative 3D 
isosurface images of Cy5-AAV2 within cells at 0hr and 8hrs p.i.. Nuclei are stained in blue, 
and viral particles (red) associated with lysosomes (green) are highlighted as yellow. B) The 
percentage of viral particles associated lysosomes was plotted. Cyan diamonds represent data 
from individual cells (n = 10-15), red bars represent mean value of each time point (0hr, 2hr, 
4hr, 8hr and 13hr), and error bars represent the standard deviation (STDEV). 
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Figure II-10. Kinetics of Cy5-AAV2 nuclear targeting.  Hela cells were incubated with 
Cy5-AAV2 (A+B: 5,000 vgs/cell, C+D: 5,000 or 25,000 vgs/cell) at 4℃ for 40 minutes and 
then transferred to 37℃ incubator. Cells were then fixed at 0, 2, 4, 8 and 13 hours and nuclei 
were stained with DAPI. The number of viral particles within cells was calculated using the 
mean value of Cy5 TFI (47568 a.u.) determined in Fig.II-7B-b. A) Representative 3D 
isosurface images of Cy5-AAV2 within cells at 0hr and 8hrs p.i.. Viral particles in nuclei are 
highlighted as yellow. Scale bars represent 5μm. B) Plots of total number of viral particles (a) 
and percentage of intra-nuclear viral particles (b) in each cell. C) Representative 3D 
isosurface images of cells infected at 5,000 or 25,000 vgs/cell at 2hrs p.i.. Viral particles in 
nuclei are highlighted as yellow. Scale bars represent 5μm. D) Percentage of intra-nuclear 
and nuclear membrane associated viral particles as shown in C. Cyan diamond represents 
data from individual cells (n=10-20), red bars represent mean value of each time point, and 
error bars represent the standard deviation (STDEV). 
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Nuclear entry of either viral proteins or genetic material, following the small vesicle 
trafficking, is one of the rate-limiting steps in most viral infection. Extensive effort has been 
made to block this step in antivirus strategies or to improve the efficiency of this step for 
more efficient gene delivery (Haffar et al. 2005; Hindley et al. 2007; Suzuki et al. 2007; 
Johnson et al. 2008; Greber et al. 2009). Like several DNA viruses (Hindley et al. 2007; 
Greber et al. 2009), AAV2 has to enter the cell nucleus to complete its life cycle (Sonntag et 
al. 2006; Johnson et al. 2008). However, such trafficking kinetics as well as the mechanism 
through which AAV enters nucleus remains unknown due to the lack of a quantitative 
method to study this process. Here we demonstrated the use of 3D tracking of single viral 
particles to explore the dynamics of AAV2 nuclear entry in cultured cells.  
Experiments were carried out as lysosomal association studies, and nuclei were 
stained with DAPI. After 3D deconvolution and reconstruction of image stacks, we 
quantitatively documented the kinetics of AAV2 nuclear targeting (Fig.II-10, & Movie S3-
S5). We observed that the number of viral particles (~200) associated with the cell did not 
change significantly over the time period we observed (Fig.II-10B-a). On average, 0% and 
14% of total intracellular viral particles were found in the nucleus at 0hrs and 2hrs p.i. 
respectively, and this percentage increased to 22% at 4hrs, 28% at 8hrs and 27% at 13hrs 
(Fig.II-10B-b). With the previous measured mean value of Cy5 TFI (47568 a.u.) for a single 
Cy5-AAV2, the corresponding viral particle numbers in the nucleus were 27, 38, 48 and 41 
at 2hrs, 4hrs, 8hrs and 13hrs respectively (data not shown). These results suggest the 
following dynamics of AAV2 nuclear targeting: 1) Half of the nuclear targeting events 
happened within the first 2hrs p.i., with the remainder occurring between 2-8 hrs p.i. . This 
correlates well with the fact that reporter gene (GFP) expression can be detected as early as 
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Figure II-11. The level of transgene EGFPsc expression at two different virion dosages 
(MOI=5,000 vgs/cell and MOI=25,000 vgs/cell). The relative mean fluorescence intensity 
(RMFI) at 5,000 vgs/cell is about 28.2 a.u., and RMFI at 25,000 vgs/cell is about 91.2 a.u.. 
 
  
 79 
6-8hrs p.i.. 2) The relative number of AAV2 in the nucleus appears to level off at 8hrs p.i., 
with about 30% (48 out of 170) intracellular AAV2 particles on average located in the 
nucleus. This result is consistent with an earlier report which found that a similar percentage 
of AAV genome (~30%) ended up in the nucleus (Zhong et al. 2008). These results were 
summarized into an in vitro model (Fig.II-13A) and quantitatively documented in a table 
(Fig.II-13C: Table1). Remarkably, the percentage of AAV2 associated with the nuclear 
membrane (~12%) at 2hrs p.i. did not change when the viral dosage was increased to 25,000 
vgs/cell. However, nuclear entry efficiency at 2hrs p.i. with 25,000 vgs/cell (~4%) was 
significantly decreased (3 fold) compared to that with 5,000 vgs/cell (~14%) (Fig.II-10C,D). 
These results suggest that limited sites for viral entry are available on the nuclear membrane 
or limited trafficking routes are available for AAV2 to enter nucleus. In accordingly, the 
transduction efficiency measured by transgene GFPsc expression at 25,000 vgs/cell is only 
about three folds of that at 5,000 vgs/cell (Fig.II-11).  
Trafficking kinetics in mouse muscle. The ultimate goal of studying particle 
trafficking is to elucidate the behavior of viral and non-viral vectors in tissues and animals. 
The in vivo setting provides the most applicable information for the development of efficient 
gene delivery vectors. Current method of studying the distribution of viral vectors in vivo 
using reporter gene assays tracks only the virions that successfully transduce cells. Given that 
the vast majority of virions are likely to be futile in infection, reporter gene imaging provides 
a biased understanding of virion distribution that can easily lead to mis-interpretation of the 
pharmacology of these agents, resulting in failed development of anti-viral and therapeutical 
delivery vectors (Hofherr et al.; Brandenburg et al. 2007). To circumvent this problem, we 
have tracked all AAV particles, both infectious and abortive, in mouse muscle over time. 
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Figure II-12. Trafficking of AAV2 in mouse muscle. A) Site of AAV injection is 
visualized by Indian ink (black spots in upper panel) and is indicated by arrows, and 
corresponding reporter gene GFP expression (Green) in muscle at 6 days post-injection 
(lower panel). Scale bar represents 100μm. B) Distribution of Cy5-AAV2 particles in mouse 
muscle at 0.5, 2 and 4hrs post-injection. Upper panel shows the DIC images with the 
injection site indicated by arrows. Lower panel shows the localization of Cy5-AAV2 
particles (red) and nuclei (blue). The inserts in upper panel are the magnified view of selected 
regions in lower panel (white boxes). Scale bars represent 10μm. C) Cy5-AAV2 particles 
were detected inside the muscle fibers at 6 days post-injection. Upper panel shows the 
expression of reporter gene GFP in muscle fibers. Lower panel shows the Cy5-AAV2 
particles (red) and nuclei (blue). Individual muscle fibers are outlined by curved white-lines. 
Arrowheads indicate the viral particles inside the fibers and arrows indicate the viral particles 
along the side of muscle fibers. Scale bar represents 10μm. 
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Figure II-13. Schematic and quantitative documentation of AAV2 trafficking in vitro 
and in vivo. A) Model for AAV2 infection in cell culture. After binding to the cell surface at 
0hr, AAV2 particles are transported via microtubules toward the perinuclear region (typically 
Microtubule Organization Center, MTOC) within the first 8 hours after viral inoculation. 
Progressive nuclear entry is observed during the first 8 hours p.i., with about 30% of viral 
particles in the nucleus at 8 hours p.i.. B) Model for AAV2 trafficking mouse muscle shown 
in cross-sectioned view. AAV2 particles traffic from the injection site to distal myofibers 
through the endomysium between those fibers. Some AAV particles penetrate the muscle 
fibers, but only at later time point (>=24hrs). To quantitatively document the intra-muscular 
trafficking in C (Table 2), four regions (I-IV) were defined from the injection site to distal 
myofibers, and the width of each region is about half of myofiber’s diameter. C) Quantitative 
documentation of AAV2 distribution and trafficking kinetics in cultured Hela cells (Table 1) 
and mouse muscles (Table 2). 
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After injection with Cy5-AAV2 particles, mouse limb muscle was collected at 
various times. Reporter gene (GFP) expression spread up to several muscle fibers away from 
the injection site, indicated by Indian ink (arrows in Fig.II-12), and was stronger in those 
fibers closer to the injection site than in the fibers distal from injection site at six days p.i. 
(Fig.II-12A). The immediate question is whether this distribution pattern represents the 
spreading of GFP molecules or viral particles across the muscle fibers. Our results showed 
that, in contrast to Indian ink remained local to the site of injection (Fig.II-12B upper panel), 
AAV particles migrated from the injection site into the neighboring fibers (three muscle 
fibers away from the injection site). We observed that numbers of AAV particles in the 
surrounding fibers and in nuclei increased from 0.5hr to 4hrs (Fig.II-12 lower panel). Almost 
all Cy5-AAV2 particles were located at the site of injection after 0.5hr post-injection. A few 
viral particles were observed on the side of fibers (sarcoplasm) adjacent to the injection site 
at 2hrs post-injection. A large amount of viral particles appeared on the side of fibers close to 
(3 muscle fibers away from) the injection site at 4hrs post-injection. Such trafficking kinetics 
was summarized in an in vivo trafficking model (Fig.II-13B) and quantitatively documented 
in a table (Fig.II-13C: Table 2).  During this time period, viral particles were only observed 
along the side of muscle fibers (sarcoplasm) but not inside the fibers prior to 4hrs post-
injection (Fig.II-12B lower panel) and the number of AAV capsids in nucleus was increased 
over time (Fig.II-13C). This observation suggests that viral particles after intra-muscular 
injection are likely to spread through the endomysium between muscle fibers, rather than by 
transcytosis. In addition, at six days p.i., AAV capsids were only observed along and inside 
the muscle fibers but not detectable in most of the nuclei (Fig.II-12C, II-13C). This 
observation suggested that most AAV genome should be readily released rapidly in vivo.  
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Discussion 
 
Understanding how nanoparticles travel through the cellular structures and how 
pharmacological reagents can affect viral trafficking is essential for the development of 
enhanced gene therapy vectors (e.g. polymers, Adenovirus and AAV) (Torchilin 2006; 
Breunig et al. 2008). Fluorophore labeling of particles has been mainstay in studying the 
dynamics of particle trafficking (Pelkmans et al. 2001; Ding et al. 2006; Schelhaas et al. 
2008). While a fancy research tool, current molecular tracking and 2D imaging analyses have 
significant limitations in studying classical viral trafficking and bio-distribution 
(Seisenberger et al. 2001; Grieger et al. 2006), in which temporal resolution is not the 
primary interest. For example, sampling all intracellular viral particles and quantitatively 
studying their distribution and trafficking kinetics in 3D animal cells and tissues has not yet 
been achieved. Although investigation of bio-distribution and trafficking kinetics of DNA 
carrier vectors have been attempted previously (Akita et al. 2004; Grieger et al. 2006), these 
studies are 2D imaging analyses that have limitations in quantitatively characterizing the 
viral behavior in 3D cellular structures. For example, classical 2D imaging and analysis can 
lead to arbitrary results, since the distribution patterns in different focal planes vary along the 
z-axis of confocal images. As a result, neither distribution data gained from a specific focal 
plane nor that simply summed up from all focal planes is able to correctly reflect the 
behavior of virus in cells. Recently, Chen et al studied the trafficking kinetics of plasmid 
carriers by measuring the volume of fluorescence spot generated by labeled particles (Chen 
et al. 2008). As known, the amount of dye molecules (or dye-labeled particles) in a 
subresolutional region (diameter < 150nm) should be calculated by the amount of emitted 
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photons linearly reflected by fluorescence intensity in confocal images (Pawley 2006; 
Zenklusen et al. 2008) but not by fluorescence volume, since there is no linear correlation 
between number of dye molecules (or labeled particles) and fluorescence volume (Fig.II-3A). 
As a result, the amount of emitted photons or fluorescence intensity instead of fluorescence 
volume should be used to quantitate dye-labeled subresolutional-sized particles (Fig.II-3). 
The method described in this study directly uses fluorescence intensity information to 
quantitatively determine the number and distribution of nano-scaled particles in three 
dimensions (Fig.II-3, II-5D-b, II-7B-b), which is fundamentally different from the volume-
based method (Chen et al. 2008). In addition, restorative 3D deconvolution was also applied 
to appropriately counteract the image distortions caused by optical systems to increase the 
accuracy of this three dimensional image analysis ((Pawley 2006), Fig.II-2). In brief, this 
method has employed multiple strategies including iso-surface assisted object-by-object 
analysis (Fig.II-1B), intensity-based calculation (Fig.II-3) and restorative 3D deconvolution 
(Fig.II-2) to significantly improve the accuracy of 3D image quantification. Compared with 
previous studies, including the improved precision of image quantification, this method not 
only allows one to view the particle trafficking from an entire viral population (Fig.II-10, II-
13C), but also for the first time allows one to locate each individual particle into finer sub-
cellular structures (i.e. inside/outside nucleus or traversing nucleus, as shown in Fig.II-1B 
and detailed localization in muscle as shown in Fig.II-12C). By determining the fluorescence 
parameter for a single Cy5-AAV2 virion (Fig.II-5, II-7), this method also allows one to 
quantitate the absolute number of particles in each cellular structure such as nucleus (Fig.II-
10), microtubules and cell surface as well as sub-resolutional vesicle structures like 
endo/lysosomes (Fig.II-9), which have never been reported previously. Finally and 
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importantly, this method for the first time allows one to quantitatively investigate particle 
bio-distribution/trafficking in animal tissues (Fig.II-12), which have not been documented by 
any of above method.  
 Our electron microscopy data demonstrates that almost all Cy5-AAV2 virions we 
used in this study are full particles (Fig.II-4A). The labeled virions are shown to preserve the 
capsid integrity as determined by A20 antibody binding (Fig.II-4E), and have similar 
infectivity as non-labeled AAV2 (Fig.II-4B,C). These labeled virions are also shown to have 
the normal ability to bind heparan sulfate and migrate on microtubules (data not shown). 
Using these Cy5-AAV2 that preserve the same morphology and functionality as unlabeled 
ones, we have generated a body of interesting and biologically meaningful results consistent 
with previous reports as well as several novel observations that have never been documented 
previously. For example, we have quantitatively demonstrated that the majority of AAV2 are 
bound to the cell surface as single particles even at a high MOI and the binding of AAV2 can 
be blocked by incubating the virus with heparin or incubating cells with heparanase (data not 
shown), supporting previous reports showing heparan sulfate is the primary receptor for 
AAV2 (Summerford et al. 1998; Bartlett et al. 2000). We then demonstrated that AAV2 can 
migrate on microtubules and that disruption of the microtubule network impaired the nuclear 
targeting of AAV2 (Chapter-4). The kinetics of AAV2 trafficking in small vesicles like 
lysosomes was illustrated using this quantitative microscopy method (Fig.II-9). In addition, 
we also explored the kinetics of AAV2 nuclear trafficking, one of the most important events 
in AAV infection, by quantitate the number and percentage of AAV particles in nuclei over 
time (Fig.II-1B, II-10, and II-13C). Importantly, we have for the first time quantitatively 
characterized the trafficking behavior of AAV2 in mouse muscle tissue (Fig.II-12B, II-13C) 
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providing rationale for the pattern of viral transgene expression in vivo. We will discuss some 
of these findings in detail in the following text. 
Nuclear entry is regarded as the most critical and rate-limiting step for the life cycle 
of most DNA viruses (e.g. adenovirus, herpesvirus and parvovirus) (Whittaker et al. 2000; 
Greber et al. 2009). Blocking the nuclear entry is an alternative way to block viral replication 
(Haffar et al. 2005; Boulo et al. 2007; Hindley et al. 2007; Greber et al. 2009), and on the 
other hand, facilitating the nuclear entry of viruses has been a promising strategy to improve 
viral vectors for gene delivery (Hansen et al. 2000; Suzuki et al. 2007; Johnson et al. 2008; 
Mudhakir et al. 2009). Several groups have suggested that AAV entered nucleus as intact 
virions (Bartlett et al. 2000; Sonntag et al. 2006; Johnson et al. 2008). For example, the 
Kleinschmidt group demonstrated that intact AAV2 particles enter the nucleus, since nuclear 
injection of the A20 antibody can block AAV2 infection and disassembled AAV particles are 
not detected by B1 antibody until 20hrs after infection (Sonntag et al. 2006). Our group 
showed that AAV enters the nucleus as intact virions and nuclear virions could be extracted 
and used to re-infect new cells (Johnson et al. 2008). These most recent studies suggest that 
AAV enters nucleus as intact virions and then uncoats there. However, the kinetics of AAV 
nuclear targeting has not been precisely documented and the exact route/site for viral nuclear 
entry is highly controversial. The method described herein was used to quantitatively 
investigate the viral nuclear entry step. Our microscopy analysis of AAV documented the 
kinetics of nuclear entry over 13hrs post infection (Fig.II-10 and Fig.II-13C: Table 1), 
summarized in the in vitro model (Fig.II-13A). The result showing that about 30% of bound 
AAV2 particles entered nucleus, together with the observation showing that only about 4-5% 
(~200 out of 5,000 virions/cell) of particles in the medium attached to cell surface, suggests 
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that only 1-2% of AAV2 virions will eventually enter the nucleus and express. Such binding 
efficiency was verified by quantitative PCR (data not shown), and also reported by other 
studies for other AAV serotypes (Shen et al.). This low binding efficiency is due to the nature 
of biochemical reaction between ligands (AAV2) and receptors (heparan sulfate on cell 
surface), rather than the quality of AAV prep because the unbound particles remaining in the 
medium can be transferred to successfully infect new cells as well. These results propose the 
existence of a non-infectious trafficking pathway as another reason for the high particle-to-
pfu phenomena in AAV infection in addition to the defective particles in AAV preparations. 
We also noticed a wide variation in the number of nuclear particles per cell at every time 
point (Fig.II-10B). This supports a highly heterogeneous susceptibility of each cell to AAV2 
infection and explains the variation of AAV2 transgene GFP expression among individual 
cells. As a result, by quantitating the number of virions in a single cell as accessible by this 
method, one will be able to correlate the number of viral particles in a cell with the amount of 
transgene expression to address questions like how many virions are needed to express a 
certain amount of transgene. Typically, one will be able to observe the expression of double-
stranded GFP transgene in vitro at about 6-8 hours after infection. Given the several hours 
required for the maturation of a GFP molecule to give fluorescence (Heim et al. 1995), such 
observation indicate that viral particle should enter nucleus and release genome within couple 
hours p.i.. The kinetics of AAV nuclear trafficking revealed in this study clearly 
demonstrated the early AAV2 nuclear entry events within 2 hours p.i. (Fig.II-10B), which 
provides a molecular rational for such a gene expression profile. In dose response studies, the 
number of virions in the nucleus does not increase linearly with the number of nuclear 
membrane associated virions at 2hrs p.i. (Fig.II-10D). This result suggests that there may be 
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limited sites/routes for AAV2 nuclear entry through the nuclear membrane, and provides a 
sound explanation for the observation that the fold increase in virion dosage does not 
translate to equivalent fold increase in transduction (Fig.II-11). Experiments to confirm this 
hypothesis are ongoing. With such scenario, this method enables one to quantitate the effects 
of pharmacological drugs and AAV variants on the nuclear transportation of AAV particles 
to facilitate the direction towards improving this vector’s performance. 
Similar to the documentation of nuclear entry dynamics, the kinetics of viral 
trafficking through other cellular structures (i.e. small vesicles, cell surface, microtubules) 
can also be documented with this method (Fig.II-6). The spatial-temporal distribution of all 
viral particles within the host cells throughout the entire trafficking pathway can be 
determined by integrating all the information regarding the kinetics of virions in various 
cellular structures. It is noted that about 1:100 rAAV2 particles are infectious consistent with 
a recent report (Zeltner et al. 2010), suggesting that only 1 out of 100 viral particles in culture 
medium will successfully infect a cell in the culture dish. Our study shows that only about 
5% of rAAV2 in the medium will attach to the cell surface for internalization (as suggested 
by Fig.II-10B). Our heparin competition and heparanase treatment studies demonstrate that 
all particles tracked in these experiments were 100% positive for first step in infectious 
pathway (i.e. viral binding), making the above observations relevant irrespective of the 
particle-to-infectious-unit ratio. 
Understanding the distribution of viral and non-viral vectors in vivo is extremely 
valuable to advance current drug/DNA delivery strategies. In this study, we have successfully 
applied our quantitative 3D microscopy method to study the distribution of AAV2 particles 
in animal tissues. We and other groups have observed the limited spreading of AAV2 
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transduction around the needle track as indicated by the expression pattern of various 
reporter genes (Fig.II-12A, and (Kessler et al. 1996; Fisher et al. 1997; Pruchnic et al. 2000)). 
However, there is no direct evidence on AAV2 trafficking that provides the molecular 
rationale for such transgene expression profiles in vivo. To address this question, we used the 
quantitative microscopy method to directly quantitate the distribution of AAV2 particles in 
mouse muscle over time. Our results for the first time showed that the AAV2 particles were 
localized at the injection site during the first 30 minutes and then uniformly spread through 
tissues up to three muscle fibers away from the injection site over 4hrs (Fig.II-12B). This 
result is significant in that it allows one to correlate viral spread with expression and should 
provide insight into vector tropism when studying capsid variants specific for muscle or 
various tissues such as brain and eye (Kessler et al. 1996; Fisher et al. 1997; Davidson et al. 
2000; Gregorevic et al. 2004; Sun et al. 2005; Wang et al. 2005). Another important question 
is how the viruses traffic to the cells distal from the injection site (Kotchey et al.; Kessler et 
al. 1996; Fisher et al. 1997; Davidson et al. 2000; Gregorevic et al. 2004; Sun et al. 2005; 
Wang et al. 2005; Di Pasquale et al. 2006). Transcytosis has been proposed as a mechanism 
for the spreading of various viruses, including HIV, poliovirus and AAV, and most of these 
studies involved epithelial cell barriers using in vitro transwell cell culture (Kotchey et al.; 
Ouzilou et al. 2002; Bomsel et al. 2003; Di Pasquale et al. 2006; Bhat et al. 2007). However, 
little information is available regarding the mechanism of trafficking for AAV particles in 
vivo. Our studies using this quantitative 3D microscopy method show that almost all viral 
particles localized to the boundary of the muscle fibers (sarcoplasm) but not inside the fibers 
when trafficking to the distant fibers (Fig.II-12B). This observation strongly suggests that 
most AAV2 particles traffic through the endomysium between muscle fibers instead of 
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traversing through myofibers. These virions between muscle fibers, we believe, are infectious 
as indicated by the transgene expression in these muscle cells (Fig.II-12A). It is also 
noteworthy that the trafficking kinetics showing virions in muscle nuclei at 30min to 4hrs 
(Fig.II-12B) combined with the absence of AAV2 in nuclei at 6 days p.i. (Fig.II-12C) 
suggests that nuclear AAV2 vectors release their genomes quite rapidly. Previous reports 
demonstrated that the expression of AAV2 transgenes in muscle did not reach the peak until 
around 5 weeks p.i. (Fisher et al. 1997; Chao et al. 2000). These studies in combination may 
support that, after uncoating, AAV2 transduction may be impacted by other cellular factors 
such as the rate-limiting step of second strand synthesis (Ferrari et al. 1996; Fisher et al. 
1996; McCarty et al. 2001). Additionally, at 6 days after injection, AAV2 particles were also 
detected inside of the muscle fibers/cells (Fig.II-12C). This observation supports a hypothesis 
that, unlike in cultured cells, viral particles in vivo can persist in myofibers potentially 
providing a temporal reservoir of virus. And these virions may traffic to the nucleus and 
contribute to viral transduction at later times (over 2 weeks), which also could be an 
explanation to the observed AAV transduction profile in muscle (Fisher et al. 1997; Chao et 
al. 2000).  
This quantitative 3D distribution microscopy approach presented here was originally 
designed to quantitatively examine how pharmacological reagents and viral genetic variants 
impact the trafficking kinetics and bio-distribution of viral vectors. With this approach, we 
have generated a panel of very interesting and biological meaningful results consistent with 
previous reports as well as several novel observations that have not been previously 
documented. These findings both support the current working knowledge of AAV biology 
and provide a better mechanistic insight into the behavior of this viral vector in vitro and in 
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vivo. It will be of particular interest to quantitatively compare the trafficking behavior of 
various AAV serotypes and chimeric vectors, as well as mutant capsids defective/enhanced 
in viral trafficking. Data from such studies should provide guidance for the rational design of 
optimal gene therapy vectors. Therefore, such an ability to quantitate the distribution and 
trafficking kinetics of nanoparticles (Fig.II-13C) should facilitate a quantitative evaluation of 
the effects of pharmacological reagents and vector variants on the delivery performance of 
these particles in cultured cells as well as animal tissues. Finally, in combination with 
pharmacological tools and live cell imaging, this 3D quantitative distribution microscopy 
approach will provide a comprehensive and powerful method to understand the physiological 
life cycle of gene-delivery vectors, as well as the intracellular behavior of other nanoparticles 
in vitro and in vivo. 
 
 
 
  
CHAPTER 3 
 
CYTOPLASMIC TRAFFICKING, ENDOSOMAL ESCAPE, AND PERI-NUCLEAR 
ACCUMULATION OF AAV2 PARTICLES ARE FACILITATED BY 
MICROTUBULE NETWORK 
 
Summary 
 
Understanding AAV trafficking is critical to advance our knowledge in AAV biology 
and exploit novel aspects of vector development. Similar to most DNA viruses, after receptor 
binding and entry, AAV traverse the cytoplasm and deposit the viral genome in cell nucleus. 
In this study, we examined the role of microtubule (MT) network on AAV productive 
infection. Using pharmacological reagents (e.g. Nocodazole), live cell imaging, and flow 
cytometry analysis, we demonstrated that AAV2 transduction was reduced by at least 2-fold 
in the absence of MT network. Cell surface attachment and viral internalization were not 
dependent on intact MT network. In treated cells at 2hrs post-infection, quantitative 3D 
microscopy determined a reproducible difference in number of intracellular particles 
associated with nuclear membrane or the nucleus compared to controls (6-7% vs 26-30% 
respectively). Confocal microscopy analysis demonstrated a direct association of virions with 
MTs, further supporting a critical role on AAV infection. To investigate the underling 
mechanisms, we employed single particle tracking (SPT) to monitor the viral movement in 
real-time. Surprisingly, unlike other DNA viruses (i.e. Ad and HSV) that display bi-
directional motion on MTs, AAV2 displays only uni-directional movement on MTs towards 
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the nuclei with peak instantaneous velocities at 1.5-3.5m/s. This rapid and uni-directional 
motion on MTs lasts for about 5-10 seconds and resulted in AAV particles migrating more 
than 10 m in the cytoplasm reaching the nucleus very efficiently. Furthermore, electron 
microscopy analysis determined that, unlike Ad and HSV, AAV2 particles were transported 
on MTs within membraneous compartments, and surprisingly the acidification of AAV2 
containing endosome was delayed by the disruption of MTs. These findings altogether 
suggest an as yet undescribed model in which after internalization, AAV2 exploits MTs for 
rapid cytoplasmic trafficking in endosomal compartments uni-directionally towards peri-
nuclear region where most acidification events for viral escape take place.  
 94 
 
Introduction 
 
Adeno-associated virus (AAV), a member of parvovirus family, is unique in that it 
requires helper virus (e.g. Ad, HSV) for productive replication. This non-enveloped 
icosahedral protein capsid (~20nm in diameter) packages a 4.7kb single-stranded genomic 
DNA. The capsid is composed of three overlapping subunit proteins, encoded by the Cap 
gene, at a ratio of 1:1:10 (Vp1:Vp2:Vp3). Due to its unique properties including non-
pathogenicity, ability to transduce dividing and non-dividing cells, breadth of tissue tropism, 
and sustainable transgene expression, several recombinant AAV capsids especially serotype 
2 (rAAV2) have been extensively exploited as gene therapy vectors (Wu et al. 2006). The 
potential of this vector has been well demonstrated by recent successes in several clinical 
trials including treating Leber’s congenital amaurosis (Maguire et al. 2008) and Hemophilia 
B (Nathwani et al. 2011). Despite many advances in vector developments, administration of 
high dose viral particles is required to achieve efficient transduction due to rate-limiting steps 
including pre-existing immune response and non-specific targeting (Rogers et al. 2011). In 
addition to these limitations, host cell also exploits various cellular components as barriers to 
AAV productive infection, including the critical steps required for viral trafficking (e.g. cell 
surface uptake, cytoplasmic trafficking, endosomal escape, nuclear entry, etc.) (Wang et al. 
2011). Better understanding of the AAV cellular trafficking will advance our knowledge in 
AAV biology and facilitate the development of enhanced AAV vectors. 
To successfully transduce a cell, AAV virions have to travel through a variety of 
cellular structures and organelles consecutively, including cell surface binding and 
internalization, cytoplasmic trafficking, and finally nuclear entry. It is known that AAV2 
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virions bind to its primary receptor Heperan Sulfate Proteoglycan (HSPG) on cell surface 
(Summerford et al. 1998) and internalized through clathrin-dynamin mediated pathway 
(Duan et al. 1999; Bartlett et al. 2000), which are facilitated by co-receptors including 
integrins (Summerford et al. 1999)  and FGF receptors (Qing et al. 1999). After entry, the 
virus remains associated with endosomes until acidification of the compartment which 
triggers exposure of the N-terminus of Vp1 protein (Sonntag et al. 2006). The N-terminus of 
Vp1 carries phospholipase activity and facilitates viral particles escaping by breaking down 
the endosomal membrane (Sonntag et al. 2006). Successful transduction of AAV requires 
that its genome be delivered into the nucleus, which is believed to be achieved by nuclear 
localization signals on the capsid subunit Vp1 (Grieger et al. 2006). However, little is known 
about how the viral particles traverse across the dense cytoplasm micro-environment from 
the cell peripheral to nuclear proximity, where AAV enters the nucleus.  
Microtubules (MTs) are a component of cytoskeleton and are rope-like polymers of 
tubulins. MTs are highly dynamic as characterized by alternate phases of elongation and 
shrinkage, and play critical roles in a variety of cellular processes including maintaining cell 
structure, intracellular transportation, forming the spindle during mitosis, to name a few 
(Desai et al. 1997). Their roles in intracellular transport are usually achieved by either their 
own growth dynamics (Roohvand et al. 2009) or the activities of associated motor proteins, 
particularly kinesin and dynein (Leopold et al. 2006). Numerous studies have shown that 
both non-enveloped and enveloped viruses utilize MTs in infecting their host cells. This is 
typically exemplified by the utilization of dynein by viral particles to traffic through the 
crowded cytoplasmic environment to the nucleus. For AAV, previous studies have reported 
that MT disruption impairs AAV transduction (Sanlioglu et al. 2000) and AAV can bind the 
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cytoplasmic dynein in an in vitro binding assay (Kelkar et al. 2006). However, these studies 
were contrasted by another publication that AAV transduction was not affected by the 
disrupted MT network or dynein motor activity (Hirosue et al. 2007). As a result, the exact 
roles of MTs on AAV transduction as well as the underling mechanisms are yet unclear.  
In this study, we have investigated the exact role(s) of MTs on AAV transduction and 
corresponding potential mechanisms using multiple techniques including confocal 
microscopy, live cell imaging, quantitative 3D microscopy, pharmacological reagents, and 
single particle tracking. Data from live cell imaging and flow cytometry analysis 
demonstrated that the viral transduction was impaired in the presence of several chemicals 
used to disrupt MTs. This result was further supported by the measurements from 
quantitative microscopy that the proportions of AAV particles associated with nuclear 
envelop or inside the nucleus, were significantly diminished upon MT disruption. In single 
particle tracking experiments, we observed that AAV virions display three classical types of 
particle motions such as confined diffusion, normal diffusion, and directed motion. For the 
first time, we demonstrated the fast and uni-directional migration of AAV2 on MTs with 
peak instantaneous velocity up to 1.5-3.5 m/s, which is consistent with the motion mediated 
by dynein motor. Furthermore, our observations from electron microscopy and 
pharmacological studies determined for the first time that AAV2 traffics on MTs in 
endosomal compartment and acidification of such structure is dependent on intact MTs. 
Above data altogether have strongly supported an as yet undocumented model in which 
AAV2 exploits MTs for its rapid-directed cytoplasmic transportation towards the peri-
nuclear sites where acidification of endosomes for viral escape take place.   
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Materials and Methods 
 
AAV2 production, purification and labeling. AAV2 was produced in HEK-293 
cells as previously described (Grieger et al. 2006). Briefly, cells were transfected with three 
plasmids: pXR2, pXX680, and pTR-CMV-GFP containing the GFP reporter transgene 
flanked by two ITRs. At 60hrs after transfection, cells were harvested and nuclei were 
isolated using hypotonic buffer and Kontes homogenizer (Grieger et al. 2006). AAV2 
particles were recovered by resuspending the nuclear pellet in PBS with 0.5% Deoxycholate 
(DOC) and then sonicated for 1min. Highly pure virus was then retrieved as described 
previously (Xiao et al. 2011). Briefly, after DNase treatment, virus suspension was subjected 
to one round of cesium chloride (CsCl) step gradient density fractionation and another round 
of fractionation using CsCl continuous gradient density. Determination of peak viral 
fractions, dialysis of virus, and measurement of viral titers by qPCR were done as described 
(Grieger et al. 2006). The infectivity of AAV is determined to about 1 transduction unit per 
100 particles. 
AAV2 was covalently labeled with Cy5 or 1.4nm Nanogold particles as described in 
manufacture’s protocol with slight modification. Briefly, purified AAV2 were incubated for 
2hr at 4℃ in PBS with a 20-fold molar excess of Mono-NHS-Cy5 (GE Healthcare) or Mono-
NHS-Nanogold (Nanoprobes) over the capsid protein units. Free dyes or Nanogold were 
removed from labeled viral particles by dialysis against PBS containing 5% sorbitol and viral 
solutions were stored at -80℃ as small aliquots. The degree of labeling (DOL) of Cy5-AAV2 
was determined by spectrophotometry as described by manufacturer’s instructions. Labeled 
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viral titers were determined by both dot blot (Grieger et al. 2006) and qPCR. Infectivity of 
the viral particles was determined by GFP reporter gene assay. 
Cell culture and drug treatment. Hela cells (American Type Culture Collection) 
were grown in Dulbecco’s modified Eagle medium (DMEM, Invitrogen) with 10% FBS in 
5% CO2 incubator. All cells were passaged every 2-3 days for up to ten passages and new 
aliquots of frozen cells were recovered from liquid nitrogen. To disrupt microtubules, the 
cells were incubated with medium containing 30M Nocodazole or 10M Vinblastine for 
30-60 minutes before experiments. For lysosomotropic reagents, 50M Chloroquine or 
64nM Bafilomycin A1 were administrated to block the acidification of endosomes. The 
drugs were maintained in the culture throughout the experiments. 
Pulse infection and Immunofluorescence. Pulse infection of AAV2 was performed 
as previously described (Xiao et al. 2011). Briefly, HeLa cells were seeded on 12-mm glass 
coverslips at 24hrs before infection. Next day, after incubation in DMEM containing 20mM 
HEPES at 4℃ for 5min, cells were inoculated with Cy5-AAV2 (~5,000 vgs/cell) at 4℃ for 
another 40min. Cells were washed with PBS to remove unbound virions and transferred to 
37℃ incubator (regarded as 0hr p.i.).  
For immunofluorescence, cells were washed with PBS and then fixed with 4% 
paraformaldehyde (PFA) for 15min at room temperature (RT). The cells were then 
permeabilized with 0.2% Triton X-100 in PBS for 5min at RT. After blocked with 
immunofluorescence buffer (IFB) (5% normal goat serum in PBS containing 0.05% Tween-
20) for 1hr at RT, the cells were incubated with primary antibody to detect tubulin (Rat 
monoclonal from Abcam Inc.) diluted in 50% IFB for overnight at 4°C. The cells were then 
incubated in secondary antibody, diluted 1:2,000 in 50% IFB (anti-mouse Alexa-Fluor 488 
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[Molecular Probes]), for 1hr at RT. After six washes with PBS, coverslips were mounted cell 
side down on glass slides with mounting medium (Prolong Antifade Gold with DAPI [4’,6’- 
diamidino-2-phenylindole]; Molecular Probes).  
Reporter gene assay and live cell imaging. At three hours after pulse infection of 
self-complementary AAV2 containing TR-CMV-GPF, Hela cells were transferred to the 
stage of Olympus IX-70 for recording the GFP expression in real-time. The camera was set 
to take a frame of GFP expression in DMSO or Nocodazole treated cells every five minutes. 
The snapshots of GFP expression were taken at the indicated time points from the video and 
the level of GFP expression were measured by the mean fluorescence intensity of GFP using 
Image J program.  
Quantitative 3D microscopy. Hela cells pulse infected with Cy5-AAV2 were fixed 
by PFA and mounted to glass slides as described above. The distribution of viral particles in 
Hela cells were examined using a Zeiss LSM710 laser scanning confocal microscope 
equipped with a Plan-Apochromat 63×/NA 1.40 oil objective. Stacks of 20-30 focal planes 
were captured at 0.31μm z-intervals through the depth of the cell. 3D images of the cells 
were reconstructed by using the image stacks. All images were acquired at pixel dimensions 
of 0.13×0.13×0.31μm (X, Y, Z) to fulfill the Nyquist sampling.  
Deconvolution was performed by AutoDeblur software (Media Cybernetics Inc.) 
using iterative and constrained algorithms as described previously (Xiao et al. 2011). The 
procedure started with a theoretical PSF derived from the actual setting of Zeiss710 confocal 
microscope, including NA of the microscope objective, refractive index of the medium, 
excitation wavelength, emission wavelength, confocal pinhole radius, pixel size, z-axis 
interval, and microscope type (i.e., wide field, confocal). A new adjusted adaptive PSF 
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derived from the previous deconvolution round was used to generate next adaptive PSF that 
fits the real imaging data better than the previous one (termed as one iteration or 
deconvolution round). A 12-round of iteration was used to deconvolve all the confocal 
images in this study.  
All deconvolved image stacks was processed using IMARIS software package 
(Bitplane AG, Zurich, Switzerland) for visualization and quantification as described 
previously (Xiao et al. 2011). Briefly, each deconvolved image stack was reconstructed using 
a volume rendering module and smoothened by a 3D-median filter. Subsequently, an 
isosurface rendering module was applied through thresholding by the fluorescence intensity 
that is slightly higher than background. For Cy5-AAV2, the isosurface rendering was 
thresholded at the fluorescence intensity of 1500a.u. (the upper boundary of background). 
For DAPI, isosurface rendering was thresholded at the fluorescence intensity of 2900a.u.. 
Parameters (volume, MFI, TFI) for these isosurface coated Cy5-AAV2 objects were 
extracted from the IMARIS program and analyzed to determine the localization of particles 
as described previously (Xiao, 2011).  
Internalization assay. Pulse infection and immunofluorescence on Hela cells were 
carried out as described above, except that the cells were not permeabilized when incubating 
with mouse monoclonal antibody A20 to specifically probe the viral capsids on cell surface. 
The co-localization between A20 and Cy5 signal was examined by 3D microscopy as 
described above. In this scenario, A20 positive Cy5-AAV2 presents the virion on cell surface 
and A20 negative Cy5-AAV2 presents the virion inside the cells.  
Single particle tracking and analysis. For fluorescence imaging, Hela cells were 
cultured in phenol red-free DMEM with 10% FBS in Petri dishes with poly (L-lysine)-coated 
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glass coverslips on the bottom. Before fluorescence experiments, cells were washed in 
serum-free, phenol red-free medium supplemented with 20mM HEPES (pH 8.0). The 
movement of Cy5-AAV2 particles was recorded by an Olympus IX-81 microscope equipped 
with Hammatsu Camera. 
The trajectories of AAV particles were generated by the “cell” module in the 
IMARIS program. The location of each viral particle was computed as the centroid of the 
bright spot. The parameters (instantaneous speed, displacement, displacement length) of the 
viral trajectories were directly extracted from the program as following:  
Instantaneous speed at time index t:   ( )  
√  (     )    (     )  
 ( )  (   )
  with Dx(t1,t2) = 
Px(t1)-Px(t2); where T(t) is time in seconds at time point t, Px(t) is x-position of particle at 
time index t.  
Displacement of particles at time ∆t after initial time point t0:   
D
2(∆t) = Dx
2
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2
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Displacement length of a viral trajectory: D(     )  √  (     )    (     )   , 
where tL is the last time index of the trajectory. 
MSD plot analysis was carried out as described previously (de Bruin et al. 2007; 
Akita et al. 2010). For each trajectory of an AAV particle, the MSD for each time interval 
was calculated by the following formula:  
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Where N is the total number of frames in the video, ∆t is the time interval between 
two successive frames, and n and i are positive integers.  
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Transmission electron microscopy (TEM). For negative staining of AAV2 and 
Nanogold-AAV2, viral particles in PBS were pipetted onto a glow-discharged copper grid. 
The grid was washed twice with water and then stained with 2% uranyl acetate. For 
visualizing Nanogold-AAV2 in cells, infected Hela cells were fixed at room temperature in 
2% glutaraldehyde (in 0.15M sodium phosphate buffer, pH7.4) for 20-30 minutes, followed 
by 1hr in 1% OsO4. Silver enhancement was applied on the ultrathin sections. Electron 
microscopy images were taken with a LEO EM910 transmission electron microscope at 
various magnifications. 
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Results 
 
Microtubule disruption impairs AAV2 transduction. Microtubule (MT) network 
has been shown to be required for successful infection and replication of viruses, including 
CPV and BPV. To investigate the role of MTs on AAV’s infection, we first examined 
whether MT disruption affects viral transduction. Recombinant AAV2 (rAAV2) carrying 
self-complementary GFP transgene cassette was used in reporter gene assays to evaluate the 
level of viral transduction. Self-complementary AAV2 (scAAV2) was designed to overcome 
the step of second strand synthesis of viral DNA for successful transduction (McCarty et al. 
2001). AAV2 particles were incubated with cells at 4 
o
C for about 40 minutes and unbound 
particles were then removed by washing before transferring cells to 37 
o
C for subsequent 
viral events. This procedure is defined as “pulse infection” to synchronize viral infection, 
which was used in all experiments throughout this study. In this study, we used mean 
fluorescence intensity (MFI) reflecting the average number of GFP molecules per cell to 
measure the level of AAV2 transduction. To better understand the viral transduction profiles, 
videos were taken on an IX70 microscope to record the expression of the viral transgene GFP 
in real-time. Briefly, three hours after pulse infection with scAAV2-GFP, Hela cells were 
transferred to the microscope stage for live imaging up to 21hrs p.i.. Snapshots were taken 
from the videos at 3hrs, 6hrs, 8hrs, 12hrs, 16hrs, and 21hrs after infection (Fig.III-1A). The 
GFP expression by AAV2 can be detected as early as 6-8hrs p.i. in DMSO treated cells, but 
was only barely detectable at 8hrs p.i. in Nocodazole treated cells. The quantitative data on 
the GFP mean fluorescence intensity (MFI) agrees with such observation (Fig.III-1B). To test 
if Nocodazole reduces AAV transduction in a viral dose-dependent manner, different MOIs 
of AAV were used to pulse infect the Hela cells in the presence of Nocodazole or DMSO and 
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GFP expression were measured by flow cytometry. To exclude the potential effects of dead 
cells on the quantification, we washed the cells in each well three times with PBS before 
harvesting them for flow cytometry analysis to remove any floating or loosely attached cells 
(typically are dead ones). With this experiment procedure, we ensured that about 95% of the 
cells subject to flow cytometry analysis are viable (data not shown). The histogram in figure 
III-1C demonstrates that Nocodazole treatment before AAV inoculation reduced the viral 
transduction at all tested dosages from 80 vgs/cell to 10,000 vgs/cell (Fig.III-1C and III-2). 
There was no significant difference between pulse infections at 37 
o
C and at 4 
o
C on the 
reduction of viral transduction by Nocodazole treatment (Fig.III-1C and III-3).   
Nocodazole induced MT disassembly could have reduced the viral transduction by impairing 
either the viral trafficking or the promoter activity of transgene cassette. To examine the 
potential effects of Nocodazole on the promoter activity of AAV transgene cassette, we 
measured the GFP expression from plasmid transfection of corresponding transgene cassette 
in AAV in the presence of DMSO or Nocodazole. Our data show that level of GFP 
expression from plasmid transfection in the Nocodazole treated cells is not significantly 
different from that in DMSO treated cells (Fig.III-4). This observation suggests that 
Nocodazole treatment does not alter the activity of promoter in transgene cassette, but 
instead, affects the AAV transduction most probably at the level of viral trafficking or 
processing. Importantly, the reduction of viral transduction was not limited to the 
Nocodazole treatment but also observed with other MT-disassembly drugs including 
colchicine and vinblastine (Fig.III-5). This result further demonstrates that it is MT 
disruption but not the side-effect of Nocodazole impairs the viral transduction.   
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Figure III-1. Microtubule disruption before viral inoculation reduces early AAV2 
transduction. At 30-60 min after pre-treatment with DMSO or Nocodazole, Hela cells were 
incubated with AAV2-CMV-GFPsc (scAAV2-GFP) particles at 4 
o
C for 40 min and 
unbound virions were washed out before transferring Hela cells to 37 
oC (“pulse infection”). 
A video was taken of the GFP expression from 3hrs to 21hrs after pulse infection. A) 
Snapshots of the video were taken at 3, 6, 8, 12, 16, 21hrs p.i. B) Quantification of GFP 
fluorescence intensity in the snapshots by Image J. C) Hela cells were treated with DMSO or 
Nocodazole 30-60 min before pulse infection with scAAV2-GFP at different dosages (80, 
400, 2000, 10000 vgs/cell). GFP expression was measured by flow cytometry at 11 hours p.i. 
and mean fluorescence intensity (MFI) was normalized to that of DMSO treatment. 
Normalized ratio of the percentage of GFP positive cells is shown in figure III-2. 
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Figure III-2. Normalized ratio of the percentage of GFP positive cells at various viral 
dosages (80, 400, 2000, 10000 vgs/cell). 
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Figure III-3. MT disruption by Nocodazole impaired viral transduction after the cells 
were pulse infected with AAV2 at 37 degree. Histogram shows the normalized GFP MFI in 
the DMSO or Nocodazole treated cells. 
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Figure III-4. MT disruption by Nocodazole does not interfere with the activity of 
promoter in viral transgene cassette. At 16-20hrs after transfected with Plasmid TR-CMV-
GFP using Polyethyleneimine (PEI), Hela cells were treated with DMSO or Nocodazole. At 
10-12hrs after drug treatments, cells were harvested for flow cytometry analysis to measure 
the GFP expression. The histogram shows that there were no significant difference on GFP 
expression between DMSO and Nocodazole treated cells. 
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AAV2 attachment and internalization on the cell surface are not affected by MT 
disruption. MTs have been previously demonstrated to be critical for clathrin-dynamin 
mediated viral entry as well as cytoplasmic trafficking of viruses (Van de Walle et al. 2001; 
Gilbert et al. 2004; Greber et al. 2006; Clemente et al. 2009). Here we examined whether 
intact MTs are required for the attachment and internalization of AAV2 particles on cell 
surface. Immediately after pulse infection, cells were harvested and subjected to viral 
genome extraction. The average number of viral genomes per cell was measured by 
quantitative PCR (Fig.III-6A). The histogram in figure III-6A shows that the amount of viral 
particles attached to the Nocodazole-treated cells is comparable to that of control cells, 
demonstrating that intact MT network is not required for cell surface binding of AAV2. To 
test if internalization of AAV2 particle was affected by the disruption of MTs, we employed 
both Cy5-AAV2 particles and a mouse monoclonal antibody A20, which can specifically 
recognize intact viral particles. For immunofluorescence on the cells with intact cell 
membrane before permeabilization, antibody will not be able to enter the cell and only probe 
the viral particles on cell surface. Under this scenario, Hela cells were pulse infected with 
Cy5-AAV2 and fixed with paraformaldehyde at 0hr or 1hr after infection. Without 
permeabilization, cells were probed with A20 antibody and co-localization between Cy5 and 
A20 signal were imaged with confocal microscopy (Fig.III-6B). Cy5 signal represents all the 
viral particles on cell surface and inside the cells, and A20 signal only highlight the viral 
particles on cell surface. As a result, A20 positive Cy5-AAV2 particles are on cell surface 
and A20 negative Cy5-AAV2 particles are internalized and inside the cells (Fig.III-6C). 
Maximum intensity projection (MIP) was applied to display 3D information of co-
localization between A20 and Cy5 signal in 2D images (Fig.III-6B). Figure III-6B shows 
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Figure III-5. Various anti-microtubule drugs can impair AAV2 transduction. At 1hr 
after treatment with various anti-microtubule drugs (Nocodazole, Colchicine, and 
Vinblastin), Hela cells were pulse infected with scAAV2-GFP at 2,000 vgs/cell. GFP 
expression was measured by flow cytometry at 10hrs p.i. and mean fluorescence intensity 
(MFI) was normalized to that of DMSO treatment. The histogram shows that all these anti-
microtubule drugs can impair the viral transduction. 
 
  
 111 
 
 
 
Figure III-6. MT disruption does not impair the attachment and internalization of 
AAV2. Hela cells were pre-incubated with DMSO or Nocodazole for 30-60 min before pulse 
infection of Cy5-AAV2. A) To determine the binding efficiency, cells were harvested at 0hr 
p.i. for viral genome extraction. The number of viral genomes per cell (vgs/cell) was 
determined by quantitative-PCR. B) and C) Cells were fixed at 0hr or 1hr p.i. without 
permeabilization. Nuclei were stained with DAPI (blue) and AAV2 capsids were stained 
with monoclonal antibody A20 (green). Before membrane permeabilization, A20 antibody is 
not able to access the viral particles inside of the cells and thus only binds to the un-
internalized AAV2 virions (yellow in the merged figures). B) Representative images from 
maximum intensity projection (MIP) show the co-staining between A20 and Cy5 signal. 
Several representative un-internalized AAV2 particles are highlighted by arrowheads. C) 
Quantification of co-localization between Cy5 and A20 as a measurement of viral particles 
remaining on cell surface and those which have internalized. 
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that almost all Cy5-AAV2 particles were also stained with A20 antibody on both control and 
Nocodazole-treated cells at 0hr after infection, which is consistent with the fact that almost 
all viral particles should be on cell surface without internalization at 0hr p.i.. At 1hr p.i., 
majority of Cy5-AAV2 particles were not stained with A20 antibody and only about 12% of 
viral particles were stained with A20 in the Nocodazole treated cells, which is comparable to 
that in control cells (Fig.III-6B,C). These data determine that neither binding nor 
internalization of AAV2 particles on cell surface is dependent on intact MT network.    
MT disruption reduces the peri-nuclear accumulation and nuclear entry of 
AAV2. Above results demonstrate that MT disruption before viral inoculation reduced the 
viral transduction by at least 2-fold and neither viral attachment nor internalization was 
impaired by Nocodazole treatment, suggesting the reduced transduction is more likely caused 
by the altered viral trafficking or processing (i.e. cytoplasmic trafficking, nuclear entry). For 
most DNA viruses, cytoplasmic trafficking from cell periphery to the peri-nuclear region is 
critical for the nuclear entry of viral components. As nuclear entry of AAV2 is known to be 
pre-requisite for successful viral transduction, we examined the efficiency of these events 
under Nocodazole or DMSO treatment. Here, we used Cy5-AAV2 particles generated by 
covalent labeling of purified AAV2 capsids with Cy5 fluorophores as described previously 
(Xiao et al. 2011). After pretreatment with Nocodazole or DMSO for 30-60min to allow fully 
disruption of MT by Nocodazole, Hela cells were pulse infected with Cy5-AAV2 and the 
localization of viral particles were examined at 2hrs p.i. using confocal fluorescence 
microscopy (Fig.III-7). Figure III-7A shows the representative distribution of AAV2 particles 
upon DMSO or Nocodazole treatment for 2hrs. To quantify such distribution, we used 3D 
quantitative microscopy as described previously (Xiao et al. 2011) and figure III-7B shows 
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Figure III-7.  Early peri-nuclear accumulation and nuclear entry is reduced by the 
disruption of MT network. Hela cells were pre-incubated with DMSO or Nocodazole 30-60 
min before the pulse infection of Cy5-AAV2. Cells were fixed at 0hr or 2hrs p.i.. Nuclei 
were stained with DAPI (blue) and MTs were stained with alpha-tubulin antibody (green). A) 
Representative 2D images show the distribution of Cy5-AAV2 particles (red) at 2hrs p.i. in 
the cells treated with DMSO or Nocodazole. B) Representative images illustrate the 
quantification of viral distribution using 3D microscopy in the cells treated with DMSO (a-c) 
or Nocodazole (d-f) as described previously (Xiao et al. 2011). a and d are top views. b-f are 
magnified side views of insets in a and d. b and e are side views observed above the nucleus 
(nuclear envelope indicated by blue layer based on DAPI signal). c and f are side views 
observed inside the nucleus (between the top and bottom nuclear envelopes). AAV2 particles 
in cytoplasm are highlighted as red, these associated with nuclear envelope are cyan, and 
these inside the nucleus are yellow. More details about viral distribution in these cells are 
shown in supplemental videos S3 and S4. C) Histogram shows the percentages of AAV2 
particles in the nuclei (a) and these associated with nuclear envelope (b) calculated from 15-
20 cells in each group based on the quantification illustrated in B).  
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the representative images to illustrate the actual quantification by presenting the views from 
different angles of the 3D images (Fig.III-7B). The quantitative data are presented in figure 
III-7C. In DMSO treated cells, AAV2 particles were distributed normally: about half of 
intracellular particles localized at nuclear periphery, 10-15% in the nucleus (with 39 particles 
per nucleus on average) and remaining particles were in the cytoplasm (Fig.III-7B, C). In the 
cells where MTs were fully disrupted by Nocodazole, only about 3% of viral particles were 
in the nucleus (about 12 particles per nucleus on average) and remaining 97% particles were 
scattered across the cytoplasm (Fig.III-7B,C). In the aspect of nuclear targeting, viral 
particles seem to get lost in the cytoplasm and randomly localize in the Nocodazole-treated 
cells. It is known that the nuclear envelope is one of the cellular structures that AAV2 
particles have to interact with before their nuclear entry. Figure III-7 clearly shows that a 
much smaller proportion of intracellular AAV2 virions localized at the peri-nuclear region in 
the Nocodazole-treated cells than that in DMSO-treated cells (Fig.III-7A, B). We then tested 
if reduced peri-nuclear localization of AAV2 has led to the reduced proportion of virions 
associated with nuclear membrane. Using the quantification method established previously 
(Xiao et al. 2011), we determined that only about 3% of AAV2 particles associated with 
nuclear membrane in the Nocodazole-treated cells compared to over 10% in the control cells 
(Fig.III-7C). This data suggest that the cytoplasmic trafficking from cell periphery to peri-
nuclear region may facilitate the virus to interact with nuclear membrane. All of these data 
support a model where MT disruption reduces the proportions of AAV2 particles in the peri-
nuclear and nuclear region, and thus reduces the viral transduction.  
 
 115 
 
 
 
 
 
 
Figure III-8.  AAV2 co-localizes with MTs. Cells were fixed at 30min (a-d) or 2hrs (e) after 
pulse infection with Cy5-AAV2. Nucleus was stained with DAPI (blue) and MTs were 
stained with alpha-tubulin antibody (green). The localization of Cy5-AAV2 (red) on MTs 
(green) is shown in a and e. b-d show the magnified view of the inset in a.  
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Figure III-9.  Fast and uni-directional movement of AAV2 towards the peri-nuclear 
region. Videos were taken at 1hr after pulse infection of Cy5-AAV2 using Olympus IX81 
inverted fluorescence microscope. A) snapshots of consecutive frames with 2.2s time interval 
shows the fast and directed movement of Cy5-AAV2 (purple and indicated by arrowheads) 
on microtubule (green) towards peri-nuclear region. B) Trajectory of Cy5-AAV2 particle 
indicated by arrowheads in A. Frames subject to the directional transport are shown as green 
points and lines, and those with confined motion in peri-nuclear region are indicated as black 
points Bar represents 5 m. C) The instantaneous velocity of the particle (indicated by 
arrowheads in A) over time. D) The displacement from the starting position (a) and mean 
square displacement (MSD) (b) are plotted for the particle indicated by arrowheads in A. In 
(b), the plot between MSD and time interval (T) is fitted by a quadratic curve (dotted line: 
MSD = 0.7269t
2 
+ 1.902t) with R
2
 = 0.9997.    
 117 
 AAV2 exploits MTs for rapid and uni-directional trafficking from cell 
periphery to peri-nuclear region. The reduced peri-nuclear accumulation and nuclear entry 
are most likely caused by the impaired MT-mediated cytoplasmic trafficking as evidenced 
for other viruses (Sodeik et al. 1997; Leopold et al. 2000; Greber et al. 2006). To further 
investigate the potential role of MTs on AAV2 infection, we first examined the co-
localization between virions and MTs in cells. At 30min or 2hrs after pulse infection with 
Cy5-AAV2, Hela cells were fixed with paraformaldehyde and MTs were probed with -
tubulin antibody. A confocal microscope was used to image the localization of AAV2 
particles on MT filaments (Fig.III-8). At 30min p.i., the majority of AAV2 were localized on 
the MTs at cell periphery. At 2hrs p.i., about 30% of viral particles were localized on the 
MTs at cell periphery, about 50% of viral particles finished trafficking from cell periphery to 
the peri-nuclear region and over 10% of intracellular particles have entered nucleus (Fig.III-8 
and (Xiao et al. 2011)).     
Next, we tested whether the role of MTs during AAV infection works at the step of 
cytoplasmic trafficking from cell periphery to peri-nuclear region. To this end, single particle 
tracking (SPT) in live cells was used to study the trafficking of AAV2 in the cytoplasm. 
From the previous SPT studies for other viruses including Ad and influenza (Lakadamyali et 
al. 2003; Akita et al. 2010), it is known that cytoplasmic transportation is usually 
characterized by fast and directional movements on MT filaments. In our SPT experiments in 
the non-treated cells, Cy5-AAV2 particles displayed rapid and uni-directional movements 
from the cell periphery to the peri-nuclear region (Fig.III-9A, B). This is different from the 
bi-directional movement of Ad or HSV on MTs. Figure III-9A suggests that such directed 
motion is on the MT tracks. Consistent with previous studies about MT-mediated trafficking 
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(Lakadamyali et al. 2003), the Cy5-AAV2 particle migrated with instantaneous velocities at 
1.5-3.5 m/sec when moving from cell periphery to the peri-nuclear region (Fig.III-9C). This 
movement persisted for only 5-10 seconds (Fig.III-9C), and allowed for a large displacement 
between the initial and final position of the particle (Fig.III-9D-a). Mean square displacement 
(MSD) analysis was employed to verify that the observed motion of the Cy5-AAV2 particle 
is an active transportation event rather than passive diffusion of virion in the cytoplasm. 
MSD analysis is typically used to describe three types of particle motions: confined 
diffusion, normal diffusion, and directed motion (Fig.III-11B). Active transportation on MTs 
is one type of directed motion, which can be described by a quadratic dependence of MSD on 
time interval T (Fig.III-11B). The MSD-T plot of the viral particle indicated by 
arrowheads in figure III-9A can be fitted into a quadratic curve, demonstrating that the 
movement of this particle is directed motion and is consistent with dynein-mediated 
retrograde trafficking on MTs (Fig.III-9D-b). 
 
Rapid-directional motion of AAV2 particle is ablated by MT disruption. To 
further investigate that such directed movement is mediated by MTs, we examined the viral 
trafficking in the presence of Nocodazole. Videos of viral trafficking were taken at 1-1.5 
hours after pulse infection of Cy5-AAV2 particles at about 1 frame/second. Compared with 
control cells, directional movement was completely ablated in the Nocodazole-treated cells 
(Fig.III-10, III-11). Based on MSD plot analysis (Fig.III-11B), the directed movement of 
AAV2 particle indicated by quadratic curve was only observed in the control cells but not in 
Nocodazole-treated cells (Fig.III-11C). Both normal diffusion characterized by linear 
dependence of MSD on T and confined diffusion indicated by 
 119 
 
 
 
 
 
Figure III-10. Trajectories of AAV2 trafficking. Trajectories (black curves) were 
generated for the viral particles continuously tracked over 20 frames in the supplemental 
movies S6 and S7. Brown lines highlight the outline of cells and cyan line highlight the 
outline of the nucleus. 
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Figure III-11.  Fast and uni-directional movement of AAV2 particles is dependent on 
intact microtubules. A) Representative trajectories for AAV2 in the DMSO or Nocodazole 
treated cells as shown in videos S6&S7. Bars represent 5 m. B) Three simulated MSD plots 
for various types of particle motion. The mean square displacement (MSD) is plotted against 
time interval T (t). Normal diffusion is usually described by a linear plot given by formula: 
MSD = 4Dt (D is diffusion coefficient). Directed motion is usually described by a quadratic 
curve given by formula: MSD = 4Dt + v
2
t
2
 (v is mean velocity of the motion). An asymptotic 
behavior with MSDt (<1) indicates confined diffusion. C) Histogram showing the 
proportions of viral particles with directed motion or diffusion from MSD analysis. D) The 
maximal instantaneous speed (a) and displacement length (b) of each AAV2 track. For C) 
and D), trajectories were generated only for these viral particles continuously tracked over 20 
frames and about 40-60 trajectories were analyzed for each group. 
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asymptotic behavior of MSD on T were not disrupted in the presence of Nocodazole. 
Particle motions with peak instantaneous velocities over 1.5 m/sec were totally lost in the 
presence of Nocodazole (Fig.III-11D-a). Correspondingly, particles motions resulting in 
large displacement (> 10 m) responsible for particle transportation from cell periphery to 
peri-nuclear region were also only observed in the control cells but not in the cells lack of 
intact MT network (Fig.III-11D-b). Above data demonstrate that rapid and uni-directional 
trafficking of AAV2 from cell periphery to peri-nuclear region requires intact MTs. Our data 
also suggest that intact MT network is unlikely to be involved in either confined or normal 
diffusions (Fig.III-11C).  
 
AAV2 migrates on MTs in the endosomes and the acidification of these 
structures is delayed by MT disruption. After internalization through clathrin-dynamin 
mediated endocytosis, several DNA viruses including parvoviruses have to escape from the 
endosomes upon the acidification of these membraneous structures. It is known that 
Adenovirus (Ad) escape from the endosome in an early stage during infection (within 30min 
p.i.) before these particles migrate on MTs (Leopold et al. 1998; Leopold et al. 2000). In 
contrast, little is known about the timing of endosomal escape and MT-mediated trafficking 
of parvoviruses. Our electron microscopy data demonstrates that AAV2 particles were inside 
the endosomes when migrating on MTs (Fig.III-12A). This observation is the first one to 
show that AAV2 particles, distinct from Ads, usurp the MT-mediated endosomal trafficking 
for their nuclear targeting. It is also known that the maturation of endosomes takes place 
during their trafficking on MTs from the cell periphery to the peri-nuclear region, where 
most matured late endosomes with low pH locate (Vonderheit et al. 2005; Huotari et al. 
2011). We used pharmacological studies to further test whether MTs mediated transportation 
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is required for the acidification of AAV-containing endosomes. Consistent with earlier report 
(Bartlett et al. 2000), chemicals (Bafilomycin and Chloroquine) that block endosomal 
acidification inhibited AAV transduction (Fig.III-12B-a). It was demonstrated previously that 
Adenovirus escapes from early endosome before migrating on MTs and its infection is not 
sensitive to the inhibition of endosomal acidification as early as 20-30 minutes after viral 
inoculation (Cassimeris et al. 1986; Leopold et al. 1998). Notably, our data demonstrate that 
the infection of most AAV2 particles was still sensitive to Bafilomycin and Chloroquine at 
1hr p.i. and these reagents were still able to partially inhibit (20% of) the viral transduction 
even added at 2hrs p.i. (Fig.III-12B-a). This observation suggests that some post-entry 
trafficking events including MT-mediated migration are required for at least a subset, if not 
all, of the viral particles before endosomal acidification to allow their escape from the late-
stage endosomes. In concert with this scenario, disruption of MTs delays the acidification of 
AAV-containing endosomes and viral escape as demonstrated by the data that administration 
of anti-MTs reagents (Nocodazole and Vinblastine) resulted in an increased inhibition on 
viral transduction by adding Chloroquine at 3hrs after pulse infection (Fig.III-12B-b). This is 
consistent with the earlier reports that AAV2 were routed to late endosomes for their 
infection (Douar et al. 2001; Ding et al. 2006; Xiao et al. 2011). These results suggest that 
AAV2 particles traffic on MTs in endosomes from the cell periphery to the peri-nuclear 
region, where acidification of these membraneous structures and viral escape take place.   
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Figure III-12. Association of AAV2-containing endosome with MTs and delayed 
endosomal acidification upon MTs disruption. A) AAV2 particles migrate on MTs in 
membraneous structures. AAV2 particles before (a) and after (b) labeling of nano-gold were 
demonstrated by TEM. Bar represents 20nm. (c) Micrograph showing the direct association 
of AAV-containing endosome with MTs at 1hr after pulse infection of nano-gold labeled 
AAV2, which is simplified in a cartoon diagram. In the cartoon, MTs are indicated with 
green lines, endosome membrane is indicated by black line, and virus is in red. (d). Bar 
represents 200nm. B) Acidification of viral containing endosomes is inhibited by 
lysosomotropic chemicals at various time points after pulse infection of AAV2 (a). At 1hr 
after pretreated with anti-MTs drugs (Nocodazole and Vinblastine), Chloroquine was added 
at 0hr or 3hrs after pulse infection of AAV2. To calculate the inhibition of viral transduction, 
the expression level of transgene GFP was measured by a flow cytometer and normalized to 
corresponding treatments without Chloroquine (b). 
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Discussion 
 
Cytoplasmic trafficking is critical for most DNA viruses to approach the peri-nuclear 
region and deposit their genomic DNA in the nucleus of host cells. Previous studies have 
demonstrated that either actin filaments or microtubules (MTs) are exploited by various 
viruses to traverse the dense cytoplasm. For AAV, the exact mechanism of cytoplasmic 
trafficking of this virus remains unclear, due to previous reports that are diametrically 
opposite in their conclusions (Sanlioglu et al. 2000; Kelkar et al. 2006; Hirosue et al. 2007). 
Here we have studied the role of MTs on AAV2 transduction and extensively investigated 
the underlying mechanisms regarding how MTs contribute to viral infection using various 
pharmacological and microscopy tools. Our data from live cell imaging and flow cytometry 
analysis determined the involvement of MTs in AAV2 infection, and the data from 
quantitative 3D microscopy and quantitative PCR analysis demonstrated that intact MT 
network is required for the nuclear targeting of AAV but not for cell surface attachment or 
endocytosis of this virus. In the present study, for the first time we have determined that the 
migration of AAV2 on MT tracks are fast (up to 1.5-3.5 m/s) which is consistent with 
dynein-mediated trafficking and are uni-directional which is different from the bi-directional 
motion of Ad or HSV on MTs. In addition, our study using electron microscopy and 
pharmacological experiments is the first one to suggest that AAV traffics on MTs in 
endosomes and acidification of these structures is dependent on intact MT network. The 
findings herein strongly support an as yet undocumented model in which after 
internalization, AAV2 exploits MTs for fast and uni-directional trafficking in endosomal 
compartments towards peri-nuclear region where most viral acidification events take place.  
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Figure III-13.  A model for the role of microtubules on the cytoplasmic trafficking and 
endosomal acidification for AAV2 escape. After binding and endocytosis on cell surface, 
AAV2 virions may take two possible trafficking routes towards the nucleus. Route I: For 
these internalized at sites distal from the nucleus, virions migrate on MT tracks in endosomes 
to traverse the dense cytoplasm towards peri-nuclear region of host cells. Route II: For these 
internalized at sites close to the nucleus, virions in endocytic vesicles can reach the nucleus 
by slower MT-independent migration through the cytoplasm between the cytoplasmic 
membrane and nuclear envelope. For both routes, acidification of AAV2 containing 
endosomal compartment happens at the peri-nuclear region and allows the escape of viral 
particles from vesicles, a pre-requisite step for nuclear entry. 
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Furthermore, our data that MT disruption never completely blocks AAV2 transduction 
suggests the existence of an alternative MT-independent trafficking pathway for this virus. 
These data together with earlier studies support a model of AAV2 trafficking during its early 
infection procedure (Fig.III-13, (Sanlioglu et al. 2000; Douar et al. 2001; Ding et al. 2006; 
Johnson et al. 2010)). 
Both DNA and RNA viruses hijack MTs to achieve productive infection in host cells. 
Several parvoviruses including CPV and BPV also have been shown to exploit MT network 
for their transduction (Suikkanen et al. 2003; Dudleenamjil et al. 2010). However, the role(s) 
of MTs on AAV infection remains controversial. To carefully examine the potential effect of 
MTs on AAV2 transduction, we employed live cell imaging to monitor the dynamics of 
transgene GFP expression in real-time as a measurement of successful viral transduction. In 
contrast to the non-treated cells where GFP fluorescence signal was readily visible as early as 
6hrs p.i., GFP expression was much lower in the Nocodazole-treated cells and was barely 
detectable until 8hrs p.i. (Fig.III-1A). This result is further confirmed by the flow cytometry 
data that the expression level of transgene GFP is lower in MT disrupted cells compared with 
control cells (Fig.III-1B). These observations are consistent with the studies from 
Englehardt’s group, supporting the involvement of MTs in AAV transduction (Sanlioglu et 
al. 2000). In contrast, a previous report concluded that intact MTs were not involved in AAV 
infection by measuring the percentage of GFP positive cells after inoculation of AAV-GFP 
(Hirosue et al. 2007). Interestingly, we also observed a similar proportion of GFP positive 
cells in both Nocodazole and DMSO treated cells with high viral loading (5k-10k vgs/cell), 
though GFP signal was much weaker in Nocodazole treated cells compared with control cells 
(Fig.III-1A, and Fig.III-2). It is known that only a few AAV2 particles in nucleus are needed 
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to turn a cell “green” (regardless how faint this “green” is) and thereby identified by flow 
cytometer as a “GFP positive cell” ((McCarty et al. 2001; Choi et al. 2005; Ding et al. 2006; 
Johnson et al. 2009) and data not shown). In addition, our quantitative microscopy data 
demonstrated that MT disruption only reduced the nuclear entry of AAV2 but didn’t 
completely block this process (Fig.III-7). Under this scenario, it is expected that only a 
decreased level of GFP fluorescence intensity but not percentage of GFP positive cells will 
be observed if the reduced number of nuclear virions upon MT disruption is still high enough 
to turn a cell “green”, which is particularly true when a high viral-dosage is used (Fig.III-1, 
III-2). As a result, GFP mean fluorescence intensity (MFI) is a more reliable measurement to 
assess AAV transduction in this study. Our data from multiple approaches including live cell 
imaging, flow cytometry analysis, and quantitative microscopy has strongly suggested that 
AAV particles exploit MT network during their infection. Additionally, MT disruption only 
reduced but not fully blocked viral transduction and nuclear entry, which suggests the 
existence of an alternative but slower trafficking route(s) in addition to MT network for AAV 
infection (Fig.III-13). And exploration of these potential alternative pathway(s) should shed 
light on the dynamics of AAV infection in various cell types. 
It was previously documented that after disassembled by Nocodazole or cold 
temperature, MT network can recover to pre-drug level by either washing out the drug or 
rewarming the cells to 37 
o
C within 10-20 minutes (Cassimeris et al. 1986). We also 
observed the full recovery of MT network from cold temperature at about 30 minutes after 
incubation at 37 
o
C (data not shown). Given that the flow cytometry assay was carried out at 
10-12hrs after pulse infection, the incubation of cells at 4 
o
C for viral binding should have 
minimal effects on AAV2 transduction. Consistently, we did not observe significant 
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difference between pulse infections at 4 
o
C and 37 
o
C on the reduction of viral transduction 
by Nocodazole treatment (Fig.III-1, III-3). To exclude the potential effect of dead cells on the 
viral transduction measurement, we washed the cells in each well three times with PBS 
before harvesting them for flow cytometry analysis to remove any floating or loosely 
attached cells. In this study, about 95% of cells used for flow cytometry analysis were viable 
as demonstrated by multiple methods including Trypan blue exclusion or 7-AAD exclusion 
assays (data not shown). The results and conclusions presented in this study are not 
influenced by the technical concerns such as contribution of dead cell artifact.  
To specifically study the cytoplasmic trafficking of viral particles after 
internalization, we carried out single particle tracking (SPT) experiments to trace virions at 1-
1.5hrs (Fig.III-9) after infection. Besides technical considerations associated with single 
particle tracking experiments, 1-1.5hrs p.i. is the better time to image MT-mediated AAV2 
trafficking for two reasons: first, at this time point, almost all AAV2 particles are internalized 
(Fig.III-6) and the observation of intracellular trafficking will not be confounded by the viral 
motions on cell surface typically happened at earlier time point; second, the location of 
MTOC can be readily visualized by the peri-nuclear accumulation of AAV particles, which 
will allow one to determine if the MT-mediated migration is towards or away from the peri-
nuclear region. As observed in other SPT studies (Akita et al. 2010), our SPT data show that 
about 8% of viral particles displayed rapid and directional motions with instantaneous speed 
up to 1.5-3.5m/s during our observation time in the normal cells. The remaining virions 
displayed either normal diffusion (Brownian motion) or confined diffusion, as an indication 
of movement of AAV in cytoplasm or actin filaments. As it takes about 2-4 hours for most 
virions to finish trafficking from cell periphery to peri-nuclear region (Fig.III-8), it is 
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expected to observe only a small subset of particles displaying rapid-directional movements 
on MTs (each event only persists for 5-10 second) in the limited time window (in the order of 
a minute) that we can trace the virions in the single particle tracking experiment. In addition, 
the live imaging only allows one to image a subset of viral particles on a certain focal plane 
in the cell and inevitably the investigator will lose track of other viral particles moving in the 
same cell at a different plane. Furthermore, fast-directional motion may be interrupted by 
temporary dissociation of viral particle from MT tracks or alternatively stalled motors 
(dynein for minus-end directed motion) (Tsai et al. 2000; Leopold et al. 2006). Under these 
experimental limitations, the “8%” from single particle tracking experiments does not 
precisely represent the portion of viral particles migrating on the MTs during the observation 
time, not along the entire viral trafficking period (several hours). Instead, this number is more 
to show the existence of MT-mediated fast and directional movements in the cells, when 
compared with the completely absence of such motion in MT disrupted cells. All and all, the 
window of observation that we utilized while short in duration supported the rapid and uni-
directional movement of AAV particles only when MT were intact.  
Interestingly, compared with control cells, AAV2 particles in a much smaller 
proportion were still detected in the nucleus of Nocodazole-treated cells (Fig.III-7). This is 
consistent with the observation in reporter gene (GFP) assay that AAV2 was still able to 
transduce cells in the presence of Nocodazole, though in a reduced level compared with 
control cells (Fig.III-1). One possibility for this observation is related to the inefficient MT-
independent trafficking of virions. Under this scenario, AAV2 particles could be internalized 
in the cell membrane close to the nucleus, where the virions only have to traverse a small 
distance to reach the nucleus (Fig.III-13 and (Leopold et al. 2006)). Movements over such 
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short distance (several microns) might be achieved by normal diffusion. Internalization in the 
sites around nucleus can be achieved by the direct binding of viral particles at these sites or 
viral surfing on cell membrane to these sites (Neumann et al. 2008). Our studies do not 
excluded the possibility that AAV2 particles may reach the nucleus through a much slower 
process by exploiting actin filaments or intermediate filaments (Ohkawa et al. 2010; Schuh 
2011). Although, it is not uncommon for viruses to exploit multiple pathways to ensure 
productive infection, we provide significant data to support the role of MTs whereas other 
putative pathways require further investigation. All these possible scenarios allow motions 
with lower velocity and/or directionality toward nucleus, and are supported by our 
observation that early AAV transduction was delayed in the presence of Nocodazole (Fig.III-
1A, 23B).  
It was also reported in an in vitro binding assay that cytoplasmic dynein can directly 
bind to AAV2 capsid (Kelkar et al. 2006). An interesting question is whether the rapid-
directed motion of AAV2 is mediated by the dynein associated with endosomes or that 
directly associated with viral capsid. It is known that AAV2 is internalized through clathrin-
dynamin mediated pathway into endosome compartments (Duan et al. 1999; Bartlett et al. 
2000). While we were not able to definitively determine dynein interaction with AAV-
containing endosome vs capsid specifically, our data strongly supports the usage of this 
motor in fast-directed movement of AAV. Interestingly, some dynactin subunits like p62 
were demonstrated to have a minimal impact on dynein-mediated functions and suggested to 
be dispensable for the function of dynactin complex (Quintyne et al. 1999; Schroer 2004). 
More importantly, recent studies have begun to demonstrate that dynein can directly bind to 
the pathogen-related cargos and suggest that dynactin may be dispensable especially for the 
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dynein-mediated pathogen trafficking (Grieshaber et al. 2003; Schroer 2004; Bremner et al. 
2009). Careful and sophisticated investigations will be required to address the issues 
regarding whether and how the dynactin complex contributes to the MT-mediated AAV2 
trafficking.  
It was interesting to note that AAV particles employed endosome for their 
transportation on MTs up to peri-nuclear region. We have employed electron microscopy 
analysis to determine that AAV2 particles are in the endosomal structures when migrating on 
MTs (Fig.III-12A). It is also known that acidification of endosomes is essential for escape of 
AAV2 from vesicle into cytoplasm (Bartlett et al. 2000; Douar et al. 2001). Our 
pharmacological study that MT disruption prolonged the sensitivity of AAV2 infection to 
Bafilomycin and Chloroquine strongly suggests that prompt acidification of AAV-containing 
endosomal compartment requires intact MTs (Fig.III-12B). These data altogether suggest an 
undescribed model for AAV in which after internalization, AAV2 rapidly and uni-
directionally traffics on MTs in endosomes directly towards peri-nuclear sites where most 
viral acidification events happen. This model is in concert with the notion that most acidic 
endosomes are localized at peri-nuclear sites where viruses escape from these membraneous 
structures such as influenza (Mellman et al. 1986; Lakadamyali et al. 2003). This model is 
also consistent with the earlier observations that AAV2 are associated with late endosomes 
(Ding et al. 2006) and that viral mutants (VP3-only and HD/AN) lacking phospholipase 
activity can be transported to the peri-nuclear region indistinguishably from parental virions 
(data not shown and (Johnson et al. 2010)), but remain non-infectious. Interestingly, AAV’s 
helper viruses like Ad and HSV are shown to exploit a different strategy. Instead of moving 
on MT in membraneous structures, both Ad and HSV have to escape from the endosomes 
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before trafficking on MTs, which is consistent with their direct interaction with both minus-
end-directed and plus-end-directed MT motor proteins, allowing the bi-directional motions 
documented for both Ad and HSV on these filaments (Dodding et al. 2011; Engelke et al. 
2011; Radtke et al. 2011). Typically, the infection of these viruses is not sensitive to the 
inhibition of endosomal acidification by Bafilomycin or Chloroquine as early as 20-30 
minutes after viral inoculation (Greber et al. 1993). In contrast, AAV particles apparently 
traffic uni-directionally on MTs determined by the interaction between the viral containing 
endosomes and dynein motors (Lakadamyali et al. 2003). Our data that the majority of 
AAV2 were still sensitive to both Bafilomycin and Chloroquine at 1hr p.i. implies that a 
more acidic environment is required for the exposure of Vp1 on viral capsid as well as the 
viral escape from these membranous structures (Mellman et al. 1986), compared with the 
early escape of Ad and HSV from endosomes at cell periphery (Sodeik et al. 1997; Leopold 
et al. 1998; Snyder et al. 2006). This result is consistent with the early notions that multiple 
viral components including Vp1 and Basic Regions on capsid have to externalize in the 
endosomes (Sonntag et al. 2006). The observation that, 80% of AAV2 was insensitive to 
Bafilomycin and Chloroquine treatments at 2hr p.i., indicates that most virions have 
accomplished all these viral events requiring endosomal acidification, and even may have 
escaped from the late endosomes. These studies altogether suggest that the rapid-directed 
motion of AAV2 happens when the viral particles are still inside the endosomes. It should be 
noted that our data does not exclude the possibility that some AAV2 can escape from the 
early endosome as an alternative pathway in the cells. Given that cytoplasmic dynein can 
directly bind to AAV2 capsid in vitro (Kelkar et al. 2006; Zhao et al. 2006), it will be of 
particular interest in the future to identify and mutate the dynein binding sites on AAV2 
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capsid and further investigate the trafficking of these mutant capsids. Furthermore, 
understanding the next steps of viral entry (i.e. nuclear entry transition from the peri-nuclear 
region) may shed critical insights into mechanism that can be exploited for more efficient 
vector transduction.   
The findings reported herein show that microtubule-dependent transport plays an 
essential role in the viral transduction, especially the early onset of transgene expression. 
Importantly, the data in this study strongly support an as yet undocumented model in which 
after internalization, AAV2 exploits fast and uni-directional transportation on MTs in 
endosomes directly toward the peri-nuclear region where acidification of most AAV-
containing endosomal compartments happen. Validating trafficking pathways in vivo (Xiao 
et al. 2011) should allow the research community to enhance the performance of viral vectors 
by manipulating intracellular events as documented in the in vitro studies. 
 
 
 
 
 
 
 
  
CHAPTER 4 
 
PERINUCLEAR RETENTION LIMITS THE INFECTION OF BOTH ENVELOPED 
AND NON-ENVELOPED VIRUSES 
 
Summary 
 
Cells have several barriers to restrict viral infection including the plasma membrane, 
dense cytoplasm, and nuclear envelope. Perinuclear retention of viral particles is a common, 
but poorly understood, phenomenon observed during the infection of many viruses including 
Ad, HIV, and parvoviruses. We used the transduction of several recombinant viruses (rAAV, 
rAd, lentivirus) to test whether perinuclear accumulation acts as a barrier to limit viral 
infection. Similarly to Ad and HIV, we first demonstrated that parvovirus AAV’s perinuclear 
localization is maintained by microtubules at the microtubule-organization center (MT-
MTOC). Disruption of this structure after viral entry led to increased susceptibility to 
infection of rAAV, rAd, and lentivirus. Using AAV as a model to study the underlying 
mechanisms, fluorescent microscopy and molecular analyses suggest that the proportion of 
viral particles entering the nucleus increased following MT-MTOC disruption and that this 
enhancement was dependent on the AAV capsid’s nuclear import signals, indicating the 
involvement of a nuclear trafficking pathway. Interestingly, after knocking down RhoA or 
inhibiting its downstream effectors (ROCK and Actin), MT-MTOC disruption did not 
increase viral transduction or nuclear entry. These data suggest that enhancement of infection 
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is the result of two consecutive steps: 1) release of viral particles from the perinuclear site 
upon MT-MTOC disruption, and 2) increased trafficking to the nucleus via the RhoA-
ROCK-Actin pathway. We extended the AAV studies in vivo and observed that viral 
transduction of brain, liver, and xenografted tumor tissues was enhanced up to 10-fold by 
disruption of the MT-MTOC, indicating a similar trafficking mechanism in vivo. In 
summary, this study for the first time experimentally demonstrates that perinuclear 
accumulation of incoming virions at the MT-MTOC is a barrier limiting infection of most 
nuclear viruses and more specifically restricting the nuclear entry of AAV, defining a novel 
defense mechanism by which host cells restrain viral invasion. 
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Introduction 
 
Cells have many structures and machineries to protect themselves from exogenous 
infectious agents (e.g. viruses, bacteria etc.). For example, the plasma membrane is the first 
structure to restrict viral infection, and molecularly dense cytoplasm and the nuclear 
envelope sever as additional barriers for viruses to reach their replication sites. As a 
consequence, viruses have to overcome these cellular barriers in host cells before delivering 
their genome to the target region for successful infection. Comprehensive knowledge in these 
barriers and virus-host interactions are critical to improve our understanding of basic 
virology and viral pathogenesis. Both strengthening these cellular barriers and weakening the 
viral capacity to penetrate these barriers present potentially powerful means for inhibition of 
viral infection. On the other hand, attenuating these barriers or designing capsid with 
enhanced ability to penetrate these barriers will offer promising opportunities to improve 
current vectors for gene therapy.   
The Microtubule-Organization-Center (MTOC) is a subcellular structure at 
perinuclear region, from which microtubules (MTs) are nucleated to form a radial 
filamentous network with minus ends anchored at MTOC and plus end reaching cell surface 
area. Due to these features, MTs and MTOC coordinate, as a trafficking center, the transport 
of intracellular molecules and organelles between the perinuclear region and other areas of a 
cell. For instance, intact MTs are required for the nuclear import of several transcription 
factors (e.g. p53, NF-kB, pRb) and on other hand, these structures are required to sequester 
other proteins (e.g. c-myc, MIZ-1, smad3) in the cytoplasm to block their nuclear entry 
(Giannakakou et al. 2000; Niklinski et al. 2000; Ziegelbauer et al. 2001; Roth et al. 2007; 
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Gong et al. 2011). Numerous studies have also shown that cellular misfolded proteins are 
transported on the MTs towards MTOC region, where these misfolded proteins are 
sequestered or degraded by proteasomes and lysosomes at this region (Garcia-Mata et al. 
2002; Wileman 2007).  
Strikingly, during the early stage of infection, many incoming viruses are also 
delivered to and retained at a perinuclear site after entering the cells (Sodeik et al. 1997; 
Dohner et al. 2002; Suikkanen et al. 2002; Mani et al. 2006; Yea et al. 2007; Boisvert et al. 
2010; Liu et al. 2012). This perinuclear site has been suggested to be co-localized with the 
MTOC region and as observed for cellular proteins, transport of these viruses is facilitated by 
dynein motors and transport along MTs (Fackler et al. 2006; Greber et al. 2006; Wileman 
2007). Although this perinuclear retention of incoming virions seems to be a common 
phenomenon among many viruses, especially those that enter the nucleus, it remains 
unknown whether this accumulation is beneficial or inhibitory to viral infection (Wileman 
2007). Previous studies have shown that several viruses including rotavirus, vaccina and 
HSV disrupt MTOC during early infection stage for reasons that have not been identified 
(Avitabile et al. 1995; Ploubidou et al. 2000; Schepis et al. 2006; Liu et al. 2010; Martin et al. 
2010). Despite the lack of understanding of the role of such perinuclear retention on viral 
infection, these observations raise an intriguing hypothesis that MTOC region serves as a 
subcellular barrier to restrict access of the incoming virions to their replication site (nucleus 
in this study) during the early stage of viral infection.  
On the other hand, during late infection stage, several viruses including HIV, HSV, 
poliovirus, and norovirus have been suggested to exploit this perinuclear accumulation to 
concentrate newly synthesized viral components through MTs to facilitate late infection 
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events including virion replication, assembly, or egress (Sfakianos et al. 2003; Nozawa et al. 
2004; Taylor et al. 2009; Hyde et al. 2012). Classical virology assays usually study 
replication-competent viruses and measure the production of viral progeny as the readout, 
which is the sum of the total effects of all events in viral infection with these viruses. Given 
the potential involvement of MTs and MTOC throughout the entire viral infection, this 
method is unable to precisely dissect the perinuclear retention of incoming virions during 
early infection stage. Furthermore, viral replication and newly synthesized viral proteins will 
also confound virion distribution assays which use antibodies (Suikkanen et al. 2002; 
Boisvert et al. 2010).  
Recombinant viruses used as gene therapy vectors (designated as viral vectors) are 
purposely designed to only exploit the early infection steps including delivering and 
expressing viral genomes and are deficient in late infection events including viral replication 
and assembly due to the deletion of critical viral proteins (Xiao et al. 2012). As a result, these 
viral vectors allow researchers to more precisely separate the early infection steps from the 
late events, offering a promising opportunity to specifically identify the mechanisms and 
roles of perinuclear retention on incoming virions. Adeno-associated virus (AAV) is a 
member in the family Parvoviridae and its recombinant form (rAAV) is currently used as a 
gene therapy vector due to many desirable traits in gene delivery (Xiao et al. 2012). As a 
gene therapy vector, rAAV does not contain any viral DNA except for two internal repeats 
(ITR) flanking the exogenous transgene (Xiao et al. 2012). Therefore, rAAV only delivers 
and expresses transgenes in cells but is incapable of replicating and producing viral progeny. 
This attribute makes rAAV a useful model to specifically investigate virus-host interplay 
during the early stage of viral infection. Like many other viruses, its trafficking pathway 
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typically starts with receptor-mediated endocytosis for cell entry, followed by cytoplasmic 
trafficking assisted by the endosomal routing system and MT network, and ends with nuclear 
entry and uncoating for successful transduction (Wang et al. 2011; Nonnenmacher et al. 
2012; Xiao et al. 2012).  
In this study, we have employed several recombinant viral vectors to investigate the 
role of perinuclear retention on the infection of both enveloped and non-enveloped viruses, 
and have further explored the detailed mechanism using Adeno-associated virus (AAV) as a 
model system. A sensitive and reliable fluorescence imaging platform allowed us to examine 
viral trafficking in detail over time that has led us to the observation that the majority of viral 
particles finished cytoplasmic trafficking and localized at perinuclear region by 6-8 hours 
post infection (p.i.). Manipulating host cells and viral particles using pharmacological 
interventions around 6-8 hours p.i. allowed us to efficiently investigate the underlying 
mechanism of perinuclear retention as well as the corresponding impact on viral infection.  
 140 
 
Materials and Methods 
 
AAV2 production, purification and labeling. HEK-293 cells were used to produce 
AAV2 as described previously (Grieger et al. 2006). Briefly, cells were transfected with three 
plasmids: pXR2 (wt or with BR mutations), pXX680, and a plasmid containing the reporter 
transgene (GFP or Luciferase) flanked by two ITRs. At 60hrs after transfection, cells were 
collected and nuclei were isolated using hypotonic buffer and Kontes homogenizer. AAV2 
particles were recovered by resuspending the nuclear pellet in PBS with 0.5% Deoxycholate 
(DOC) and then sonicating for 1min. Highly pure virus was then retrieved as described 
previously (Xiao et al. 2012). Briefly, after DNase treatment, the virus suspension was 
subjected to one round of cesium chloride (CsCl) step gradient density fractionation and 
another round of fractionation using a continuous CsCl gradient. Determination of peak viral 
fractions, dialysis of virus, and measurement of viral titers by quantitative PCR (qPCR) were 
performed as previously described. The infectivity of AAV was determined to be 
approximately 1 transducing unit per 100 particles. 
AAV2 was covalently labeled with the Cy5 fluorophores as described in 
manufacture’s protocol with slight modification. Briefly, purified AAV2 were incubated for 
2hr at 4℃ in PBS with a 20-fold molar excess of Mono-NHS-Cy5 (GE Healthcare) over 
capsid protein units. Free dyes were removed from labeled viral particles by dialysis against 
PBS containing 5% sorbitol and viral solutions were stored at -80℃ as small aliquots. 
Labeled viral titers were determined by both dot blot (Grieger et al. 2006) and qPCR. 
Infectivity of the viral particles was determined by GFP reporter gene assay. 
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Cell culture, viral infection, and drug treatment. All cells (American Type Culture 
Collection) were grown in Dulbecco’s modified Eagle medium (DMEM, Invitrogen) with 
10% FBS in 5% CO2 incubator. Cells were passaged every 2-3 days for up to ten passages, 
when new aliquots of frozen cells were recovered from liquid nitrogen.  
For pulse infection, cells were seeded on 12-mm glass coverslips at 24hrs before 
infection. The next day, after incubation in DMEM containing 20mM HEPES at 4℃  for 
5min, cells were inoculated with Cy5-AAV2 (~5,000 vgs/cell), non-labeled AAV2 (~1,000-
5,000 vgs/cell), recombinant Adenovirus (~20 pfu/cell), or lentivirus (~10 pfu/cell) at 4℃ for 
another 40min. Cells were then washed with PBS to remove unbound virions and transferred 
to a 37℃ incubator (regarded as 0hr p.i.). Pharmacological drugs were added at 6-8hrs after 
pulse infection unless otherwise indicated. The concentrations of drugs were: 30M 
Nocodazole, 25M Colchcine, 10M Taxol, 10M Rhizoxin, 10M Maytansine, 2M 
MG132, 20M ALLN, 10M H1152, and 10M Cytochalasin D. The drugs were maintained 
in the culture for approximately 3 hours unless otherwise indicated. 
Flow cytometry and Immunofluorescence. To evaluate viral transduction, flow 
cytometry analysis was used to measure the mean fluorescence intensity (MFI) of GFP 
expression. To exclude the potential effect of dead cells on the viral transduction 
measurement, we washed the cells in each well three times with PBS before harvesting for 
flow cytometry analysis, removing any floating or loosely attached cells. Either Trypan blue 
exclusion or 7-AAD exclusion assays was used to assure that most cells (~ 95%) used for 
flow cytometry analysis were viable.  
For immunofluorescence, cells were washed with PBS and then fixed with 4% 
paraformaldehyde (PFA) for 15min at room temperature (RT). The cells were then 
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permeabilized with 0.2% Triton X-100 in PBS for 5min at RT. After blocking with 
immunofluorescence buffer (IFB) (5% normal goat serum in PBS containing 0.05% Tween-
20) for 1hr at RT, the cells were incubated with primary antibody to detect tubulin (Ab6161, 
Rat monoclonal from Abcam Inc.), Golgi (Ab24586, Mouse monoclonal from Abcam Inc.) 
and/or  AAV capsid (A20 mouse monoclonal antibody) diluted in 50% IFB for overnight at 
4°C. The cells were then incubated with secondary antibody, diluted 1:2,000 in 50% IFB 
(anti-mouse Alexa-Fluor 488 [Molecular Probes]), for 1hr at RT. After six washes with PBS, 
coverslips were mounted cell side down on glass slides with mounting medium (Prolong 
Antifade Gold with DAPI [4’,6’- diamidino-2-phenylindole]; Molecular Probes). After 
images were acquired using confocal microscopy, the existence of perinuclear accumulation 
in a cell in each image was examined by human eyes.  
Nuclear isolation and viral genome quantification. Nuclei were isolated from cell 
fractionations as previously described (Grieger et al. 2006), with minor modifications 
allowing for viral infection. After incubation with AAV and drugs, cells were washed three 
times with ice-cold PBS and harvested by centrifugation at 500g for 10 min. The cell pellet 
was divided into two aliquots: one for direct viral genome extraction and the other for nuclei 
isolation. One aliquot was resuspended in hypotonic buffer and homogenized on ice using a 
Kontes homogenizer to the point where ~90% of cells were broken with nuclei remaining 
intact. The homogenate was spun at 500g for 10 min to separate the nuclei from the 
cytoplasmic components. The purity of nuclear fraction was assured by phase-contrast 
microscopy and immunoblotting using anti-tubulin and anti-lamin A/C antibodies.   
AAV genomes were recovered from both whole cells and nuclear fraction using 
DNeasy Blood and Tissue Kit (Qiagen Inc.) according to the manufacturer’s protocol. The 
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copy number of AAV genomes was determined by qPCR on a LightCycler 480 using Sybr 
green (Roche) as described for viral titering (Grieger et al. 2006). 
Animal studies. Housing and handling of the BALB/c mice and SCID mice used in 
the current study were carried out in compliance with National Institutes of Health guidelines 
and approved by the IACUC at the University of North Carolina-Chapel Hill. To grow 
xenografted breast cancer tumors, 10^6 ~10^7 MDA-231 breast cancer cells were injected 
into the mammary fat pad of SCID mice. When the tumor size was about 0.5cm in diameter, 
the mice were used for intratumoral injection. Recombinant AAV2 vectors packaging 
luciferase or GFP transgenes were administered through the intravenous route (2e+10vgs into 
tail vein) in a volume of 200μl PBS or the intratumoral route (1e+10vgs). DMSO or 
Nocodazole (2mg/kg) were administered via intraperitoneal or intratumoral injection at about 
10-12hrs after viral injection. Bioluminescence from luciferase expression was visualized by 
using a Xenogen IVIS100 imaging system (Caliper Lifesciences) after intraperitoneal 
injection of luciferin substrate (120 mg/kg of body weight; Nanolight). Image acquisition and 
analysis were carried out by using Living Image software. Quantitative data are based on 
values from 3-4 mice per group.  
For vector infusions into mouse brain, animals were anesthetized with isoflurane and 
placed into a stereotaxic frame. Using a 32-gauge stainless steel injector and a Fisher 
Scientific infusion pump, mice received 1μl per hemisphere (total of 5e+08vgs) into the 
striatum over 15 min. The injector was left in place for 3 min after infusion to allow diffusion 
from the site of injection.  
To image viral trafficking in mouse tissues, Cy5-AAV2 was administrated through 
intra-brain, intra-hepatic, or intratumoral routes. DMSO or Nocodazole were administrated 
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through the intraperitoneal route at about 12hrs after viral inoculation. At 1hr or 12hrs after 
vector injection or 4-6hrs after Nocodazole injection (16-18hrs after viral injection), animals 
received an overdose of pentobarbital (100 mg/kg intraperitoneally) and were perfused 
transcardially with ice-cold 100 mM sodium PBS (pH 7.4), followed by 4% 
paraformaldehyde in phosphate buffer (PB) (pH 7.4). After tissues were post-fixed for 24hrs 
at 4°C in paraformaldehyde (Xiao et al. 2011), 10-20 μm coronal sections were cut using a 
cryosection microtome and then the slides were directly sealed with mounting medium 
(Prolong Antifade Gold with DAPI [4’,6’- diamidino-2-phenylindole]; Molecular Probes). 
Quantitative 3D microscopy. Hela cells pulse infected with Cy5-AAV2 were fixed 
with PFA and mounted to glass slides as described above. The distribution of viral particles 
in Hela cells were examined using a Zeiss LSM710 laser scanning confocal microscope 
equipped with a Plan-Apochromat 63×/NA 1.40 oil objective. Stacks of 20-30 focal planes 
were captured at 0.31μm z-intervals through the depth of the cell. 3D images of the cells 
were reconstructed using the Z-stacks. All images were acquired at pixel dimensions of 
0.13×0.13×0.31μm (X, Y, Z) to fulfill the Nyquist sampling.  
Deconvolution was performed by the AutoDeblur software (Media Cybernetics Inc.) 
using iterative and constrained algorithms as described previously (Xiao et al. 2012). The 
procedure started with a theoretical PSF derived from the actual settings of Zeiss710 
confocal microscope, including NA of the microscope objective, refractive index of the 
medium, excitation wavelength, emission wavelength, confocal pinhole radius, pixel size, z-
axis interval, and microscope type (i.e., wide field, confocal). A new adjusted adaptive PSF 
derived from the previous deconvolution round was used to generate the next adaptive PSF 
that fit the real imaging data better than the previous one (termed as one iteration or 
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deconvolution round). Twelve rounds of iteration were used to deconvolve all the confocal 
images in this study.  
All deconvolved image stacks were processed using the IMARIS software package 
(Bitplane AG, Zurich, Switzerland) for visualization and quantification as described 
previously (Xiao et al. 2012). Briefly, each deconvolved image stack was reconstructed using 
a volume rendering module and smoothed by a 3D-median filter. Subsequently, an isosurface 
rendering module was applied through thresholding by the fluorescence intensity that was 
slightly higher than background. For Cy5-AAV2, the isosurface rendering was thresholded at 
the fluorescence intensity of 2000 a.u. (the upper boundary of background). For DAPI, 
isosurface rendering was thresholded at the fluorescence intensity of 3200 a.u.. Parameters 
(volume, MFI, TFI) for these isosurface coated Cy5-AAV2 objects were extracted from the 
IMARIS program and analyzed to determine the localization of particles as described 
previously (Xiao et al. 2012).  
Negative staining and electron microscopy. Purified and dialyzed virus particles in 
1× PBS were pipetted onto a glow-discharged copper grid. The grid was washed twice with 
water and then stained with 2% uranyl acetate. Electron microscopy images were taken with 
a LEO EM 910 transmission electron microscope at various magnifications. 
Transient transfection of reporter plasmid and siRNA. For transfection of Hela 
cells with reporter plasmids, Hela cells were plated at a density of 4e+5 cells/well and 24 hr 
later were transfected with TR-CMV-EGFP reporter plasmids using PEI. For each well 500 
ng DNA was mixed with 5 l PEI (1 mg/ml) in 100 l of serum-free DMEM and incubated 
at room temp for 10 min before addition to cell medium. Culture media was refreshed at 6hrs 
after transfection. At 16-20hrs after transfection, cells were treated with DMSO or other 
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drugs as indicated. At about 20hrs post-drug treatments, cells were harvested for flow 
cytometry analysis of GFP expression as indicated above. 
Knockdown of RhoA was obtained by double transfection of siRNA (Dharmacom, 
Thermo Scientific) using Nucleofector (Lonza Inc.) performed with an Amaxa Electroporator 
according to the manufacturer’s protocol. Knockdown efficiency was verified by Western-
blot using RhoA antibody (Abcam Inc.). Efficient knockdown was achieved at two days after 
the first siRNA transfection. After verifying knockdown, approximately two days post-
transfection cells were processed with pulse infection and drug treatments as described 
above. Viral transduction was analyzed using flow cytometry. 
Statistical analysis. Experiments were performed in triplicates and repeated at least 
three times independently, unless otherwise noted. For studies comparing quantification of 
luciferase or GFP expression in one treatment group to the corresponding control group, a 
student t-test of the mean expression value was performed. For studies comparing 
quantification of luciferase or GFP expression in more than two treatments group to the same 
control group, a one-way analysis of variance (ANOVA) was performed to test the global 
hypothesis that all mean values are the same across groups. If the global hypothesis is 
rejected, Dunnett’s test was used to compare the mean of each treatment to the mean of 
control group simultaneously. Luciferase or GFP expression was presented as Mean ± SD 
(standard deviation) and all tests were considered significant if p<0.01, which was indicated 
by *. 
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Results 
 
Retention of AAV particles at the perinuclear region. Perinuclear accumulation of 
many viruses including adenovirus (Ad), HSV, and HIV has been observed in previous 
studies. Using AAV as a model to study this phenomenon in detail, we first investigated the 
intracellular trafficking of AAV2 over time using viral particles labeled with Cy5. With our 
optimized protocol, we were able to visualize a single viral particle and the labeled virions 
remain as infectious as unlabeled particles. Specifically, homogeneous labeling of virions 
was achieved as demonstrated by confocal microscopy of labeled particles on glass 
coverslips (Fig.IV-1A, left). The intensity profile of fluorescent spot followed a single 
Gaussian distribution, suggesting that the fluorescence signal was from a single particle 
(Fig.IV-1A, right) (Vonderheit et al. 2005). The signal had a diameter of about 0.4 m as 
determined by Full Width at Half Maximum (FWHM), consistent with the fluorescent signal 
from other nano-sized viruses (Vonderheit et al. 2005). Data from negative staining and 
electron microscopy demonstrated that the virion structure remained unchanged and that 
most of the labeled virions were single particles (Fig.IV-1B). To test whether labeling would 
affect the functionality of the virions, we compared labeled and unlabeled AAV particles in 
their ability to transduce cells using GFP reporter gene assay. We found that the labeled 
virions can express GFP transgene as efficiently as the unlabeled ones, indicating that the 
particles labeled with Cy5 were fully competent at transduction (Fig.IV-1C). It has been 
relatively difficult to visualize virions on the cell surface presumably because most virions 
bound as single particles and the visualization method was not sensitive enough to detect 
them at single particle level (Johnson et al. 2009). In contrast, we were able to visualize the 
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AAV particles on the cell surface after 40 minutes incubation of cells with Cy5-AAV at 4℃ 
(Fig.IV-1D, left). In addition, the Cy5 fluorescent signal was successfully co-stained with the 
signal from monoclonal A20 antibody that specifically recognizes the AAV capsids (Fig.IV-
1D, right). These data demonstrate that our labeling and imaging systems are sufficiently 
robust and reliable to study the viral trafficking and infection at the level of a single particle.          
To study the intracellular trafficking of AAV, we synchronized particle trafficking 
using “pulse infection”, in which cells are incubated with virions at 4℃ for 40 minutes and 
unbound virions are then washed away before cells are transferred to 37℃ for subsequent 
viral infection. After pulse infection, we studied the distribution of AAV particles at several 
time points over 12 hours (Fig.IV-2A). During the first 2-4 hours post-infection (p.i.), the 
majority of viral particles were scattered in the cytoplasm and trafficking towards the 
perinuclear region. At 4 hours p.i., the majority of viral particles had finished their 
cytoplasmic trafficking and localized at the perinuclear region in approximately 30-40% of 
cells. At 8hrs p.i., perinuclear accumulation was observed in over 80% of cells and persisted 
for over 6 hours, suggesting retention of viral particles at this perinuclear site (arrows in 
Fig.IV-2A). To specifically investigate the role of the perinuclear retention, we focused on 
the time period between 6-8 hours after pulse infection, a time point at which, in majority of 
cells, most virions have finished cytoplasmic trafficking and remain at the perinuclear region. 
Perinuclear retention is dependent on intact MT-MTOC. Previous studies based 
on fluorescence signal co-localization have shown that several viruses including Ad and 
HIV, traffic to a perinuclear region that coincides with the Microtubule-Organization-Center 
(MTOC). Previous studies have co-localized perinuclear AAV particles to the Golgi 
apparatus (Johnson et al. 2010; Nonnenmacher et al. 2011), and others have suggested that  
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Figure IV-1. Fluorescent labeling of AAV particles. A) A representative confocal image 
(left) showing the fluorescence signal of Cy5-AAV2 bound to coverslip. Right panel: A 
single Gaussian distribution (red curve) fits the representative distribution of fluorescence 
intensity (blue curve) from a Cy5-AAV2 particle (arrow in left panel). B) Negative staining 
and electron micrographs of AAV2 and Cy5-AAV2. C) GFP transgene expression from 
AAV2 and Cy5-AAV2 as captured with epi-fluorescence microscope. D)  A representative 
confocal image showing the bound Cy5-AAV2 on the surface of Hela cells after 40min 
incubation at 4 ℃.  AAV particles are visualized by Cy5 signal (red) and staining with 
monoclonal antibody A20 that recognize AAV capsid (green). Nucleus is stained with DAPI 
(blue). 
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Figure IV-2.  Perinuclear retention of AAV by the MT-MTOC. Hela cells were fixed to 
examine the distribution of viral particles at various times after pulse infection. Nuclei were 
stained with DAPI (blue). A) Representative images showing the distribution of intracellular 
AAV2 over 12 hours after viral inoculation. Arrows indicate perinuclear accumulation in the 
cells. B) Schematic diagram showing the procedure used for drug intervention and confocal 
imaging experiments. C-E) Confocal images showing the localization of the MT-MTOC, 
Golgi apparatus, and AAV2 when cells treated with DMSO (C), 2 g/ml Brefeldin-A (D), 30 
M Nocodazole (E). MTs were stained with -tubulin antibody (green) and Golgi apparatus 
was stained with Giatin antibody (cyan). Arrows indicate the perinuclear accumulation of 
AAV. The right most panels in C-E display schematic cartoons showing the localization of 
AAV particles, Golgi, and MTs in the cells. 
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these virions may co-localize with the MTOC (Johnson et al. 2011). As the perinuclear 
region is highly crowded and the resolution of classical fluorescent microscopy is only about 
0.3 m in lateral, images solely generated by such fluorescent microscopy alone could falsely 
co-localize viral particles with many cellular organelles at perinuclear region, namely Golgi, 
MTOC, ER etc. (Johnson et al. 2011). To effectively discern which cellular structure(s) at the 
perinuclear region co-localize with AAV particles and retain these virions, we combined 
fluorescence microscopy with pharmacological interventions (Fig.IV-2B) to circumvent the 
above resolution limit issues. Specifically, if AAV particles do co-localize to and are retained 
by a particular structure at the perinuclear region, we shall be able to predict that: 1) the viral 
accumulation will be ablated upon the disruption of that structure by pharmacological agents; 
2) the majority of virions will still co-localize with that structure after release from the 
perinuclear region upon disruption of microtubules (MTs) and the MTOC. 
Using several antibodies, we demonstrated that AAV particles can be co-stained with 
markers for Golgi apparatus and MT-MTOC (peri-MTOC microtubules) at the perinuclear 
region (Fig.IV-2C). To distinguish whether virus localized to the Golgi or MT-MTOC, we 
used a panel of pharmacological reagents to disrupt these structures individually and 
visualized the localization of viral particles in each case. Upon Brefeldin-A treatment to 
specifically disrupt Golgi apparatus, perinuclear accumulation of AAV was not dispersed 
(Fig.IV-2D). In contrast, when MT-MTOC was fully disrupted by Nocodazole, the 
perinuclear localization of AAV was ablated and few AAV particles co-localized with 
dispersed Golgi cisternae (Fig.IV-2E). These data demonstrate that AAV is localized to and 
retained by the MT-MTOC but not Golgi apparatus at the perinuclear region. This finding is 
consistent with previous studies that show many other viruses traffic and localize to the 
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MTOC or MT-MTOC (Sodeik et al. 1997; McDonald et al. 2002; Bailey et al. 2003; Fackler 
et al. 2006; Greber et al. 2006; Yea et al. 2007). 
 
MT-MTOC retention limits the transduction of rAAV, rAd, and lentivirus. 
Given that the majority of cytoplasmic virions were retained at the MTOC region, we 
examined the effects of this retention on viral transduction. To do so, we used several anti-
MT drugs (AMDs, e.g. Nocodazole, Colchicine, Rhizoxin, and Maytansine) to disrupt MTs 
at approximately 6-8 hours p.i., after viral particles have completed microtubule-mediated 
cytoplasmic trafficking to perinuclear region in most cells (Fig.IV-3A). Because our previous 
study showed that MTs also facilitates viral cytoplasmic trafficking from the cell periphery to 
the perinuclear region (Xiao et al. 2012), the timing of above treatment allowed us to 
separate the effects on viral infection of MT mediated cytoplasmic trafficking from those of 
MT-MTOC dependent perinuclear retention. To exclude potential effects of the reagents on 
the second strand synthesis of viral DNA, self-complementary AAV (AAV2-CMV-GFPsc) 
was used in the transduction assay.  
Disruption of MTs by Nocodazole treatment at 6~8 hours p.i. induced a 2~4-fold 
increase in viral transduction in multiple cell lines as measured by the expression of the 
transgene GFP (Fig.IV-3B). To rule out the possibility that the increased viral transduction 
was specific to Nocodazole, a panel of ADMs was used (Colchicine, Rhizoxin, Maytansine), 
all of which disrupt MTs. Similar increases in GFP expression were observed with all of the 
drugs (Fig.IV-3C). We also tested whether stabilization of MT-MTOC by Taxol would 
reverse the effect of Nocodazole, through comparing the viral transduction in cells treated 
with Nocodazole alone or with Nocodazole and Taxol. We found that co-administration of 
Taxol with Nocodazole restored the enhanced viral transduction to the control  
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Figure IV-3. Disruption of MT-MTOC increases transduction of rAAV, rAd, and 
lentivirus.  A) Schematic diagram showing the procedure used for the experiments in B-E. 
B) A variety of cell lines used to measure AAV2 transduction with and without Nocodazole 
treatment. Mean Fluorescence Intensity (MFI) of GFP expression is normalized to the 
DMSO treatments. C) AAV2 transduction was determined by MFI of GFP expression in 
Hela cells treated with various AMDs. D) The MFI of GFP expression was measured in cells 
treated with DMSO, Nocodazole, Nocodazole+Taxol, or Taxol only. E) The MFI of GFP 
expression from recombinant Adenovirus (rAd) and lentivirus was determined in cells treated 
with DMSO or Nocodazole. (*) indicates statistically significant difference with p<0.01. 
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level (Fig.IV-3D). Together, these results demonstrated that the increase in AAV 
transduction was due to MT-MTOC disruption.  
As both Ad and HIV accumulate at MTOC in HEK293 cells (McDonald et al. 2002; 
Yea et al. 2007), we tested whether MT-MTOC disruption can also lead to an increase in 
transduction of these viruses. Interestingly, treatment of Nocodazole resulted in 2.5-fold and 
3.6-fold increases for the transduction of rAd and lentivirus respectively (Fig.IV-3E). This 
data provides yet another layer of evidence to support the hypothesis that perinuclear 
retention by MT-MTOC limits viral transduction. Furthermore, this hypothesis holds true for 
both enveloped and non-enveloped viruses.   
 
Increased transduction upon MT-MTOC disruption is independent of promoter 
activity, cell cycle arrest, and viral degradation. Next, we explored the underlying 
mechanism associated with the increase in viral transduction induced by MT-MTOC 
disruption. We envisioned three possible mechanisms for the increase in transgene 
expression: 1) MT-MTOC disruption leads to the activation of the promoter on the viral 
transgene cassette; 2) MT-MTOC disruption results in cell cycle arrest which, in turn, leads 
to increased viral transduction; 3) MT-MTOC disruption affects intracellular viral processing 
or trafficking. First, we employed in vitro plasmid transfection to examine the potential effect 
of MT-MTOC disruption on promoter activity. Our flow cytometry data demonstrated that 
MT-MTOC disruption by AMDs did not affect the reporter gene (GFP) expression from the 
viral transgene cassette, which was directly transfected into the cells using PEI (Fig.IV-4A). 
This data excludes the possibility of AMD treatment affecting promoter activity (mechanism 
1). To test the second possible mechanism, we measured the effects of AMD treatment on 
viral transduction in cells whose cell cycle was already arrested at S-phase by double 
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thymidine block, a step preceding the M-phase block caused by AMDs. Our data showed that 
MT-MTOC disruption also induced an enhancement of viral transduction in these pre-
arrested cells, suggesting that the increase in viral transduction was independent of cell cycle 
arrest induced by disruption of MT-MTOC (mechanism 2, Fig.IV-4B). Additionally, it was 
previously reported that intracellular degradation of AAV limits viral transduction and its 
blockage using proteasome inhibitors resulted in dramatic increase in viral transduction 
(Zhong et al. 2008). It was also previously proposed that MT-MTOC facilitates the 
degradation of intracellular proteins by transporting these proteins to and retaining 
proteasome machineries at the perinuclear region. As a result, we tested if MT-MTOC 
disruption has reduced the AAV degradation. Data from quantitative PCR demonstrate that 
the amount of AAV measured as genome copy number (vgs/cell) was not significantly 
changed upon MT-MTOC disruption, suggesting AMD treatment did not affect the viral 
degradation (Fig.IV-4C). This notion was further supported by our data from 
pharmacological intervention studies which showed that proteasome inhibitor can further 
enhance viral transduction if co-administrated with AMDs (Fig.IV-4D). Therefore, we have 
excluded the hypotheses 1) that MT-MTOC disruption directly increases transgene 
expression; 2) that MT-MTOC disruption acts to increase transduction through cell cycle 
arrest; and 3) that MT-MTOC disruption increases AAV transduction by decreasing the 
degradation of AAV virions. 
Interestingly, our (and others’) previous studies demonstrated that disruption of MTs 
during AAV entry has a negative effect on transduction due to impaired cytoplasmic 
trafficking. Our current findings suggest that: 1) MTs are not required for steps of 
transduction subsequent to the trafficking to perinuclear region, and 2) though MTs play a  
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Figure IV-4. MT-MTOC disruption does not affect promoter activity and viral 
degradation. A) At 16-20hrs after transfected with plasmid TR-CMV-GFP using 
Polyethyleneimine (PEI), Hela cells were treated with drugs for 3hrs. At approximately 20hrs 
after drug treatments, cells were harvested for flow cytometry analysis to measure the GFP 
expression. B) Cells were cell cycle arrested using a double thymidine block and then the 
MT-MTOC was disrupted as in Figure IV-3A and AAV transduction was measured. C) Cells 
were treated as in Figure IV-1B and quantitative PCR (qPCR) was used to determine the 
copy number of the viral genome. D) Cells were treated as in Figure IV-3A except that 
proteasome inhibitors were added with AMD and transduction was measured. (*) indicates 
statistically significant difference between DMSO and Nocodazole treatments with p<0.01.   
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Figure IV-5. Release of AAV and increased nuclear entry upon MT-MTOC disruption. 
A) Schematic diagram showing the procedure for the experiments in B-E. Specifically, Hela 
cells were treated with DMSO or Nocodazole at 6~8hrs after pulse infection of Cy5-AAV2, 
and fixed at 1-1.5hrs or 3-4hrs after drug treatments. Nuclei were stained with DAPI (blue). 
B) Representative images from 2D confocal microscopy of one focal plane (a-c) and 3D 
images reconstructed from confocal Z-stacks as described in Methods. (d-l) showing the viral 
distribution in cells treated with DMSO (a,d,g,j), or with Nocodazole for 1-1.5hrs (b,e,h,k) or 
3-4hrs (c,f,i,l). d-f are top views, while g-i are magnified side views from directions indicated 
by arrows in d-f respectively. j-l are views observed inside the nucleus (from the directions 
indicated by arrows in g-i respectively, between the top and bottom nuclear envelopes, which 
is  indicated by the blue layer based on the DAPI signal). AAV2 particles in cytoplasm are 
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highlighted as red and those inside the nucleus highlighted as yellow. C) The proportion of 
cells with perinuclear accumulation of AAV particles after DMSO or Nocodazole treatment 
(for 1.5hrs or 3hrs) was quantified in 50-100 cells for each group. The perinuclear 
accumulation is defined as concentrated viral particles at a single perinuclear region (arrows 
in Fig.IV-2 and arrowheads in Fig.IV-5B). D) The proportion of AAV particles entering 
nucleus in cells treated with DMSO or Nocodazole at 3hrs was quantified from the 3D 
microscopy data (Fig.IV-5B). 20-30 cells from each group were used for the 3D quantitative 
microscopy described in Methods. E) Nuclei were fractioned from cells and qPCR was used 
to determine the copy number of AAV genomes in the nucleus of cells treated with 
Nocodazole for 3hrs, in comparison with DMSO treated cells. F) Cells were treated with 
DMSO or Nocodazole as described in Fig.IV-3A then transduced with AAV or BR mutants 
of AAV and transduction was analyzed by flow cytometry. GFP expression is normalized to 
that in DMSO treated group. (*) indicates statistically significant difference between DMSO 
and Nocodazole treatments with p<0.01.   
  
 159 
central role in trafficking of the virus to the perinuclear region, at later time points these 
structures act to retain virions and thus, limit transduction. 
 
Nuclear entry of AAV is increased upon the disruption of MT-MTOC. Based on 
the above findings, the most likely mechanism for elevated viral transduction upon MT-
MTOC disruption occurs at the level of trafficking. It has been previously demonstrated that 
nuclear entry is an essential trafficking event for AAV’s infectious pathway (Grieger et al. 
2006; Sonntag et al. 2006). Moreover, nuclear entry is the most probable event subsequent to 
and being limited by perinuclear retention in AAV’s infectious trafficking pathway. We 
hypothesized that the retention of viral particles at the MTOC region may limit the 
subsequent nuclear trafficking of the virus. To test this hypothesis, we visualized viral 
trafficking steps with and without Nocodazole treatment by fluorescent confocal microscopy 
and quantitatively evaluated the distribution of viral particles at different time points after 
administration of Nocodazole at 6-8 hrs p.i. (Fig.IV-5A). At about 1-1.5 hrs after MT-MTOC 
disruption (~8-9 hrs p.i.), the perinuclear retention of AAV particles was ablated in most 
cells examined (Fig.IV-5C) and the viral particles spread around the outside of nucleus 
(Fig.IV-5B). Later, ~3-4 hours after MT-MTOC disruption (~10-11 hrs p.i.), an approximate 
2-fold increase of viral particles was observed in the nucleus as shown by the representative 
images from confocal microscopy (Fig.IV-5B-c) and quantitative data from 3D microscopy 
(Fig.IV-5B-f/i/l, and 4D). Increased viral entry into the nucleus was also supported by 
quantitative PCR analysis of the viral genome copy number in the nuclear fractions of treated 
and untreated cells (Fig.IV-5E). Together, these results demonstrate that disruption of the 
MT-MTOC at 6-8hrs p.i. leads to an increase in nuclear entry of AAV particles, explaining 
the increased transduction we observed (Fig.IV-3).  
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Three major basic regions (BRs) on the capsid have been shown to function as 
nuclear localization signals (NLS) with varying strengths (Grieger et al. 2006; Sonntag et al. 
2006). AAV mutants with deletions at these regions can still accumulate at the perinuclear 
region but are unable to enter nucleus (Johnson et al. 2010). To test whether NLS are 
required for the increased nuclear entry and viral transduction, we examined the effects of 
MT-MTOC disruption on these BR deletion mutants. In both DMSO and Nocodazole treated 
cells, BR deletions resulted in the reduced viral transduction (Fig.IV-5F). Importantly, 
Nocodazole treatment was unable to restore the impaired transduction of these BR mutants, 
indicating that AMD-induced enhancement of viral transduction and nuclear entry requires 
the capsid NLSs. These data suggest that MT-MTOC disruption releases AAV to continue 
down its normal nuclear entry pathway and does not cause AAV’s nuclear entry pathway to 
change. 
 
AAV is imported into the nucleus via the RhoA-ROCK-Actin pathway upon 
MT-MTOC disruption. The above findings suggested that MT-MTOC disruption itself only 
allows the release of AAV particles from the perinuclear region. The subsequent increase in 
nuclear entry is achieved by a mechanism that requires the NLS on viral capsid. It is well 
established that MT disruption can lead to RhoA-ROCK mediated rearrangement of actin 
filaments (AFs), which in turn affects actin-mediated intracellular trafficking (Krendel et al. 
2002; Chang et al. 2008). Perinuclear AFs have been demonstrated to associate with the 
nuclear envelope and nuclear pore complexes at the nuclear envelope and were proposed to 
be involved in nuclear import/export of intracellular materials (Hofmann et al. 2001; van Loo 
et al. 2001; Minakhina et al. 2005; Broers et al. 2006; Favoreel et al. 2007; Schneider et al. 
2008). As a result, we tested whether the AFs regulated by the activation of RhoA-ROCK 
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Figure IV-6. Disruption of the MT-MTOC increases viral transduction and nuclear 
entry through a RhoA-ROCK-Actin pathway. A) Immunoblot showing the siRNA-
mediated transient knockdown of RhoA protein in Hela cells. Scramble siRNA used as a 
control. B) The level of AAV transduction was measured in Scramble or RhoA siRNA 
transfected cells treated with or without Nocodazole treatment at 6-8hrs after AAV infection. 
C) The level of AAV transduction was determined in cells treated with DMSO or 
Nocodazole alone or in combination with H1152 or CytoD. D) The proportion of cells with 
perinuclear accumulation of AAV particles was measured in the presence of DMSO or 
Nocodazole alone or in combination with H1152 or CytoD. E) The proportion of AAV 
particles in the nucleus was determined in cells treated with DMSO or Nocodazole alone or 
in combination with H1152 or CytoD. (*) indicates statistically significant difference 
between DMSO only and other drug treatments with p<0.01.  
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upon MT disruption contributed to the increased nuclear entry and transduction of AAV we 
observed. First, we transiently transfected siRNA to knockdown the expression of 
endogenous RhoA as demonstrated by immunoblotting for the RhoA protein (Fig.IV-6A). 
Interestingly, treatment with Nocodazole only induced an increase in viral transduction in 
cells transfected with the control (scrambled) siRNA and had minimal effect in RhoA 
knockdown cells (Fig.IV-6B). H1152 is a potent inhibitor of ROCK, a downstream effector 
of RhoA and induces actin filament alterations. Cytochalasin D (CytoD) is an inhibitor of 
AFs that induces the de-polymerization of these filaments (Schelhaas et al. 2008). Both 
H1152 and CytoD were found to ablate the transduction enhancement induced by MT-
MTOC disruption with Nocodazole; therefore, the enhancement of transduction required that 
ROCK not be inhibited and that AFs be intact (Fig.IV-6C). These data suggest that the 
RhoA-ROCK-Actin pathway is required for the increased viral transduction upon MT-
MTOC disruption. Visualization of viral particles by fluorescence microscopy revealed that 
Nocodazole-induced viral dispersion from the perinuclear region was unaffected by co-
administration with H1152 or CytoD (Fig.IV-6D). Our data from 3D quantitative microscopy 
further demonstrated that co-administration of either H1152 or CytoD only blocked the 
increase in viral nuclear entry after MT-MTOC disruption (Fig.IV-6E). Additionally, 
administration of H1152 or CytoD alone at 6-8 hrs p.i. did not affect the transduction and 
nuclear entry of AAV (Fig.IV-6C and E). 
Together, the above data suggest a two-step working mechanism for the increased 
AAV transduction observed upon MT-MTOC disruption: 1) viral particles are released from 
the perinuclear region and spread around the outside of nucleus upon MT-MTOC disruption; 
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and 2) some of these viral particles are then transported into the nucleus via the RhoA-
ROCK-Actin pathway.     
 
Perinuclear retention of AAV and Nocodazole-mediated enhancement on viral 
transduction also occur in vivo. In cell culture, we observed a bottleneck in viral 
transduction at the stage of accumulation and retention of AAV at MTOC region. rAAV is 
currently widely used as a gene therapy vector in many clinical trials to tackle a variety of 
human diseases (Xiao et al. 2012). The effort to improve its efficiency in gene delivery has 
been compromised by the lack of knowledge about AAV trafficking in in vivo settings. With 
the sensitive imaging technique used in this study, we examined whether perinuclear 
retention of AAV also acted as a bottleneck in vivo. To examine this hypothesis, we injected 
Cy5-AAV into mouse brain, liver, or xenografted tumor, and determined the viral 
distribution at different time points after viral infection. At an early stage (~1 hour) after viral 
inoculation, viral particles were scattered across cells in these tissues, as is clearly observed 
in the brain image (Fig.IV-7A). Due to the relatively high background fluorescence observed 
in both liver and xenografted tumor, we were not able to visualize single viral particles in 
these tissues as observed in brain, and instead were only able to visualize particles at the sites 
of viral injection, where a higher concentration of labeled virions was present (arrowheads in 
Fig.IV-7A). At 6-12 hours p.i., a large number of viral particles were observed to accumulate 
at the perinuclear region, consistent with our in vitro studies (Fig.IV-7A). Approximately 60-
80% of cells in these tissues had perinuclear accumulation by 12 hours after infection (arrows 
in Fig.IV-7A).  
Furthermore, we tested whether AMD treatment could disrupt this perinuclear 
retention and increase viral transduction as was observed in our in vitro studies. 
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Approximately 10 hours after viral inoculation, Nocodazole was administrated to the animal 
through intraperitoneal or intratumoral injection. At 4-6 hours after Nocodazole injection 
(~14-16 hrs p.i.), perinuclear retention (arrows in Fig.IV-8A) was only observed in DMSO-
treated animals and was ablated in the cells of both liver and xenografted breast tumor in 
Nocodazole-treated animals (Fig.IV-8A). Using GFP as a reporter gene packaged by AAV, a 
significantly stronger GFP fluorescent signal was observed in the Nocodazole-treated breast 
tumors (Fig.IV-8B). Moreover, by measuring luciferase activity using the IVIS imaging 
system, we observed a roughly 10-fold increase of viral transduction in both liver and 
xenografted tumor of Nocodazole-treated mice (Fig.IV-8C, D). Together, these data suggest 
that AAV takes a similar subcellular trafficking route in the animal tissues we tested to that 
we found in vitro and is retained at the perinuclear region, a trafficking bottleneck for viral 
transduction.   
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Figure IV-7. Perinuclear accumulation in mouse tissues. Mouse tissues (brain (cerebrum), 
liver, xenografted breast tumor) were removed at 1hr or 12hrs after injection of Cy5-AAV 
and sectioned using a cryo-microtome. Nuclei are stained with DAPI (blue). The viral 
particles were visualized by confocal microscopy. A) Representative confocal images 
showing the viral distribution in uninfected mouse tissues (control), or tissues that were 
infected with AAV for 1hr or 12hr. Arrowheads indicate concentrated AAV at the injection 
site. Arrows indicate perinuclear accumulation of virions. B) The percentage of cells with 
perinuclear accumulation of AAV in each tissue was measured at 1hr p.i. and 12hr p.i.. 50-
100 cells were analyzed for each group.       
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Figure IV-8. Perinuclear accumulation of AAV particles is disrupted and viral 
transduction is increased upon Nocodazole treatment in various mouse tissues. A) 
Representative images showing the distribution of AAV particles (red) in tissues treated with 
DMSO or Nocodazole. Nuclei are stained with DAPI (blue). Arrows indicate the perinuclear 
accumulation of virions. B) Representative images showing the viral injection sites as 
visualized with injected India ink (arrows on the upper panel) and transgene GFP expression 
(green in lower panel) in the xenografted tumors. C) IVIS imaging of luciferase signal in 
xenografted breast tumor and liver at one week after viral injection. Left panel shows the 
luciferase activity in the xenografted tumor before (upper image) or after (lower image) 
removal from the mice. Right panel shows the luciferase activity from liver expression.  D) 
The relative luciferase activity in the tumor and liver were quantitated as photons/sec/cm^2 
(n=3-4). (*) indicates statistically significant difference between DMSO and Nocodazole 
treatments with p<0.01.  
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Discussion 
 
Viral accumulation at the perinuclear region is commonly observed during the 
infection of many viruses (e.g. Ad, HSV, HIV, influenza, parvoviruses) (Dohner et al. 2002; 
McDonald et al. 2002; Mani et al. 2006; Yea et al. 2007; Boisvert et al. 2010). However, it 
remains unclear regarding whether and how this accumulation affects viral infection. Two 
plausible hypotheses are (Wileman 2007): 1) viruses exploit the cellular protein-trafficking 
machineries to approach the replication site or to concentrate viral components for viral 
replication and later virion assembly, thus supporting viral infection; 2) perinuclear 
accumulation represents an innate cellular response that recognizes virus components as 
foreign or misfolded proteins and targets them for sequestration and degradation at the 
perinuclear region, thus interfering with viral infection. Our present study has supported the 
hypothesis that perinuclear accumulation is a cellular defense mechanism to sequester virions 
in order to limit the infection of both enveloped virus (HIV) and non-enveloped viruses (Ad 
and AAV).  
Both Golgi and MTOC are perinuclear structures that coincidentally colocalize at the 
perinuclear region with many viruses (Sodeik et al. 1997; Dohner et al. 2002; Mani et al. 
2006; Yea et al. 2007; Boisvert et al. 2010; Liu et al. 2012). However, prior to this study, it 
remained unclear which cellular structure maintains perinuclear accumulation of AAV. 
Earlier studies have suggested that the perinuclear viral particles co-localize to the Golgi 
apparatus (Johnson et al. 2010; Nonnenmacher et al. 2011). Another study suggests that these 
virions may co-localize with the MTOC (Johnson et al. 2011). In this study, to examine 
which structure was involved, we combined confocal fluorescence microscopy with 
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pharmacological intervention to circumvent the difficulties in studying the interactions 
between virions and cellular structures at the highly crowded perinuclear region caused by 
the resolution limits of classical fluorescence microscopy (~ 0.3 m in lateral). Our results 
demonstrate that it is MT-MTOC but not the Golgi that co-localize with and retain the AAV 
particles at perinuclear region (Fig.IV-2). Consistent with our findings, many other viruses 
including Ad, HSV, and HIV have also been shown to move on MTs to the MTOC region 
and associated with MT-MTOC (Sodeik et al. 1997; McDonald et al. 2002; Bailey et al. 
2003; Fackler et al. 2006; Greber et al. 2006; Leopold et al. 2006; Yea et al. 2007). 
Furthermore, figure IV-2E shows that only a small portion of viral particles co-localized with 
the dispersed Golgi cisternae which are released from highly packed MTOC region upon 
MT-MTOC disruption. This suggests that few particles physically localize in the Golgi 
apparatus. Consistent with previous reports, we did find disruption of the Golgi apparatus at 
an earlier time during infection can impair AAV transduction. These data indicate that the 
Golgi does play a role in viral infection, probably through viral capsid modifying critical for 
viral infection, but is dispensable for perinuclear retention of incoming virions. Further 
investigation of the exact role of the Golgi apparatus on the infection of AAV and other 
viruses may advance our current knowledge of virology.   
Our results, together with previous studies strongly suggest that perinuclear retention 
at MTOC during early infection serves as a cellular barrier limiting viral transportation to the 
replication sites, and leads to decreased viral transduction. During early infection stage, in 
which a virus delivers its genome to the target site for replication, accumulation of incoming 
virions at MTOC region is observed for most viruses that exploit MTs for earlier cytoplasmic 
trafficking (Sodeik et al. 1997; Dohner et al. 2002; McDonald et al. 2002; Suikkanen et al. 
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2002; Mani et al. 2006; Yea et al. 2007; Boisvert et al. 2010). Combining our observations 
with these previously published findings prompted us to test whether the MT-MTOC serves 
as a subcellular barrier restricting access of the virions to their replication site (nucleus in this 
study) during the early stage of viral infection. In order to do so, we have disrupted MT-
MTOC using AMDs specifically at about 6-8 hours p.i. to exclude the potential 
complications from earlier MT-mediated cytoplasmic trafficking. In addition, we have 
utilized recombinant viruses to rule out the potential complications from viral replication and 
assembly. Using these experimental strategies, we demonstrated that retention of AAV by 
MT-MTOC limits viral transduction. Additionally, both Ad and HIV are also known to 
accumulate at MTOC region in HEK293 cells (McDonald et al. 2002; Yea et al. 2007), and 
the nuclear delivery of their components is essential for infection (Goff 2001). Interestingly, 
our data shows that disruption of MT-MTOC during infection with these viruses also led to 
an increase in viral transduction (Fig.IV-4E). Though further studies are required to 
demonstrate the mechanism in each of these cases, these findings are consistent with our 
observations using AAV and the model that retention of incoming virions at MTOC region 
during early infection limits transduction. Strikingly, some viruses may have evolved to 
overcome the MTOC retention by breaking MTs during their infection (Avitabile et al. 1995; 
Ploubidou et al. 2000; Schepis et al. 2006; Liu et al. 2010; Martin et al. 2010).  For instance, 
HSV dismantle the MT-MTOC after entering the cells as one of the functions of viral protein 
ICP0 and deletion of ICP0 seems to limit viral infection (Liu et al. 2010). 
Our current study raises an interesting question for future exploration, which is 
whether and how the endosomal vesicles at MTOC region may contribute to the transduction 
enhancement observed upon MT-MTOC disruption. A reasonable hypothesis is that at 6-8 
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hrs p.i., some viral particles observed at the MTOC region still remain inside the MT-
localized endosomes/lysosomes (Ding et al. 2006; Xiao et al. 2012), while others have 
escaped the endosomes and directly associate with MTs. Direct interaction between MTs and 
the AAV capsid has been demonstrated previously (Kelkar et al. 2006). Both endosomal and 
escaped viral particles would be released from the MTOC region upon MT-MTOC 
disruption. Using AAV mutants with defects in the phospholipase (PLA) domain, we 
determined that MT-MTOC disruption was unable to rescue the impaired viral transduction 
of these mutants (data not shown), which suggests that MT-MTOC disruption does not 
promote the escape of AAV from endosomes. Furthermore, increased viral particles reaching 
the nucleus upon disruption of MT-MTOC are most likely the subset of virions that have 
escaped from endosomes and are directly associated with MTs. Those virions that failed to 
escape endosomes are not eligible for nuclear entry regardless of the integrity of MT-MTOC. 
This notion is consistent with our observation that the proportion of nuclear particles only 
increases from about 30% to 50%, potentially because about 30-40% of virions are still 
inside the endo/lysosomes at 8 hrs p.i. (Xiao et al. 2012). In the future, it will be interesting 
to investigate the potential role of endo/lysosomal vesicles on viral retention at the 
perinuclear region, which would add valuable information to the mechanism of this 
perinuclear phenomenon.  
Actin filaments (AFs) and small Rho GTPases have been shown to be involved in 
viral infection including cell entry, cytoplasmic trafficking, and nuclear entry (Lehmann et al. 
2005; Favoreel et al. 2007; Schelhaas et al. 2008; Ohkawa et al. 2010; Nonnenmacher et al. 
2011). Recently, perinuclear and nuclear AFs were shown to associate with the nuclear 
envelope and nuclear pore complex, and were suggested to be involved in nuclear transport 
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of macromolecules and viral particles (Hofmann et al. 2001; van Loo et al. 2001; Minakhina 
et al. 2005; Broers et al. 2006; Favoreel et al. 2007; Schneider et al. 2008). In addition, AAV, 
as well as other viruses, has been suggested to utilize AFs to enter nucleus during an earlier 
stage of infection when MTs were disrupted (Xiao et al. 2012). Furthermore, the disruption 
of MTs leads to a RhoA-ROCK mediated rearrangement of AFs (Krendel et al. 2002; Chang 
et al. 2008). Consistent with these studies, our data show that AFs may facilitate the increase 
in nuclear entry through the RhoA-ROCK pathway upon MT-MTOC disruption (Fig.IV-6). 
Interruption of this pathway in the presence of intact MTs does not affect the level of viral 
transduction. This finding indicates that, at this time point, nuclear import of AAV by AFs 
only occurs upon the disruption of the MT-MTOC. It is possible that the AAV capsid has a 
much higher binding affinity for MTs than for AFs, and therefore remains associated with 
MT-MTOC. Moreover, the requirement of RhoA and ROCK activity indicates that MT 
disruption-induced alterations of AFs are necessary for the increase in viral nuclear entry and 
transduction. One possibility is that activated RhoA-ROCK results in more AFs connecting 
to the nuclear pore complex, which in turn transports more AAV particles into the nucleus. 
Further study of this mechanism will add more detail to current knowledge of viral nuclear 
entry as well as the biology of cellular cytoskeletons.  
Although tremendous progress has been made in understanding the trafficking of 
AAV virions in cell culture, little is known about the trafficking pattern of this virus in vivo. 
This has limited one’s ability to improve the efficiency of viral transduction for gene delivery 
in its natural environment. In this study, we examined the trafficking of AAV in mouse 
tissues including brain, liver, and xenografted tumors. In each of these tissues the viral 
particles accumulate at a perinuclear site, resembling our in vitro observations (Fig.IV-7). 
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Treatment with Nocodazole was able to disrupt the perinuclear retention of AAV and 
increase the viral transduction in all tissues tested (Fig.IV-8). Although further investigations 
are needed to refine the details of viral trafficking in these tissues, to our best knowledge, this 
is the first study to verify an in vitro trafficking pathway in in vivo settings. Additionally, the 
data showing that Nocodazole treatment can enhance AAV transduction in breast cancer cells 
indicates that there may be a synergistic effect between chemotherapeutic drugs, such as 
AMDs, and AAV-mediated gene therapy in treating cancer patients.     
In summary, our current study examined the mechanism of perinuclear retention of 
the parvovirus AAV and the corresponding effects on viral infection. Our data demonstrated 
that perinuclear retention by MT-MTOC serves as a subcellular barrier and limits viral 
infection, specifically at the step of nuclear entry, providing a novel host defense mechanism 
to sequester incoming virions. Our observations with Ad and HIV suggest a similar 
mechanism is active during the infection of these viruses as well, expanding our findings to 
both non-enveloped and enveloped viruses. These studies may shed light on mechanisms of 
viral pathogenesis, especially under circumstances of MT disassembly during cell division 
and that of MTOC malfunction caused by misfolded-protein diseases or treatment with 
chemotherapy drugs. Moreover, further understanding the determinants on the virus 
responsible for perinuclear retention may also lead to novel strategies for the enhancement of 
vectors for gene delivery.  
  
CHAPTER 5 
 
CONCLUSIONS AND FUTHER EXPLORATIONS 
 
Summary of results 
 
Gene therapy, an idea conceived several decades ago to introduce a functional copy 
of nucleic acid sequences into patients with genetically defects, is gaining momentum as a 
method to treat human diseases. AAV is a promising viral vector to deliver therapeutic genes. 
Like many other viruses, AAV has to interact with and travel through a variety of cellular 
organelles in order to successfully deliver its genetic material into host nucleus. 
Understanding how this virus transits from cell surface to deposit its genome in nucleus is the 
central research in AAV biology and vectorology. Importantly, understanding how 
nanoparticles travel through the cellular structures and how pharmacological reagents can 
affect viral trafficking is essential for the development of enhanced gene therapy vectors  
(Torchilin 2006; Breunig et al. 2008). For instance, attenuating the barriers of viral 
trafficking or designing capsid with enhanced ability to penetrate these barriers will offer 
promising opportunities to improve current vectors for gene therapy. Consequently, 
development of therapeutic delivery vectors has concentrated on pharmacological reagents 
and vector variants that affect these pathways (Duan et al. 2000; Maheshri et al. 2006; 
Asokan et al. 2009; Yang et al. 2009). In this dissertation, we have sought to establish a 
reliable methodology to effectively study the vector trafficking (chapter-2), study the role of 
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MTs on AAV trafficking (chapter-3), and finally highlighted a novel trafficking barrier 
during AAV infection (chapter-4). Using our quantitative 3D microscopy as well as other 
experimental tools, we determined that after internalization AAV particles inside endosomes 
migrate on MTs toward perinuclear region and its nuclear entry is then restricted by MTOC 
retention, illustrating the fine tuning of AAV infection by MT system (Fig.V-1). 
Effective achievement of such efforts requires quantitatively evaluating the biological 
effect(s) of those reagents or vector variants on these complex trafficking routes and bio-
distribution of delivery vehicles. In chapter-2, based on recent advances with computational 
image processing(Sedarat et al. 2004; Feng et al. 2007), we developed a sensitive and reliable 
methodology by integrating single particle imaging and 3D quantification into classical 
immunofluorescence to quantitate the trafficking kinetics and bio-distribution of 
nanoparticles in three dimensional animal cells and tissues. Using Cy5-labeled AAV as a 
working model, we quantitatively investigated the nuclear entry kinetics and bio-distribution 
of AAV2 in human cells and mouse tissues. We uncovered an as yet uncharacterized rate-
limiting step during viral cell entry, while delineating nuclear accumulation of virions during 
the first 8hrs post-infection. Additionally, our studies revealed for the first time that 
following intramuscular injection, AAV spread progressively across muscle tissues through 
endomysium between myofibers instead of traversing through target cells. This observation 
supports a hypothesis that, unlike in cultured cells, viral particles in vivo can persist in 
myofibers potentially providing a temporal reservoir of virus. These virions may traffic to the 
nucleus and contribute to viral transduction at later times (over 2 weeks), which also could be 
an explanation to the observed AAV transduction profile in muscle (Fisher et al. 1997; Chao 
et al. 2000) .  These findings both support the current working knowledge of AAV biology  
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Figure V-1. Updated scheme for AAV trafficking. After binding to the heparan sulfate 
proteoglycan (HSPG) on cell surface, AAV2 interacts with cell surface receptors (i.e. 
integrin and FGFR) and is internalized through clathrin-dependent and independent 
endocytosis. After binding and endocytosis on cell surface, AAV2 virions may take two 
possible trafficking routes towards the nucleus. Route I: For these internalized at sites distal 
from the nucleus, virions migrate on MT tracks in endosomes to traverse the dense cytoplasm 
towards peri-nuclear region of host cells. Route II: For these internalized at sites close to the 
nucleus, virions in endocytic vesicles can reach the nucleus by slower MT-independent 
migration through the cytoplasm between the cytoplasmic membrane and nuclear envelope. 
For both routes, acidification of AAV2 containing endosomal compartment happens at the 
peri-nuclear region and allows the escape of viral particles from vesicles, a pre-requisite step 
for nuclear entry. After cytoplasmic trafficking, most virions are retained by MT-MTOC, 
which restricts the nuclear entry of viral particles. Nuclear entry of viral genome is regarded 
as an essential event for successful AAV transduction. Currently, it remains unclear whether 
nuclear entry is through the nuclear pore complex or other routes. It is also unknown when 
and where and how genome uncoating takes place.     
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and provide a better mechanistic insight into the behavior of this viral vector in vitro and in 
vivo. This study demonstrates the potential of this methodology in screening pharmacological 
reagents and vector variants for the development of therapeutic-material delivery strategies, 
as well as in understanding the intracellular behavior of delivery viral vectors in vitro and in 
vivo. 
Cytoplasmic trafficking is critical for most DNA viruses to approach the peri-nuclear 
region and deposit their genomic DNA in the nucleus of host cells. Previous studies have 
demonstrated that either actin filaments or microtubules (MTs) are exploited by various 
viruses to traverse the dense cytoplasm. For AAV, the exact mechanism of cytoplasmic 
trafficking of this virus remains unclear, due to previous reports that are diametrically 
opposite in their conclusions (Sanlioglu et al. 2000; Kelkar et al. 2006; Hirosue et al. 2007). 
In chapter-3 we have studied the role of MTs on AAV2 transduction and extensively 
investigated the underlying mechanisms regarding how MTs contribute to viral infection 
using various pharmacological and microscopy tools. Our data from live cell imaging and 
flow cytometry analysis have determined the involvement of MTs in AAV2 infection, and 
the data from quantitative 3D microscopy and quantitative PCR analysis have demonstrated 
that intact MT network is required for the nuclear targeting of AAV but not for cell surface 
attachment or endocytosis of this virus. In this study, for the first time we have determined 
that the migration of AAV2 on MT tracks are fast (up to 1.5-3.5 m/s) which is consistent 
with dynein-mediated trafficking and are uni-directional which is different from the bi-
directional motion of Ad or HSV on MTs. In addition, our study using electron microscopy 
and pharmacological experiments is the first one to suggest that AAV traffics on MTs in 
endosomes and acidification of these structures is dependent on intact MT network. The 
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findings herein strongly support an as yet undocumented model in which after 
internalization, AAV2 exploits MTs for fast and uni-directional trafficking in endosomal 
compartments towards peri-nuclear region where most viral acidification events take place. 
Furthermore, our findings that MT disruption never completely blocks AAV2 transduction 
suggest the existence of an alternative MT-independent trafficking pathway for this virus. 
These data together with earlier studies support a model of AAV2 trafficking during its early 
infection procedure (Fig.III-13, (Sanlioglu et al. 2000; Douar et al. 2001; Ding et al. 2006; 
Johnson et al. 2010)). 
Like many other viruses (e.g. Ad, HSV, HIV, influenza, parvoviruses), after MT-
mediated cytoplasmic trafficking, AAV particles accumulate at the perinuclear region.   
However, it remains unclear regarding whether and how this accumulation affects viral 
infection. Two plausible hypotheses are (Wileman 2007): 1) viruses exploit the cellular 
protein-trafficking machineries to approach the replication site or to concentrate viral 
components for viral replication and later virion assembly, thus supporting viral infection; 2) 
perinuclear accumulation represents an innate cellular response that recognizes virus 
components as foreign or misfolded proteins and targets them for sequestration and 
degradation at the perinuclear region, thus interfering with viral infection. In chapter-4, we 
test the hypothesis that perinuclear accumulation is a cellular defense mechanism to sequester 
virions in order to limit the infection of both enveloped virus (HIV) and non-enveloped 
viruses (Ad and AAV). In this study, we first demonstrate that, similarly to Ad and HIV, 
parvovirus AAV’s perinuclear localization is maintained by microtubules at the microtubule-
organization center (MT-MTOC). Disruption of this structure after viral entry leads to 
increased susceptibility to infection of rAAV, rAd, and lentivirus. We further used AAV as a 
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study model and fluorescent microscopy and molecular analyses as experimental approaches 
to study the underlying mechanisms. The results suggest that the proportion of viral particles 
entering the nucleus increases following MT-MTOC disruption and that this enhancement is 
dependent on the AAV capsid’s nuclear import signals, indicating the involvement of a 
nuclear trafficking pathway. Interestingly, after knocking down RhoA or inhibiting its 
downstream effectors (ROCK and Actin), MT-MTOC disruption did not increase viral 
transduction or nuclear entry. These data suggest a two-step mechanism for the enhancement 
of infection: 1) release of viral particles from the perinuclear site upon MT-MTOC 
disruption, and 2) increased trafficking to the nucleus via the RhoA-ROCK-Actin pathway. 
Furthermore, we extended the AAV studies in vivo and observed that viral transduction of 
brain, liver, and xenografted tumor tissues was enhanced up to 10-fold by disruption of the 
MT-MTOC, indicating a similar trafficking mechanism in vivo. In summary, this study for 
the first time experimentally demonstrates that perinuclear accumulation of incoming virions 
at the MT-MTOC is a barrier limiting the infection of most nuclear viruses and more 
specifically restricting the nuclear entry of AAV, defining a novel defense mechanism by 
which host cells restrain viral invasion. 
All in all, our studies documented in this dissertation, through three chapters (chapter 
2-4), create a robust microscopy method for viral trafficking and exploit this method together 
with other experimental tools to dissect the intracellular trafficking of AAV in detail. Briefly, 
in chapter-2, by exploiting recent advances with computational image processing and 
fluorescence labeling, we developed a sensitive and reliable methodology by integrating 
single particle imaging and 3D quantification into classical immunofluorescence to quantitate 
the trafficking kinetics and bio-distribution of nanoparticles in three dimensions. The 
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associated studies demonstrate the potential of this methodology in screening 
pharmacological reagents and vector variants for the development of therapeutic-material 
delivery strategies, as well as in understanding the intracellular behavior of delivery viral 
vectors in vitro and in vivo. In chapter-3, we employed the 3D quantitative microscopy 
together with multiple other techniques including confocal microscopy, live cell imaging, 
single particle tracking, electron microscopy, and pharmacological analysis to examine the 
role(s) of MTs during AAV infection and to investigate the underlying mechanisms in detail. 
Besides providing a comprehensive understanding of the role of MTs on AAV trafficking, 
the findings in the study also suggest an as yet undescribed model in which after 
internalization, AAV2 exploits MTs for rapid cytoplasmic trafficking in endosomal 
compartments uni-directionally towards peri-nuclear region where most acidification events 
for viral escape take place. In chapter-4, we investigated the role and mechanism of 
perinuclear accumulation of AAV, a subcellular event that is subsequent to the MT-mediated 
cytoplasmic trafficking documented in chapter-3 and is associated the nuclear entry. In this 
study, we experimentally demonstrates that perinuclear MT-MTOC retains incoming virions 
and serves as a barrier to limit the infection of most nuclear viruses and more specifically 
restrict the nuclear entry of AAV, suggesting a novel host defense mechanism against viral 
invasions. Our above studies will advance the current model of AAV infectious pathway by 
adding the roles of MTs into the trafficking picture (Fig.V-1). I personally believe the work 
described in this dissertation have advanced our knowledge in AAV biology and 
vectorology, as well as provided some critical insights for several research fields including 
virology, cell biology, biophysics, and gene therapy.  
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Unpublished data and future directions 
 
Our above studies demonstrate the roles of MTs on AAV trafficking and transduction in the 
host cells. It should be noticed that these studies mostly focused on the behavior of AAV 
particles during the interphase of cultured cells. Although AAV is not a popular vector for 
gene delivery into the dividing cells in our body, it is yet a quite interesting question whether 
and how MTs may play roles on AAV trafficking during cell division. The MT dynamics is 
critical to the mitotic process as evidenced by the appearance of high tubulin turnover in MTs 
during mitosis. During prophase, the long interphase MTs start to disappear and are replaced 
with astral MTs, the major component of the spindle. These mitotic MTs nucleated from the 
centrosomes are more numerous, shorter, and less stable than interphase ones. Typically, the 
average lifetime of a MT diminished from about 10 minutes in interphase cells to roughly 30 
seconds in the mitotic spindle. To study whether such change in MT dynamics will alter the 
trafficking or distribution of viral particles in host cells, we observed Cy5 labeled AAV in 
mitotic cells (Fig.V-2). In mitotic cells, most virions are associated with MTs especially 
those at the mitotic spindle that are ‘corresponding’ to the MTOC in the interphase cells. 
However, a surprising observation is that a lot of virions are not confined to the perinuclear 
region in the mitotic cells, differing from our previous results in interphase cells where most 
of the virions are retained at the perinuclear MTOC region (Fig.V-2b, 2d, 2e). An immediate 
question is how these virions that originally localized at the perinuclear region spread out 
into the cytoplasm. One possible mechanism could be that these unstable and highly dynamic 
mitotic MTs are less efficient to hold viral particles at the perinuclear region. It is also known 
that the nuclear envelope will be dissolved during prometaphase, a stage that is exploited by 
some retroviruses to import viral materials into the nucleus. As a result, another interesting 
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hypothesis is that host cells utilize MTs to temporally move virions away from the 
perinuclear region to reduce the opportunistic nuclear entry of AAV particles when nuclear 
envelope is broken down during cell division. In this case, a positive-end MT motor like 
kinesin may mediate the movement of AAV on the MTs away from the perinuclear region. 
While addressing this question will not necessarily be directly relevant to the vector 
development, it may advance our knowledge on AAV biology, especially the interaction 
between this virus and its host.      
Interestingly, in chapter-3, we notice that AAV2 particles in a much smaller 
proportion were still detected in the nucleus of Nocodazole-treated cells (Fig.III-7). This is 
consistent with the observation in reporter gene (GFP) assay that AAV2 was still able to 
transduce cells in the absence of MTs, though in a reduced level compared with control cells 
(Fig.III-1). One possibility for this observation is related to the inefficient MT-independent 
trafficking of virions. Under this scenario, AAV2 particles could be internalized in the cell 
membrane close to the nucleus, where the virions only have to traverse a small distance to 
reach the nucleus (Fig.III-13 and (Leopold et al. 2006)). Movements over such short distance 
(several microns) might be achieved by normal diffusion (Fig.III-13, V-1). Internalization in 
the sites around nucleus can be achieved by the direct binding of viral particles at these sites 
or viral surfing on cell membrane to these sites (Neumann et al. 2008). Current work does not 
exclude the possibility that AAV2 particles may reach the nucleus through a much slower 
process by exploiting actin filaments or intermediate filaments (Ohkawa et al. 2010; Schuh 
2011). It is not uncommon for viruses to exploit multiple pathways to ensure productive 
infection. Further explorations are needed to validate these putative pathways and may bring 
new insights into the infectious pathway of AAV particles.   
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Figure V-2. Peri-nuclear localization of AAV2 requires intact MTs and associated with 
MTs throughout cell cycle. 8hrs after incubation with AAV, cells were fixed and stained 
with -tubulin antibody for MTs (green), Giatin antibody for Golgi (Cyan), and DAPI for 
Nuclei (blue). A) Hela cells were pulse infected with Cy5-AAV2 (red) and drugs were 
administrated at 7-10hrs after infection. Upper panel: Disruption of Golgi apparatus by 
Brefeldin A did not ablate the peri-nuclear localization of AAV2 particles. Lower panel: 
Peri-nuclear localization of AAV2 was ablated by the disruption of intact MTs using 
Nocodazole (30 M). B) AAV2 is associated with MTs throughout all stages of cell cycle. 
Hela cells were pulse infected with Cy5-AAV2 (red) and fixed at 6hrs after pulse infection. 
Confocal images were taken to examine the distribution of viral particles at various stages of 
cell cycle: a) interphase, b) prometaphase, c) metaphase and anaphase, d) telophase, e) post-
telophase. 
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After internalized, AAV has to traffic through a variety of endocytic vesicles, 
including early endosome, late endosome, recycling endosome, and so on. Dr. John 
Engelhardt’s group and others reported that AAV particles were found in various endosomes 
and might take different endosomal trafficking routes at different viral dosages (Douar et al. 
2001; Ding et al. 2006). However, the details about AAV trafficking in endosomes remain 
unknown. A previously debating issue is whether AAV escapes from early endosomes or late 
endosomes, both of which are supported by literatures (Bartlett et al. 2000; Douar et al. 2001; 
Ding et al. 2006). For its helper viruses like Ad and HSV, the virions escape from early 
endosomes before their migration on the MTs (Dodding and Way 2011; Engelke, Burckhardt 
et al. 2011; Radtke, Kieneke et al. 2011). Our studies in chapter-3 demonstrate that AAV 
does not escape from endosome until it finishes MT trafficking from cell periphery to 
perinuclear region where most endosomal acidification takes place and late endosomes 
localized (Mellman, Fuchs et al. 1986; Lakadamyali, Rust et al. 2003). This is in concert with 
the notion that endosomal acidification is required for AAV escape and supports that AAV 
escape from acidic late endosomes. To further look into the details regarding how AAV 
particles transit between different endosomes, we used confocal microscopy to lively track 
the viral particles in cells expressing fluorescence protein fused Rab proteins (Fig.V-3). At 
perinuclear region, an AAV virion is observed to reside in a Rab5-associated early endosome 
and then transit into a Rab7-associated endosome. This transition seems to be really fast as it 
only takes about 10 seconds. This also supports the notion that AAV particles escape from 
the late endosomes instead of early ones.  
It should be noted that our current data does not exclude the possibility that some AAV2 can 
escape from the early endosome as an alternative pathway in the cells. Given that 
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cytoplasmic dynein can directly bind to AAV2 capsid in vitro (Kelkar et al. 2006; Zhao et al. 
2006), it will be of particular interest in the future to identify and mutate the dynein binding 
sites on AAV2 capsid and further investigate the trafficking of these mutant AAVs. There 
might be of some interest to study whether the rapid-directed motion of AAV2 is mediated 
by the dynein associated with endosomes or that directly associated with viral capsid. It is 
known that AAV2 is internalized through clathrin-dynamin mediated pathway into endosome 
compartments (Duan et al. 1999; Bartlett et al. 2000).While we were not able to definitively 
determine dynein interaction with AAV-containing endosome vs capsid specifically, our data 
strongly supports the usage of this motor in fast-directed movement of AAV. Interestingly, 
some dynactin subunits like p62 were demonstrated to have a minimal impact on dynein-
mediated functions and suggested to be dispensable for the function of dynactin complex 
(Quintyne et al. 1999; Schroer 2004). More importantly, recent studies have begun to 
demonstrate that dynein can directly bind to the pathogen-related cargos and suggest that 
dynactin may be dispensable especially for the dynein-mediated pathogen trafficking 
(Grieshaber et al. 2003; Schroer 2004; Bremner et al. 2009). Careful and sophisticated 
investigations will be required to address the issues regarding whether and how the dynactin 
complex contributes to the MT-mediated AAV2 trafficking. 
Our observations in this dissertation also raise an interesting question for future 
exploration, which is how and when the AAV particles escape from endosomal vesicles at 
perinuclear MTOC region. How this mechanism may contribute to the transduction 
enhancement observed upon MT-MTOC disruption. A reasonable hypothesis is that at 6-8 
hrs p.i., some viral particles observed at the MTOC region still remain inside the MT-
localized endosomes/lysosomes (Ding et al. 2006; Xiao et al. 2012), while others have  
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Figure V-3. Transition of AAV particles from early endosome to late endosome. Video 
from zeiss510 confocal microscopy was captured at 0.5s per frame and 5s between two 
frames. Selected frames with indicated time point are displayed. AAV particles are visualized 
by Cy5 fluorescence (red, arrow), early endosomes are visualized by EGFP fused Rab5 (blue, 
arrowhead), and late endosomes are visualized by DsRed fused Rab7 (green, double 
arrowhead).    
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escaped the endosomes and directly associate with MTs. Direct interaction between MTs and 
the AAV capsid has been demonstrated previously (Kelkar et al. 2006). Both endosomal and 
escaped viral particles would be released from the MTOC region upon MT-MTOC 
disruption. Using AAV mutants with defects in the phospholipase (PLA) domain, we 
determined that MT-MTOC disruption was unable to rescue the impaired viral transduction 
of these mutants, which suggests that MT-MTOC disruption does not promote the escape of 
AAV from endosomes. Furthermore, increased viral particles reaching the nucleus upon 
disruption of MT-MTOC are most likely the subset of virions that have escaped from 
endosomes and are directly associated with MTs. Those virions that failed to escape 
endosomes are not eligible for nuclear entry regardless of the integrity of MT-MTOC. This 
notion is consistent with our observation that the proportion of nuclear particles only 
increases from about 30% to 50%, potentially because about 30-40% of virions are still 
inside the endo/lysosomes at 8 hrs p.i. (Xiao et al. 2012). In the future, it will be interesting 
to investigate the potential role of endo/lysosomal vesicles on viral retention at the 
perinuclear region, which would add valuable information to the mechanism of endosomal 
trafficking and perinuclear accumulation.  
Both Golgi and MTOC are perinuclear structures that coincidentally colocalize at the 
perinuclear region with many viruses (Sodeik et al. 1997; Dohner et al. 2002; Mani et al. 
2006; Yea et al. 2007; Boisvert et al. 2010; Liu et al. 2012). However, prior to this work, it 
remained unclear which cellular structure maintains perinuclear accumulation of AAV. 
Earlier studies have suggested that the perinuclear viral particles co-localize to the Golgi 
apparatus (Johnson et al. 2010; Nonnenmacher et al. 2011). Another study suggests that these 
virions may co-localize with the MTOC (Johnson et al. 2011). In chapter-4, we determined 
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that it is MT-MTOC but not the Golgi that co-localize with and retain the AAV particles at 
perinuclear region. Consistent with our findings, many other viruses including Ad, HSV, and 
HIV have also been shown to move on MTs to the MTOC region and associated with MT-
MTOC (Sodeik et al. 1997; McDonald et al. 2002; Bailey et al. 2003; Fackler et al. 2006; 
Greber et al. 2006; Leopold et al. 2006; Yea et al. 2007). Our observation that only a small 
portion of viral particles co-localized with the dispersed Golgi cisternae which are released 
from highly packed MTOC region upon MT-MTOC disruption further suggests that few 
particles physically localize in the Golgi apparatus. Consistent with previous reports, we did 
find disruption of the Golgi apparatus at an earlier time during infection can impair AAV 
transduction. These data indicate that the Golgi does play a role in viral infection, probably 
through viral capsid modifying critical for viral infection, but is dispensable for perinuclear 
retention of incoming virions. Further investigation of the exact role of the Golgi apparatus 
on the infection of AAV and other viruses may advance our current knowledge of virology.   
Actin filaments (AFs) and small Rho GTPases have been shown to be involved in 
viral infection including cell entry, cytoplasmic trafficking, and nuclear entry (Lehmann et al. 
2005; Favoreel et al. 2007; Schelhaas et al. 2008; Ohkawa et al. 2010; Nonnenmacher et al. 
2011). Recently, perinuclear and nuclear AFs were shown to associate with the nuclear 
envelope and nuclear pore complex, and were suggested to be involved in nuclear transport 
of macromolecules and viral particles (Hofmann et al. 2001; van Loo et al. 2001; Minakhina 
et al. 2005; Broers et al. 2006; Favoreel et al. 2007; Schneider et al. 2008). In addition, AAV, 
as well as other viruses, has been suggested to utilize AFs to enter nucleus during an earlier 
stage of infection when MTs were disrupted (Xiao et al. 2012). Furthermore, the disruption 
of MTs leads to a RhoA-ROCK mediated rearrangement of AFs (Krendel et al. 2002; Chang 
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et al. 2008). Consistent with these studies, our data show that AFs may facilitate the increase 
in nuclear entry through the RhoA-ROCK pathway upon MT-MTOC disruption (Fig.IV-6). 
Interruption of this pathway in the presence of intact MTs does not affect the level of viral 
transduction. This finding indicates that, at this time point, nuclear import of AAV by AFs 
only occurs upon the disruption of the MT-MTOC. It is possible that the AAV capsid has a 
much higher binding affinity for MTs than for AFs, and therefore remains associated with 
MT-MTOC. Moreover, the requirement of RhoA and ROCK activity indicates that MT 
disruption-induced alterations of AFs are necessary for the increase in viral nuclear entry and 
transduction. One possibility is that activated RhoA-ROCK results in more AFs connecting 
to the nuclear pore complex, which in turn transports more AAV particles into the nucleus. 
Further study of this mechanism will add more detail to current knowledge of viral nuclear 
entry as well as the biology of cellular cytoskeletons. 
Nuclear entry is regarded as the most critical and rate-limiting step for the life cycle 
of most DNA viruses (e.g. adenovirus, herpesvirus and parvovirus) (Whittaker et al. 2000; 
Greber et al. 2009). Blocking the nuclear entry is an alternative way to block viral replication 
(Haffar et al. 2005; Boulo et al. 2007; Hindley et al. 2007; Greber et al. 2009), and on the 
other hand, facilitating the nuclear entry of viruses has been a promising strategy to improve 
viral vectors for gene delivery (Hansen et al. 2000; Suzuki et al. 2007; Johnson et al. 2008; 
Mudhakir et al. 2009). Several groups have suggested that AAV entered nucleus as intact 
virions (Bartlett et al. 2000; Sonntag et al. 2006; Johnson et al. 2008). In chapter-2, while 
characterizing the kinetics of AAV nuclear targeting, in dose response studies, the number of 
virions in the nucleus does not increase linearly with the number of nuclear membrane 
associated virions at 2hrs p.i. (Fig.II-10D). This result suggests that there may be limited 
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sites/routes for AAV2 nuclear entry through the nuclear membrane, and provides a sound 
explanation for the observation that the fold increase in virion dosage does not translate to 
equivalent fold increase in transduction (Fig.II-11).  
Nuclear pore complex (NPC) is designed for the transportation of cellular materials 
into and out of nucleus, and is also exploited by many viruses to deposit their genetic 
materials in the nucleus. Both NPC-dependent and independent pathways have been 
proposed and reported for the nuclear entry of DNA viruses. The strong association of virus 
particles with MT structures throughout the cell cycle suggests that AAV is unlikely to 
exploit the breakdown of nuclear envelope during mitosis (Fig.V-2). In figure V-4, we first 
tested the co-localization between AAV2 and NPC. Viral particles were co-localized with 
NPC and representing virions were highlighted by arrowheads in figure V-4. Consistently, 
our electron microscopy (EM) data also demonstrate the close association between AAV2 
particles and NPC (Fig.V-4B). It was previously demonstrated that while docking at the NPC 
to release the genome, HSV interacts with the cytoplasmic filaments (30-50 nm in length) 
and typically sits about 40-80 nm away from the luminal spoke rings of the NPC (Peng et al. 
2010). Our EM image suggests an interaction between AAV2 and cytoplasmic filaments for 
the viral access to the nuclear pore (Fig.V-4B, C). Further we used a recent established 3D 
microscopy method to study the localization between AAV2 and those NPCs on nuclear 
envelope in the DMSO or Nocodazole treated cells. In DMSO-treated cells, more viral 
particles were associated with the NPCs close to the peri-nuclear viral accumulation site than 
with those at the distal site. In contrast, viral particles evenly co-localized with NPCs across 
the entire nuclear membrane in Nocodazole treated cells (Fig.V-4D).  
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Both our confocal fluorescence imaging and electron microscopy data demonstrate the 
association of AAV particles with NPC, indicating the potential involvement of NPC in viral 
nuclear entry. Although the diameter of the opening of NPC is about 9nm compared to 
20nm-sized AAV particles, it has been suggested that the pore can be dilated up to 26nm 
which would potentially allow for the nuclear import of AAV (Dworetzky et al. 1988). In 
addition, the increased association of AAV2 particles we observed with NPC especially at 
distal site of MTOC after disruption resulted in both enhancement of viral nuclear entry 
consistent with the barrier hypothesis. Although a previous study using isolated nuclei 
suggested that nuclear pore is not required for the nuclear entry of AAV2 virions (Hansen et 
al. 2001), this premise has not been formerly tested in intact cells. In addition, other DNA 
viruses have been shown to deliver viral genomes into the nucleus through NPC (Greber et 
al. 1997; Ojala et al. 2000), so it remains to be determined what contribution the NPC may 
play in the nuclear entry of AAV in intact cells. Examination of the roles of nuclear import 
machinery on AAV transduction and nuclear entry is essential. Better understanding the 
mechanism of viral nuclear entry could potentially increase our ability to improve vector 
performance by either manipulating the cellular machinery for nuclear import or designing 
better capsids. 
Another important but under-studied research direction is the trafficking of AAV 
particles in animal tissues. Although tremendous progress has been made in understanding 
the trafficking of AAV virions in cell culture, little is known about the trafficking pattern of 
this virus in vivo. This has limited one’s ability to improve the efficiency of viral transduction 
for gene delivery in its natural environment, as the in vivo setting provides the most 
applicable information for the development of efficient gene delivery vectors. However,  
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Figure V-4. AAV2 co-localizes with nuclear pore complex (NPC) and disruption of viral 
accumulation at MTOC results in viral access to the NPC distal from this region. A) 
Confocal image showing colocalization between NPC (green) and Cy5-AAV2 (red) at 6hrs 
after pulse infection. Nuclei were stained with DAPI (blue). In the magnified right panel, 
viral particles co-localized with NPC were highlighted by arrowheads. B) Electron 
microscopy graph showing the close association between AAV2 particles (labeled with 
nanogold, arrowhead) and NPC (indicated by arrow as a discontinuous region on nuclear 
envelope, short for NE)., Cyto: cytoplasm, Nuc: nucleus. Bar represents 200 nm. C) A 
cartoon illustrates the content in B. AAV particle is associated with NPC through the 
cytoplasmic filaments (in orange) of the pore complex. D) At 6hrs p.i., AAV2 access to the 
NPCs that mostly locate on nuclear envelope next to the peri-nuclear viral accumulation in 
DMSO treated cells (upper panel). At 1-1.5hrs after Nocodazole treatment, virions are evenly 
co-localized with NPCs across the entire nuclear envelope. Cy5-AAV2 in red, those inside 
the nucleus are in yellow, and those co-colocalize with NPC on nuclear envelope are 
highlighted as green. Nuclei were stained with DAPI (blue). 
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studying viral trafficking is an extremely challenging task with current experimental tools.  
By employing the newly established imaging method described in chapter-2, we have 
attempted to study the distribution of AAV2 particles in animal tissues and made several 
intriguing discoveries. In chapter-2, we for the first time showed that the AAV2 particles 
were localized at the injection site during the first 30 minutes and then uniformly spread 
through tissues up to three muscle fibers away from the injection site over 4hrs (Fig.II-12B). 
This result is significant in that it allows one to correlate viral spread with expression and 
should provide insight into vector tropism when studying capsid variants specific for muscle 
or various tissues such as brain and eye (Kessler et al. 1996; Fisher et al. 1997; Gregorevic et 
al. 2004; Sun et al. 2005; Wang et al. 2005). We also addressed the question how the viruses 
traffic to the cells distal from the injection site (Kessler et al. 1996; Fisher et al. 1997; 
Gregorevic et al. 2004; Sun et al. 2005; Wang et al. 2005; Di Pasquale et al. 2006) by 
showing  that most AAV2 particles traffic through the endomysium between muscle fibers 
instead of traversing through myofibers as proposed by previous studies (Bomsel et al. 2003; 
Di Pasquale et al. 2006; Bhat et al. 2007). Additionally, at 6 days after injection, AAV2 
particles were also detected inside of the muscle fibers/cells (Fig.II-12C). This observation 
supports a hypothesis that, unlike in cultured cells, viral particles in vivo can persist in 
myofibers potentially providing a temporal reservoir of virus. And these virions may traffic 
to the nucleus and contribute to viral transduction at later times (over 2 weeks), which also 
could be an explanation to the observed AAV transduction profile in muscle (Fisher et al. 
1997; Chao et al. 2000). In chapter-4, we briefly examined the trafficking of AAV in several 
mouse tissues including brain, liver, and xenografted tumors. Our study show that AAV also 
experiences perinuclear accumulation resembling our in vitro observations and disruption of 
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this perinuclear retention increases the viral transduction in all tissues tested. Although 
further investigations are needed to refine the details of viral trafficking in these tissues, to 
our best knowledge, this is the first study to verify an in vitro trafficking pathway in in vivo 
settings.      
It is an interesting question how AAV particles traffic in brain tissue, particularly the 
shuttling between different brain regions (e.g. from Thalamus to Cortex or Substantial Nigra 
(SN); from Striatum to Cortex, Thalamus, or SN). It is proposed that such trafficking is 
mediated by axonal antegrade or retrograde transportation. We have also studied the 
trafficking of AAV in rat cerebrum after striatum injection (Fig.V-5). At 1hr after viral 
injection, while most virions are remain at the injection site, many particles spread out into 
the brain tissue and distributed in a gradually reduced density as the distance from injection 
site increases. At 24hrs, virions start to accumulate at the perinuclear region of neuronal cells 
within regions at various distances from injection site except the region that is immediately 
next to the injection site. This observation implies that the virions can reach the cells right 
next to the injection site through a MT-independent route, but may have to migrate on MTs 
in the axons to reach those neurons that are away from the injection site. It is likely that the 
axonal mediated retrograde transportation is exploited by AAV to infect those cells that 
localized away from the virion reservoir. However, we didn’t find any viral particles at SN, a 
distal site from the injection site. This does not necessary mean that the axonal mediated 
retrograde transportation from Striatum to SN is not utilized by AAV. A likely explanation 
could be that the sensitivity of tissue imaging is insufficient to detect viral particles at low 
abundance in SN. The axonal mediated transportation is also varying among different AAV 
serotypes. More investigations are needed to better understand the AAV trafficking 
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mechanism in brain, which shall greatly advance our knowledge on the application and 
development of this vector for neuronal gene delivery.   
Both fluorophore labeling and fluorescent imaging are the mainstay in understanding the 
virus and host interactions, especially the trafficking of virions in host cells. In chapter-2, we 
described a quantitative 3D microscopy to study viral trafficking and distribution both in 
vitro and in vivo. The data acquired in our study was not limited by traditional light 
microscope and incorporation of deconvolution technique improves the contrast and 
resolution of digital images by correcting image distortions, making the fluorescence images 
suitable for quantitative measurement. In the future, super-resolution microscopes (e.g. 
STORM, STED, PALM) shall provide additional means to improve the quantification of 
fluorescence images (Huang et al. 2008; Huang et al. 2009). At the moment, these super-
resolution microscopes typically require longer time to capture images and access is limited 
for most virology labs. For further studying the distribution of viral particles in tissues, two-
photon microscopy will enable this method to deal with much thicker tissues by providing 
larger imaging depth. 
In summary, with the studies documented in this dissertation, we have refined the 
protocols for vector preparation and purification, advanced current methodologies to study 
the virus-host interactions, and provided an approach to effectively evaluate the effects of 
pharmacological reagents or vector variants on the delivery efficiency of viral vectors in 
cultured cells as well as animal tissues. In addition, studies on MT-mediated cytoplasmic 
trafficking of AAV have advanced our understanding of AAV trafficking dynamics and 
elaborated the roles of cellular machinery specifically MTs and MT-associated structures on 
AAV transportation and infection. Furthermore, our study has also identified 
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Figure V-5. AAV trafficking in rodent cerebrum. Viral particles are visualized by Cy5 
fluorescence and nuclei are visualized by DAPI signal. Top panel is micrograph of a control 
slide without viral injection. Middle panel is the distribution of AAV particles at various 
distances from injection site at 1hr after viral inoculation. Bottom panel is the distribution of 
AAV particles at various distances from injection site at 24hr after viral inoculation. Right 
side is most close to the injection site and left side is most distant from the injection site. 
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perinuclear retention as a novel subcellular barrier that limits AAV infection, specifically at 
the step of nuclear entry, which provides a new host defense mechanism to sequester 
incoming virions. Altogether, these studies may shed light on mechanisms of viral 
pathogenesis especially under the circumstances of MT disassembly during cell division and 
that of MTOC malfunction caused by misfolded-protein diseases or treatments with 
chemotherapy drugs. Further understandings of the determinants on the virus responsible for 
perinuclear retention may also facilitate the development of viral variants with enhanced 
delivery efficiency using rational design. Lastly, this work has significantly advances our 
knowledge regarding the trafficking of AAV2 particles in animal tissues, the natural 
environment of this virus.  
This dissertation provides valuable research tools, rationales, and assays for future 
exploration of the details of AAV trafficking. It is my personal prediction that such 
exploration shall focus on the details of endosomal trafficking, cytoskeleton-mediated 
cellular trafficking, nuclear importation, intra-nuclear processing of virions, as well as the 
associated determinants on AAV capsid. Meanwhile, validating trafficking pathways in vivo 
shall draw the attention of the research community as such information is more critical to 
enhance the performance of AAV vector for gene therapy. I sincerely believe that the 
comprehensive combination of multi-principle methodologies including those in cell biology, 
virology, biophysics, chemistry, applied math, statistics, and pharmacology will pickup the 
power in advancing the field of vector research and development. 
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APPENDICES: PLASMIDS 
 
For production of AAV virions 
TR-promoter-gene, the vector plasmid provides the transgene cassette flanked by TRs 
at both ends to be packaged into the virions. Plasmid ‘pTR-CBA-ssDNA’ (map provided in 
Fig.S-1) provides a single stranded genomic DNA to be packaged in the virions, and plasmid 
‘dsEMBL-TR-CMV-EGFPsc’ (map provided in Fig.S-1) provides a self-complementary 
genomic DNA to be packaged in the virions.  
pXR(s), packaging plasmid expresses the viral proteins (Rep78/68/52/40 and 
VP1/2/3) that are essential to make virions. Plasmid ‘pXRs’ (map provided in Fig.S-2) 
contains a ‘Rep’ coding sequence from serotype-2 and a ‘Cap’ coding sequence from various 
serotypes. The ‘Rep’ coding sequence encodes all the essential ‘Rep’ proteins as non-
structural proteins for virion production. The ‘Cap’ sequence encodes the structural proteins 
to make virions and thus determines the serotype of virions made from the ‘pXRs’ plasmid.     
HEK-293 (ATCC, cat. no. CRL-1573, provides E1a and E1b) and plasmid pXX680 
(provides E2a, E4, and VA) together to provide Ad helper function for the expression of 
AAV proteins from packaging plasmid, essential processing of vector plasmid into a 
packageble viral genomic DNA, assembly of virions, and packaging of genomic DNA. 
pXX680 plasmid is composed of E2a, E4, and VA from Adenovirus genome and the 
backbone of Bluescript KS(+) II as illustrated in figure S-3.  
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For endosomal trafficking 
EGFP-Rab5, a plasmid used to be expressed in live cells and highlight the Rab5-
associated early endosomes. This plasmid was constructed by inserting the human Rab5 
coding sequence into mono-clonal-site (MCS) of construct pEGFP-C3 using restriction 
enzyme Hind III and BamH I. The representative map is shown in figure S-4.   
DsRed-Rab7, a plasmid used to be expressed in live cells and highlight the Rab7-
associated late endosomes. This plasmid was constructed by inserting the human Rab7 
coding sequence into mono-clonal-site (MCS) of construct pDsRed2-C1 using restriction 
enzyme Hind III and BamH I. The representative map is shown in figure S-5.   
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Figure S-1. Maps of TR-CBA-ssDNA and dsEMBOL-TR-CMV-EGFPsc. Plasmid ‘TR-
CBA-ssDNA’ provides a single stranded genomic DNA for packaging where ‘ssDNA’ part 
can be reporter genes (e.g. GFP, Luciferase) or therapeutic genes. Plasmid ‘TR-CMV-
EGFPsc’ provides a double stranded genomic DNA for packaging where ‘EGFPsc’ may be 
replaced by other reporter genes or therapeutic genes. 
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Figure S-2. The map of packaging plasmid ‘pXRs’. Rep2 is from AAV2 and Cap(s) can 
be from any serotypes.  
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Figure S-3. The representative map of Ad helper plasmid pXX680. 
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Figure S-4. The representative map of plasmid EGFP-Rab5. 
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Figure S-5. The representative map of plasmid EGFP-Rab7. 
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